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Remodeling of cell surface to install new features has continuously attracted attention 
for cell therapy. This dissertation focuses on a method of cell surface engineering using 
bioactive molecules to transiently award distinct functions to ordinary cells. Spontaneous 
incorporation of lipid-conjugated biomaterials to the cell membrane through hydrophobic 
interaction provides the basis for noninvasive cell surface modification.  
First, mesenchymal stem cells (MSCs) were surface-engineered to embed a 
recombinant protein, stromal-derived factor 1 (SDF-1), for an enhanced target-specific 
homing effect. The SDF-1-embedded MSCs showed augmented migration towards the 
concentration gradient of their molecular target, CXC chemokine receptor 4 (CXCR4). 
Next, Jurkat cells were surface-engineered with magnetic resonance imaging (MRI) 
contrast agents to demonstrate the suitability of surface engineering in cell tracking. The 
contrast agent-embedded Jurkat cells were detectable by MRI. 
To demonstrate the applicability of this technology in translational research, immune 
effector cells were surface-engineered with antibody-drug conjugates (ADCs) and their 
combined efficacy was examined in animal tumor models. This combination of 
chemotherapy and immunotherapy showed significant efficacy in treating cancers; 
however, the immunomodulatory effects of chemotherapy were difficult to control. This 
observation was due to the off-target toxicity of chemotherapy that damages the host 
immune cells: many cancer patients often require replenishment of immune cells after a 
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series of chemotherapy in order to benefit from immunotherapy. In order to overcome the 
challenge, new chemoimmunotherapeutic strategies require sufficient immunomodulatory 
ability of chemotherapy, targeted chemotherapy for reduced toxicity, and enhanced 
recruitment of immune cells to the tumor tissue. Surface engineering to affix 
chemotherapeutic agents on the cell membrane of immune effector cells is therefore an 
attractive approach. 
In the main study of this dissertation, natural killer 92 (NK92) cells were  
surface-engineered to carry ADCs on their membranes. A lipid-conjugated model ADC, 
trastuzumab-DM1 (T-DM1), homogeneously modified the allogeneic NK92 cells without 
affecting the viability of NK92 cells. T-DM1-embedded NK92 (SE-NK/T-DM1) cells 
exerted strong anti-cancer activity through targeted chemoimmunotherapy. Although a 
wide range of experimental observations has proven that the SE-NK/T-DM1 cells are 
effective over the co-treatment of T-DM1 and NK92 cells, further investigations should be 
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1.1. Cell Surface Engineering 
Cell surface engineering to provide new characteristics and functions to cells has 
drawn continual interest from researchers in biomedical science. Biomaterials including 
proteins, surface receptors, antibodies, peptides, genetic materials, and protective polymers 
have been used to endow specific functions to cells.1-8 The research areas that have 
benefitted from cell surface modification are (1) investigation of adding new functions,  
(2) reducing graft rejection for transplantation by masking the surface antigens, (3) creation 
of heterogeneous cluster of cells by cell-to-cell attachment, and (4) enhancing immune 
effector functions for therapeutic benefits. Inarguably, the last area has become one of the 
most intensively investigated topics involving genetically engineered immune cells for 
cancer therapy.9 In order to introduce the new functionalities, cell surface was initially 
modified through covalent conjugation,5,6,8,10 electrostatic interaction,11-13 and hydrophobic 
interaction.4,14-18 Continuous research on cell surface modification has ultimately arrived 
at genetic modification that permanently reprograms cells.3,19,20 Ideal surface engineering 
methods should provide control over the fate and functions of the modified cells without 
interfering with cell survival, proliferation, and cellular activities. Therefore, the methods 
listed above should be carefully selected to meet the purpose of modifying the cell surface 
2 
 
properties. Biomaterials commonly used for all surface engineering techniques and their 
representative applications are summarized in Figure. 1.1 and Table 1.1.  
 
1.1.1. Covalent Conjugation 
Covalent conjugation chemically, metabolically, or enzymatically attaches bioactive 
substances to the cell membrane.5-8,21-23 Chemical conjugation is the most straightforward 
method that takes advantage of surface-exposed functional groups, such as amines and 
thiols, on the membrane proteins as grafting points. Currently, N-hydroxyl-succinimidyl 
ester (NHS) groups,5-8 maleimide,23 and pyridyldithiol24,25 are the most frequently used 
chemical cross-linkers (Figure 1.1a). Metabolic surface modification has been reported by 
Saxon et al. and Prescher et al.21,22 Interestingly, human cells undergo unnatural sialic acid 
biosynthesis when exposed to unnatural sugar N-α-azidoacetylmannosamine (ManNAz), 
an analog of the native sugar N-acetylmannosamine (Figure 1.1b). This process 
incorporates N-α-azidoacetyl sialic acid (SiaNAz), a metabolite of ManNAz, to the 
membrane glycoconjugates. The added azide groups further provide attachment points for 
biomaterials through Staudinger ligation21,22 or click-chemistry.26,27 Covalent conjugation 
can be also achieved through enzymatic conjugation. As reported by Swee et al., 
transpeptidase sortase A from Staphylococcus aureus efficiently conjugates peptides or 
proteins with LPETG motif to the N-terminal glycine exposed on the surface of different 
types of cells (Figure 1.1c).28 Although chemical conjugation provided stable modification, 
conjugated biomaterials gradually disappeared over time.5,8,16 Moreover, the degree of 
modification is difficult to control with covalent conjugation and higher degree of 






















Figure 1.1 Cell surface engineering with biomaterials. (a) Incorporation of cross-linkers, 
such as NHS, Maleimide, or pyridyldithiol, allows cell surface modification with 
biomaterials. Cell metabolism of unnatural sugar (b) and enzymatic reactions (c) can be 
exploited to attach functional groups on the cell surface. (d) Electrostatic interactions 
between the cell surface and the charged polymers such as PEI, PLL, PAA, and PSS can 
modify cells through layer-by-layer technique. Also, charged block-co-polymers, such as 
PLL-PEG, can modify the cell surface through electrostatic interaction. (e) Lipid-
conjugated bioactive molecules or polymers with long alkyl chains can be embedded into 
the cell membrane through hydrophobic interaction. Genetic modifications can remodel 



















































physiological alterations, such as reduction of membrane mobility and diffusion kinetics to 
the modified cells.2,14,29 
 
1.1.2. Electrostatic Interactions 
Electrostatic interactions modify the cell surface by establishing self-assembled 
structures between the negatively charged cell surface and cationic polymers (Figure 1.1d). 
Cells initially modified with cationic polymers can be further engineered via a  
layer-by-layer technique by sequentially applying anionic and cationic polymers.11,13,30-32 
Because modified cells encapsulated by multiple polymeric layers can reduce molecular 
recognition, the electrostatic layer-by-layer approach has been often investigated  
in cell transplantation research.13,31 Many cationic/anionic polymers and poly  
electrolytes, such as poly-L-lysine, (PLL), poly(styrene) sulfate (PSS), poly(allylamine  
hydrochloride) (PAH), poly(diallydimethylammonium) chloride (PDADMAC or PDDA), 
poly(ethyleneimine) (PEI), polyphosphoric acid (PPP), and poly(acrylic acid) (PAA),  
and hyaluronic acid (HA) have been used to generate multiple layers on cell 
membrane.11,13,30-33 Thickness of the polymer layer can be controlled by changing the 
number of layers. The new surface properties of the modified cells rely on the polymer 
characteristics of the outermost layer. Despite the advantage of cell surface modification 
through electrostatic interaction, the high charge density of cationic polymers significantly 
reduces the viability of modified cells.30,34,35 In an attempt to reduce the toxicity,  
PLL-graft-poly(ethylene glycol) (PLL-g-PEG) was introduced to coat the surface islet 
cells.31,36 Surface modification of PLL-g-PEG was further developed to incorporate 
functional groups, such as biotin, hydrazide, and azide, to capture streptavidin, aldehyde, 
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and cyclooctyne.36 While the cytotoxicity of cationic polymers was improved through PEG 
conjugations on primary amines of PLL, biocompatibility of cationic polymers has not 
been fully resolved.  
 
1.1.3. Hydrophobic Interaction 
Amphiphilic polymers polymerized with long alkyl chains, such as phospholipid-
conjugated PEGs and poly(vinyl alcohol) (PVA), provide noninvasive modifications of  
the cell surface through hydrophobic interaction (Figure 1.1e). Similarly, a large number 
of different cell types have been modified via hydrophobic interaction with lipid-
conjugated biomaterials for specific function.4,14-18,29,37-42 Most lipophilic membrane dyes 
currently available in the market, such as Dil, DiD, DiR, and DiO, are developed  
upon cell surface modification through hydrophobic interaction. Interaction of  
lipid-conjugated PEGs with lipid bilayers was examined by Yamamoto et al. using  
surface plasmon resonance (SPR) spectroscopy.43 Lipids with different lengths of alkyl  
chains—1,2-dimyristoyl-sn-glycerol-3-phosphatidylethanolamine (DMPE, 14 carbons), 
1,2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine (DPPE, 16 carbons), and  
1,2-distearoyl-sn-glycerol-3-phosphatidylethanolamine (DSPE, 18 carbons)—were 
conjugated with PEG (5 kDa) and applied onto the lipid bilayer. Out of all lipid-PEG 
conjugates, DMPE showed the most rapid incorporation to the membrane (Figure 1.2). 
Insertion of DPPE showed concentration-dependent behavior; however, incorporation of 
DSPE was only observed at high concentration. Dissociation of DMPE was more rapid 
compared to DPPE when modified lipid bilayer was washed with PBS. No dissociation 




























Figure 1.2. SPR sensorgram of (a) DMPE-PEG-NH2, (b) DPPE-PEG-NH2, and (c) DSPE-
PEG-NH2 incorporation into supported lipid layer. The upper panels show lipid-PEG 
concentrations above 5 µg/ml and lower panels show lipid-PEG concentrations below  




longer hydrophobic chains reduce the incorporation rate and the dissociation rate  
of lipid molecules.43 Interestingly, fluorescence of FITC-labeled lipid-PEGs was  
recovered in a few minutes in fluorescent recovery after photobleaching (FRAP)  
assay.43 This observation indicates that lipid-PEGs embedded in the lipid bilayer  
were able to diffuse laterally within the lipid bilayer. Unlike covalent conjugation  
and electrostatic interaction, surface modification with hydrophobic interaction  
allows membrane-anchored bioactive molecules to participate in the dynamic  
movement of cell membrane. Most importantly, cells modified with lipid-conjugated 
biomaterials showed negligible toxicity, and the modified cells resumed 
normal cellular activities.37-39 Instead of preparing the lipid-conjugated molecules, 
modification of cell surface can be achieved by liposomal fusion strategy.44  
Because liposomes are vesicles composed of lipids and lipid-conjugated molecules,  
large sections of the liposomes containing specialized lipids can be incorporated  
into the membrane without causing severe toxicity.44-46 Fate of the lipid-conjugated 
bioactive molecules has not been fully understood, and the exclusion pathway  
requires further investigation; however, the endocytosis of membrane-anchored  
lipid-conjugated biomaterials has not been observed.47 Lipid-conjugated biomolecules  
are believed to be released from the cells to the surroundings due to equilibrium 
difference.16 Although molecules of interest must be hydrophobized by lipid or alkyl  
chain conjugation and the retention time on the surface is variable, hydrophobic 
interaction is an attractive surface engineering technology that offers rapid and  
nontoxic surface modification to virtually any type of cell. 
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1.1.4. Genetic Modification 
Out of all cell modification methods discussed in this section, genetic modification 
is the most advanced and complicated surface modification technique. Strength of genetic 
modification lies within its versatility to introduce or knock-out specific surface proteins 
for desired effects.48 Amber suppression technology has been developed to introduce  
noncanonical amino acids (ncAAs) bearing special functional groups for chemical 
attachments to the surface proteins synthesized by the cells (Figure 1.1f).49-54 This method 
involves transfecting cells with plasmids that express a protein of interest containing an 
amber stop codon at the desired site and aminoacyl-tRNA synthetase/tRNA (RS/tRNA) 
pair. These orthogonal RS/tRNA pairs do not interfere with the native RS/tRNA pair but 
rather work in conjunction with the host protein machinery. When native and orthogonal 
RS/tRNA pairs encounter the amber codon without ncAA supplementation, translation 
terminates and a truncated protein is synthesized. However, when ncAAs are supplied to 
the media, the orthogonal RS/tRNA pair adds the corresponding ncAAs to the growing 
peptide chain and synthesizes the final protein with specific modifications. Various ncAAs 
have been synthesized to provide biocompatible modifications.49,55-57 Although amber 
suppression technology is a fascinating surface modification method, its apparent  
limitations—including competition between orthogonal and native RS/tRNA pairs, low 
expression efficiency, and adverse effects of truncated proteins—should be evaluated for 
therapeutic applications.50,58    
Advances in genetic engineering, fueled by the growing interest in cell-based 
immunotherapy, have enabled the expression of new receptors to enhance the efficacy  
of therapeutic immune cells. Because tumors have evolved to manipulate the 
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microenvironment as a means of evading the host immune system,59-62 readministrating a 
large number of ex vivo expanded autologous immune effectors cells, such as T cells and 
natural killer (NK) cells, is often ineffective against cancers. In order to overcome this 
major obstacle in cell-based immunotherapy, anti-cancer effects of T cells and NK cells 
must be activated through a different signaling pathway. Genetic modification to express 
chimeric antigen receptors (CARs) specific for tumor-associated antigens (TAAs) has  
redirected T cell and NK cell activity towards tumors in many reported studies (Figure 
1.1g).9,62-77 While genetically modified T cell receptors (TCRs) can recognize both 
intracellular and cell surface antigens, CARs are more advantageous because they are not 
restricted by major histocompatibility complex (MHC) and HLA type and can be applied 
to NK cells.62,78 Table 1.2 provides a list of CAR-T cells currently undergoing clinical 
investigation. Also, Table 1.3 shows CAR-NK cells under preclinical and clinical 
evaluations as an alternative to CAR-T cells. Generally, as shown in Figure 1.1, CARs are 
composed of a single-chain antibody fragment (scFv), a hinge region connected to 
transmembrane domain, and tandem intracellular domains. The two most important 
components are the scFv and the intracellular domains: scFv determines the antigen 
specificity, and the intracellular domains control the degree and persistency of cytolytic 
activity and activation.78 Adoptively transferred CAR-T cells and CAR-NK cells migrate 
towards the TAAs, bind to their targeted TAAs, stimulate the intracellular domains, and 
ultimately activate the cytolytic functions of T cells and NK cells. CAR-T cells have 
targeted many TAAs associated with different types of cancers, and numerous TAAs are 
currently being evaluated in the clinical setting (Table 1.2).9,62 Genetic modification is not 






Table 1.2. Currently ongoing CAR-T cell clinical trials 
 





NCT01860937, NCT02146924, NCT02228096, NCT02435849, NCT02028455, 




NCT02443831, NCT02529813, NCT02546739, NCT01430390, NCT01853631, 
NCT02050347, NCT02456350, NCT02081937, NCT02132624, NCT02349698, 
NCT01475058, NCT02537977 
Lymphoma 
NCT02650999, NCT02431988, NCT02631044, NCT02445248, NCT02277522, 
NCT02624258, NCT01493453, NCT01840566, NCT02134262, NCT02247609, 
NCT02348216, NCT02030834 
Multiple myeloma NCT02135406, NCT02135406 
CD22 B cell malignancy NCT02588456, NCT02315612 
Igκ light 
chain 
B cell malignancy NCT00881920 
CD30 Lymphoma NCT02259556, NCT02274584 
CD138 Multiple myeloma NCT01886976 






Table 1.2. (Continued)   
 
Target Indication Clinical Trials 
CD33 Myeloid malignancies NCT01864902 






ROR1 Leukemia NCT02194374 
EGFR EGFR+ solid tumors NCT02331693, NCT01869166 
EGFRvIII Glioblastoma NCT02209376, NCT02209376, NCT02209376, NCT01454596,  
GD2 
Neuroblastoma, Ewing's 
sarcoma, osteosarcoma and 
melanoma 
NCT01822652, NCT02107963 
IL13Rα2 Glioma NCT02208362 
HER2 HER2+ solid tumors NCT00902044, NCT01109095 
Mesothelin 
Mesothelioma, pancreatic 
cancer and ovarian cancer 
NCT02159716, NCT02414269, NCT01897415, NCT02580747, NCT02465983 






Table 1.2. (Continued) 
 





GPC3 Hepatocellular carcinoma NCT02395250 
MET Breast cancer NCT01837602 
MUC16 Ovarian cancer NCT02498912 
CEA Various solid tumors NCT02349724, NCT01723306 
Lewis-Y 












BCMA, B cell maturation antigen; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; EGFRvIII, EGFR variant 
III; FAP, fibroblast activation protein; GPC3, glypican 3; HER2, human epidermal growth factor receptor 2; Ig, immunogloulin; 
IL13Rα2, interleukin 13 receptor α2 subunit; MUC, mucin; NSCLC, nonsmall cell lung carcinoma; ROR1, receptor tyrosine kinase-
like orphan receptor. 
 








Table 1.3. Preclinical and clinical studies on CAR-NK cells 
 
Abbreviations:  
PBMC NK, NK cell isolated from the peripheral blood mononuclear cells; EBNA3C, Epstein-Barr nuclear antigen 3C; Her2, human 
epidermal growth factor receptor 2; EPCAM, epithelial cell adhesion molecule; GD2, ganglioside GD2; CS1, surface glycoprotein.  
 
Adapted from Klingemann et al.69 Glienke et al.20 and www.clinicaltrials.gov.     
 
Target Indication NK cell types Reference Clinical trials 
CD19 Lymphoid malignancies PBMC NK / NK92 79, 80-83 
NCT00995137 
NCT01974479 
CD20 Lymphoid malignancies PBMC NK / NK92 71, 84, 85  
CD38 Multiple myeloma PBMC NK / NK92 86  
Her2 
Breast carcinoma 
Head and neck cancer 
Ovarian carcinoma 
Glioblastoma 
PBMC NK / NK92 70, 87, 88  







EBNA3C EBV infections NK92 90  




receptors that are constitutively expressed at low levels. In this approach, genes coding for 
NKG2D, an NK cell activating receptor, and CD16 (FcγRIII), an Fc receptor responsible 
for antibody-dependent cellular cytotoxicity (ADCC), can be employed for augmented 
expression on T cell and NK cell membranes.92-96 There is no doubt that genetic 
engineering technology empowers unresponsive immune effector cells against cancer and 
other difficult-to-treat diseases; however, its potential weaknesses should be addressed for 
smoother clinical application. Viral vectors are readily employed to generate genetically 
modified T cells and NK cells; however, the transduction efficiency is unimpressive and 
varies widely. The transduction efficiency was only between 50% to 75% even with the 
lentiviral transduction.97,98 Although no observation was reported on oncogenic 
transformation of genetically modified T cells, manipulation at the gene level yields the 
potential risk of gene integration regardless of vectors. This consequently leads to gene 
dysregulation, as seen in gene-modified stem cell transfer.99 Moreover, current protocols 
to prepare genetically engineered T cells used in the clinical trials are extremely expensive 
and time-consuming.62,100,101 
 
1.2. Challenges in Surface Engineering of Living Cells 
For clinical translation, surface-engineered cells must satisfy several fundamental 
principles of biocompatibility. Because cells are the most critical component of cell 
therapy, any modifications applied to the cell surface should not have detrimental effects 
on cell viability. At any stage of preparation, cell viability should not be altered by changes 
in pH, osmolality, temperature, pressure, degree of agitation, and exposure to organic 




of necessary nutrients. This is particularity important for islet cell transplantation, where 
surface-modified islet cells secrete insulin in response to glucose levels.15,38,102 Unless  
the purpose for surface engineering is to mask the surface antigens during transplantation  
or adoptive transfer of immune cells—for the sake of reducing the occurrence of  
graft-versus-host disease (GVHD)—surface proteins and receptors should be exposed on 
the surface without hindrance to bind growth factors and ligands to signal cell survival, 
proliferation, and activation. For example, binding of interleukin-2 (IL-2) to IL-2 receptors 
on T cells and NK cells triggers cell expansion.103 Moreover, surface engineered 
biomolecules should not reduce the membrane flexibility and elasticity, which are the 
essential properties of cell membrane that allows cell adhesion, migration, and 
signaling.104-107 Lastly, the cost of surface engineering cells for therapeutic purposes must 
be affordable. Genetic modification of CAR-T cells can be finely tuned to provide 
personalized cell therapy for many cancers and diseases; however, the cost of treatment is 
extremely expensive, estimated at $25,000 per treatment.101 The high cost arises from the 
labor-intensive and time-consuming certified process to prepare CAR-T cells. The surface 
modification methods discussed in this chapter have the potential to be applied as an 
alternative technology to CAR-T cells and are more economical with rapid preparation of 
therapeutic cells. 
 
1.2.1. Cell Membrane Dynamics 
Cell membrane is in a dynamic state. It is subjected to undergo constant remodeling 
where most of its components—lipids and membrane proteins—are internalized, degraded, 




lipids and proteins and varies widely from hours to weeks.110 Cell membrane lipids and 
proteins are routinely internalized through endocytosis, pinocytosis, and phagocytosis. Due 
to their size, type, and property, biomaterials that are chemically conjugated, 
electrostatically adsorbed, hydrophobically embedded, or genetically expressed on the 
membrane, may internalize mostly through endocytosis.111 The process of endocytosis is 
initiated as complementary ligands bind to surface receptors or as bioactive substances are 
absorbed on the cell membrane.112-114 These events trigger invaginations of small areas 
containing the receptors and affected regions of cell membrane. Subsequently, the 
invaginated pockets are closed, and newly formed vesicles are transported to the 
intracellular compartments. During endocytosis, any molecules and materials on the 
invaginated cell membrane and in the proximal media will be taken up by the cells, 
resulting in the loss of desired functions installed via surface engineering. Therefore, 
surface engineering methods should consider cell membrane dynamics in order to improve 
the surface residence time of the desired biomaterials for prolonged therapeutic effects.    
 
1.2.2. In Vivo System 
Unlike the in vitro experimental settings, the in vivo environment is an integrated 
system of many complex mechanical and biochemical interactions. Transplanted or 
adoptively transferred surface-engineered therapeutic cells are exposed to sheer stress and 
hemodynamic forces that can strip off the installed surface modification.48 Migration in the 
circulation and endothelial transmigration in the tissues, as demonstrated by leukocytes and 
stem cells, require extensive reshaping of the cell membrane.115,116 In the spleen, circulating 




and aged cells.117 In order to compensate for the mechanical stress from the in vivo 
environment, surface-engineered cells must display unaltered membrane flexibility and 
elasticity. Surface-engineered cells in blood circulation are also exposed to coagulation 
factors, the complement immune system, and inflammation mediators that drastically 
reduce duration of therapeutic effects.118,119 Macrophages and monocytes of innate  
immune defense are often stimulated in response to the bioactive substances on surface-
modified cells and subsequently eliminate them from the body by phagocytosis.120 
Immunogenic biomaterials, such as proteins synthesized from bacterial host and antibodies 
isolated from animals, are opsonized by neutralizing antibodies and are cleared by the 
innate immune system and complement activation.121-124 Moreover, CAR designs can 
produce genetically modified cells with a high risk of adverse effects. Hombach et al. 
described that CAR-T cells bearing constant IgG1 Fc domains in the hinge regions 
simultaneously activated the CAR-T cells and cross-activated the host immune cells with 
CD16 receptors.125 As a result, the off-target activation of CAR-T cells was increased and 
the undesired proinflammatory cytokines were released from the CD16-expressing host 
innate immune cells activated against the IgG1 Fc domains of CAR-T cells. Potential 
adverse effects of unintentionally activated innate immune cells were minimal as they were 
removed by activated CAR-T cells; however, off-target activation of CAR-T cells reduced 
the anti-cancer activity of CAR-T cells and increased the risk of cytokine release syndrome 
(CRS).126,127 In conclusion, cell surface modification, regardless of the methods employed, 
must not sacrifice the membrane flexibility and elasticity but rather provide new 





1.3. Applications of Surface-Engineered Cells Prepared  
by Hydrophobic Interaction 
Surface engineering methods discussed in this chapter, (1) covalent conjugation,  
(2) electrostatic interaction, (3) hydrophobic interaction, and (4) genetic modification, have 
both advantages and limitations for biomedical applications. Although covalent 
conjugation provides stable modification on lipids, proteins, glycolipids, and 
polysaccharides, high degrees of modification may result in impairment of native protein 
function, altered membrane flexibility, and reduced viability. Electrostatic interaction 
allows for layer-by-layer techniques, but the cytotoxicity resulting from cationic polymers 
is too significant to be considered for clinical application. Genetic modification is an 
attractive method to generate customized surface proteins and receptors; however, gene 
transfer efficiency, generation process, and the safety of genetically modified cells need to 
be improved. Although short retention time is a potential limitation, aforementioned in the 
previous section, cell surface engineering with lipid-conjugated biomaterials through 
hydrophobic interaction provides noninvasive, nontoxic, and uniform modification of cells. 
Virtually any cell or structure encapsulated with a lipid bilayer can be rapidly modified 
with hydrophobized biomaterials. In this section, applications of cell surface modification 
with lipid-conjugated biomaterials will be presented. 
 
1.3.1.  Islet Cell Transplantation 
Patients with transplanted cells, tissues, and organs are administered 
immunosuppressive drugs to reduce the risk of GVHD.128 Without immunosuppression, 
the host immune system recognizes the transplanted cells, tissues, and organs as foreign 




Even before the immune recognition, coagulation factors and complement activators in the 
blood circulation in contact with the transplanted grafts trigger an inflammatory response 
directed for destruction.129-134 Both membrane and surface antigens on the graft should be 
protected and masked in order to reduce the risk of transplant rejection. As shown in Table 
1.1, many studies have used hydrophobic interactions to modify the islet cell surface. 
Teramura and Iwata reported to encapsulate islet cells with multiple protective layers 
created by DPPE-PEG-biotin, streptavidin, and biotin-conjugated bovine serum albumin 
(biotin-BSA).38 First, islet cells were incubated with DPPE-PEG-biotin to install initial 
biotinylated surface. Next, streptavidin followed by biotin-BSA were applied in sequence 
20 times. This layer-by-layer technique produced multiple protective layers with a total 
thickness of 30 nm on the islet cells without significantly affecting the cell viability.38 
Glucose molecules were able to diffuse through the protective membrane and finally into 
the cell. In response to glucose levels, surface-engineered islet cells were able to release 
insulin accordingly. Effects of surface modified islet cells were examined in streptozotocin-
induced diabetic mice.40 Islet cells with DPPE-PEG were transplanted in the liver through 
the portal vein. Compared to the control mice transplanted with unmodified islet cells, mice 
transplanted with modified islet cells showed improved graft survival; however, glucose 
regulatory functions of surface-modified islet cells were achieved only for a short period 
due to increased cell damage.40 Teramura and Iwata continued to attach living cells to 
protect islet cells.39 The rationale for this approach was that the attachment of vascular 
endothelial cells or fibroblast isolated from a recipient on islet cells would increase the 
transplantation compatibility.39 In order to test the new strategy, both HEK293 cells and 




HEK293 cells and subsequently immobilized on biotin-functionalized islet cell surface. 
Interestingly, HEK293 cells continuously proliferated to completely cover the islet cells a 
few days after the immobilization. Histological analysis confirmed that islet cells at the 
core did not undergo necrosis or show signs of damage.39 Unfortunately, transplantation of 
living cell-modified islet cells has not been examined in animal models yet. 
 
1.3.2. Mesenchymal Stem Cell Delivery for Myocardial Infarction 
Mesenchymal stem cells (MSCs) have been used to remodel the left ventricle and 
rescue the cardiac function for myocardial infarction (MI) in animal models.135-137 At the 
ischemic sites, administrated MSCs secreted arteriogenic cytokines, such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), placental growth 
factor (PIGF), and monocyte chemoattractant protein-1 (MCP-1), to repair the damaged 
tissues.138,139 Unfortunately, systemic delivery of large amount of MSCs to the target site 
has been difficult to achieve; only 1% of systemically administrated MSCs migrated to the 
infarct site.140 Poor migration of MSCs is related to the loss of CXC chemokine receptor 4 
(CXCR4).141 Ex vivo expansion of MSCs is necessary to generate a therapeutically relevant 
number of cells; however, during the expansion, MSCs express heterogeneous CXCR4 
with significantly reduced affinity to their corresponding ligands, stromal cell-derived  
factor 1 (SDF-1). This effect ultimately reduces the chemotaxis of MSCs along the 
chemokine gradient to specific sites.142 Systematic administration of MSCs should 
therefore be improved with a reliable targeting method to enhance therapeutic efficacy. 
Immediately after myocardial infarction, injured cardiomyocytes up-regulate SDF-1 




migration of CXCR4+ bone marrow stem cells along the SDF-1 concentration gradient is 
critical for cardiac recovery,143,145,146 it has been suggested that the responsiveness to  
SDF-1 in these cells may mature over 4-7 days after MI.147,148 Conversely, expression of 
SDF-1 in the heart starts to decline 4-7 days after the ischemic injury.143 Thus, expanding 
autologous MSCs—which takes several weeks—for the treatment of MI is not ideal due to 
the small therapeutic window of SDF-1 expression. Previously, CXCR4 expression on 
MSCs had been induced by hypoxic culture conditions, addition of cytokine cocktails, and 
viral gene transduction. However, these methods are now discouraged due to the lengthy 
generation time and risk of altering the MSC properties.149-152 In order to exploit the  
SDF-1 gradient for targeted delivery of MSCs to the MI site, pre-expanded MSCs should 
be rapidly modified with the targeting moiety. To comply with the requirements, Won et 
al. modified the MSCs with DMPE-PEG conjugated recombinant CXCR4 and examined 
the behavior of CXCR4-modified MSCs in the presence of SDF-1.18 Compared to the 
unmodified MSCs, CXCR4 modified MSCs demonstrated enhanced migration towards  
the SDF-1 gradient.18 Although the efficacy of CXCR4 modified MSCs has not been 
evaluated in the animal models of MI, the reported in vitro results imply that surface 
engineering of therapeutic cells with targeting moieties through hydrophobic interaction 
may allow specific migration towards the desired site in the living system.  
 
1.3.3. Enhancing Antigen Presentation for Dendritic Cells 
Immunotherapy has become one of the central cancer therapeutic strategies; all 
components of immunotherapy, including T cells, NK cells, dendritic cells (DCs), 




mechanisms and to improve efficacy against cancer. From these continuous efforts, 
advanced immunotherapies, including CAR-T cells,9 CAR-NK cells,153,154 antibody-drug 
conjugates (ADCs),155 and dendritic cell (DCs) vaccines,156,157 were developed. DC 
vaccines are attractive because DCs are the primary antigen presenting cells that can not 
only activate T cell, B cells, and NK cells, but also induce immunological memory to 
control tumor relapses for long-term protection.156,158 In this approach, DCs isolated from 
patients are challenged with tumor antigens found on their tumors and reinfused back into 
patients.159 In turn, DCs degrade the tumor antigens into small peptides and transfer them 
onto MHC for CD8+ T cells and CD4+ T cells activation.160,161 Although clinical efficacy 
of DC vaccines has been demonstrated with MUC1 antigen, it has become clear that the 
method of loading cancer antigens onto DCs is critical because it determines the efficiency 
of antigen presentation and magnitude of immune activation.162,163 Ideally, DCs should be 
exposed to a wide range of tumor antigens in order to provide extended protective coverage. 
Unfortunately, the current library of tumor antigen peptides used for DC priming is limited. 
Also, the fact that tumor cells can escape host immune surveillance by expressing variant 
antigens further limits the potential to use peptide antigens for DC priming.164 Alternatively, 
whole cancer cells can be used for antigen-loading of DCs.163,165,166 DCs loaded with 
apoptotic cancer cells enable broad recognition of cancer cells by potentially expressing all 
known and unknown cancer-associated antigens and activating a repertoire of immune cells, 
including CD8+ T cells, CD4+ T cells, NK cells and γδ T cells.4,163,165,166 To demonstrate 
the ex vivo whole cell loading of DCs, Tomita et al. first induced apoptosis in cancer cells 
by brief ultraviolet (UV) light exposure and then surface engineered the apoptotic cancer 




apoptotic cells were incubated with the isolated DCs. As a result, DCs recognized the 
antibodies on the surface of apoptotic cancer cells, captured Fc domains of antibodies via 
Fc receptors, and internalized the apoptotic cells via phagocytosis.4 It is interesting to note 
that the antibody used in this study was an arbitrary IgG not specific for any particular 
antigen or DC surface receptor. This process mimics the internalization of neutralizing 
antibody-opsonized dying cells by Fc receptors on DCs. With the surface modification of 
apoptotic cancer cells using any antibodies, DCs can be readily and efficiently loaded with 
all potential antigens associated with specific cancer cells. 
 
1.4. Conclusions 
Cell therapy has advanced to the point where it aims to provide treatments for tissue 
degeneration, chronic inflammation, autoimmunity, genetic disorders, cancer, and 
infectious diseases.48 Because the efficacy of cell therapy heavily depends on the fate and 
function of therapeutic cells, innovative strategies are continuously being introduced to 
enhance cell survival and improve native functions and therapeutic effects. Synthetic and 
natural biomaterials were incorporated onto the cell surface through covalent conjugation, 
electrostatic interaction, hydrophobic interaction, and genetic modification in order to 
provide unique properties and functionalities to cells. Although covalent conjugation and 
electrostatic interaction provide stable surface modification, the degree of modification is 
difficult to control. Excessive modification may disrupt the membrane integrity, resulting 
in severe cytotoxicity. Genetic modification has an advantage to express heterologous 
proteins in cells; however, the expression of desired protein heavily depends on the amount 




targeted cells. Nonetheless, viral gene transfer limits the application of genetically 
modified cells for therapies due to safety and economical concerns, including the use of 
viral vectors, expensive production cost, and extensive generation time. Compared to other 
surface engineering methods, hydrophobic interaction is a safer membrane modification 
method of chemistry that noninvasively modifies the cell surface by inserting  
lipid-conjugated molecules into the membrane. Limitations of surface engineering through 
hydrophobic interaction should be addressed for clinical application. Internalization of 
lipid-conjugated biomaterials can rapidly reduce the therapeutic efficacy and viability of 
modified cells. Inui and coworkers, however, reported that endocytosis of PEGylated lipids 
such as DMPE-PEG, DPPE-PEG, and DSPE-PEG was not observed.47 Despite limited 
understanding of the fate of lipid-PEG conjugated bioactive substances, surface 
engineering with hydrophobic interaction is an attractive technique because it can be 
applied to virtually any cell. Since the modification process is rapid and straightforward, it 
can be incorporated to “off-the-shelf” cells as “off-the-self” reagents. 
The next two chapters of this dissertation concentrate on the applications of cell 
surface engineering with hydrophobic interaction to improve the target-site homing effects 
for cell delivery and to integrate special functions to therapeutic cells. Traditionally, 
therapeutic cells had been directly injected into the accessible target sites, such as the left 
ventricle for MI and the portal veins of the liver for islet cell transplantation.167,168 However, 
systematic administration of therapeutic cells is preferred due to the fact that most diseases 
and tumor tissues are inaccessible for direct injection. Although therapeutic cells are living 
drugs that can navigate through the endothelial and stromal barriers to arrive at their 




of accumulation at target sites.171 Therefore, cell delivery must incorporate a targeted 
mechanism to enhance therapeutic efficacy. In Chapter 2, surfaces of MSCs were modified 
with SDF-1 protein. This approach aims to take advantage of the CXCR4/SDF-1 axis to 
deliver MSCs towards injured cardiomyocytes expressing CXCR4 at the late stage of acute 
MI. In Chapter 3, NK cells were surface-engineered to embed antibody-drug conjugates 
(ADCs). Trastuzumab-DM1 (T-DM1) was selected as a model ADC. Surface-engineered 
NK cells with T-DM1 selectively targeted Her2-positive SK-BR-3 cells and Calu-3 cells 
but not Her2-negative MDA-MB-231 cells. Two experimental studies have demonstrated 
the ability of cell surface engineering—with different targeting moieties—to redirect 
therapeutic cells towards the sites of interest. 
The ability to empower cells with therapeutic functions—by modifying the cell 
surface with desired bioactive materials—was investigated in the subsequent chapters. In 
Chapter 2, imaging agents were used to modify cells for cell tracking purposes. It is 
important to understand the fate of administered therapeutic cells. Currently, positron 
emission tomography (PET) imaging and magnetic resonance imaging (MRI) are 
employed to noninvasively monitor the behavior of therapeutic cells in real-time. In 
Chapter 2, Jurkat cells were modified to carry superparamagnetic iron oxide nanoparticles 
(SPIONs) on their surface. These SPION-modified Jurkat cells did not show significant 
alterations in cell viability and produced a sharp contrast for MRI. In Chapter 3,  
targeted chemotherapeutic agents were embedded in the immune cells to enhance the  
anti-cancer efficacy of chemoimmunotherapy. In addition to the tumor homing effect, 
ADCs delivered powerful cytotoxic agents to the target cells. Cooperative anti-cancer 




death: (1) ADCs on the surface delivered NK cells closer to cancer cells; (2) cancer cell 
death was induced by cytolytic activity of NK cells; (3) internalized ADCs induced 
apoptosis in cancer cells; and (4) NK cells recognized the apoptotic cancer cells and 
eliminated them. Moreover, ADC-embedded NK cells induced strong tumor growth 
suppression in animal models. Experimental approaches are provided in subsequent 
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CELL SURFACE ENGINEERING TO EMBED TARGETING LIGANDS OR 
TRACKING AGENTS ON THE CELL MEMBRANE† 
 
2.1 Abstract 
Efficient modification of cells with specific molecules or compounds that can guide 
the cells to the target tissues provides an attractive means of improving the efficacy of cell 
therapy. To address this, we have developed a cell surface engineering technology to  
noninvasively modify the cell surface. This technology can embed a wide variety of 
bioactive molecules on any cell surface and allows for targeting of a wide range of tissues 
in a variety of disease states. Using cell surface engineering technology, mesenchymal stem 
cells (MSCs) or Jurkat cells were modified with: 1) a homing peptide or a recombinant 
protein to facilitate the migration of the cells toward a specific molecular target; or  
2) magnetic resonance imaging (MRI) contrast agents to allow for in vivo tracking of the 
cells. The incorporation of a targeting peptide or protein on MSCs facilitated the migration 
of cells toward their molecular target. MRI contrast agents were successfully embedded on 
                                                          
†
Modified with the permission from KS Lim, GM Valencia, YW Won, and DA Bull. Biochemical and 
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the cell surface without adverse effects and the contrast agent-labeled cells were detectable 
by MRI. Our technology is a promising method of cell surface engineering that provides a 
broad range of applicability for cell therapies. 
 
2.2. Introduction 
Cell therapy typically involves systemic infusion of living cells to exert a direct or 
indirect effect against human disease.1 The efficacy of cell therapy may be improved by 
the following measures: increasing the injection dose and the graft yield, reducing  
immune-mediated rejection, enhancing circulation time, and/or facilitating migration 
toward the target tissues.2 The modification of cells to present targeting ligands and the 
encapsulation of cells in delivery vehicles have improved the yield of engraftment to the 
target tissues.3,4 Such methods, however, still face one or more of the following  
limitations: (1) exposure of the cells to harsh conditions, (2) use of viral-gene transfer,  
(3) complicated processes, and (4) permanent modification.5  
Cell preconditioning requires ex vivo expansion of cells in the presence of toxic 
chemicals or under a specific condition.6 Gene-based approaches to induce expression of  
a particular ligand against the target receptor are highly versatile; however, poor 
transfection efficiency and uncontrolled gene expression remain to be critical challenges.7,8 
Conjugation of targeting ligands to proteins or polysaccharides present on the cell 
membrane can alter the membrane structure permanently, suggesting that the activity  
of surface-modified cells can be unpredictable.9,10 Electrostatic interaction may be an 
alternative to chemical conjugation.11 Because molecules bound to the cell surface through 
charge interaction are able to dissociate and internalize into the cells, this method has the 
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potential to affect cell metabolism and viability.12 Thus, there is a need for an alternative 
technology that can noncovalently modify cells without altering the cellular viability, 
metabolism or function. 
We have developed a cell surface engineering technology based on hydrophobic 
interaction, allowing any biological molecule to be noninvasively embedded on the cell 
membrane, while maintaining the inherent cellular activiity.13 This technology allows for 
homogeneous and rapid modification of cell surface with a variety of biological molecules 
such as homing peptides, proteins, antibodies, and tracking agents, regardless of the cell 
type. In this study, the applicability of our surface engineering method to mesenchymal 
stem cells (MSCs) and Jurkat cells with a homing peptide, a small protein, and magnetic 
resonance imaging (MRI) contrast agents, was examined. 
 
2.3. Materials and Methods 
2.3.1. Materials 
All 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-poly (ethylene glycol) 
conjugates (DMPE-PEG-NHS, DMPE-PEG-Maleimide, DMPE-PEG-NH2, 5 kDa),  
NHS-activated PEG (5 kDa), and FITC-labeled carboxyl-terminated SPIONs  
(SPIONs-FITC, 25-30 nm) were purchased from Nanocs (New York, NY). Recombinant 
human SDF-1 was obtained from Peprotech (Rocky Hill, NJ), and recombinant human 
CXCR4 was purchased from SPEED BioSystems (Rockville, MD). CRPPR-FITC and 
CRPPR peptide were synthesized by the University of Utah Peptide Core Facility. 
Recombinant cysteine-rich protein 2 (CRIP2) was purchased from Sino Biological Inc. 
(Beijing, China). The anti-SDF-1 antibody and FITC-conjugated secondary antibody were 
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obtained from R&D systems (Minneapolis, MN). All cell culture products—FBS, DPBS, 
PBS, HBSS, DMEM, and RPMI 1640—were obtained from Invitrogen (Carlsbad, CA). 
Cell Counting kit-8 (CCK-8) was purchased from Dojindo (Kumamoto, Japan). All other 
materials were purchased from Thermo Fisher Scientific (Waltham, MA). 
 
2.3.2. Characteristics of MSCs 
MSCs obtained from the Pharmicell Co., Ltd. (Sungnam, Korea) were isolated  
from the bone marrow aspiration in healthy adult male donors under informed  
consent. Mononuclear cells isolated from the bone marrow aspirate by density  
gradient centrifugation were briefly cultured with DMEM containing low glucose,  
10% FBS, and 20 µg/mL gentamicin for 5 to 7 days. Nonadherent cells were removed 
while the culture flask-adhering cells displaying fibroblast-like spindle-shapes were 
continuously enriched. MSCs were subcultured at 80% confluency and maintained  
up to four passages. Flow cytometric analysis showed that the cultured MSCs were  
positive for mesenchymal stem cell markers, such as CD105 and CD73, but negative  
for hematopoietic markers, such as CD45, CD34, and CD14.    
 
2.3.3. Cell Culture 
All cells were cultured in DMEM containing 20% FBS and 1% antibiotics  
at 37ºC under 5% CO2 atmosphere. Jurkat cells were grown in the same conditions  
with RPMI-1640 containing 10% FBS and 1% antibiotics. At 90% cell confluency,  
the cells were detached, washed and suspended at 7.5×105 cells/mL concentration  
in HBSS.  
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2.3.4. Surface Engineering with a Homing Peptide 
DMPE-PEG-maleimide was conjugated to a CRPPR or CRPPR-FITC peptide.  
DMPE-PEG-maleimide dissolved in PBS at 1 mg/mL concentration and a 1 mg/mL stock 
solution of CRPPR in PBS were mixed and produced a final molar ratio of DMPE-PEG to 
CRPPR=15:1. After 1 hour of incubation at room temperature, impurities were removed 
by using Amicon Ultra Centrifugal Filters (3 kDa; Millipore, Billerica, MA). Conjugates 
were kept at -80°C until use. MSCs were cultured as described above, and the  
DMPE-PEG-CRPPR was added directly to the cell suspension. The modified MSCs were 
collected, washed, and suspended in HBSS for confocal microscopy (Nikon A1R, Nikon, 
Japan) and FACS analysis (BD FACSCanto, BD Bioscience, USA). The cell viability and 
the proliferation after the modification were determined by the MTT assay and CCK-8 
assay, respectively. 
 
2.3.5. Modification of MSCs with SDF-1 
To prepare DMPE-PEG-SDF-1, 0.5 mg/mL SDF-1 in PBS was mixed with a  
15-molar excess amount of DMPE-PEG-NHS, followed by 2 hours of reaction at room 
temperature. The resulting DMPE-PEG-SDF-1 was dialyzed (MWCO: 20 kDa) against 
PBS for 24 hours, sterilized by filtration, and stored at -80°C until use.  
DMPE-PEG-SDF-1 amounts ranging from 5 to 100 μg were added to 7.5×105 cells of 
MSCs. The modified MSCs were labeled with primary mouse anti-SDF-1 antibodies and 
secondary FITC-goat anti-mouse antibodies. These labeled cells were observed by 
confocal microscopy to visualize the location of SDF-1 on the cell surface and analyzed by 
FACS to quantify the percentage of the modified cells. 
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2.3.6. Migration Assay 
The CRPPR-modified MSCs were placed in the insert of a transwell system, and the 
outer wells were filled with culture media with or without CRIP2. After 24 hours of 
incubation, MSCs remaining on the topside of the insert were removed, and the MSCs on 
the bottom of the insert were harvested and counted. To determine the dose effect of the 
CRPPR on the migration, different amounts of the DMPE-PEG-CRPPR were added to a 
fixed number of MSCs. The modified MSCs were plated in the transwell system as 
described above. The effect of CRIP2 dose on MSC migration was investigated. The MSCs 
modified with 60 μg of the DMPE-PEG-CRPPR were seeded in the transwell system. 
Subsequently, the outer wells were filled with the culture media with increasing 
concentrations of CRIP2. After 24 hours of incubation, the number of migrated MSCs was 
determined by measuring the viable cells on the bottom of the insert using a MTT assay. 
To test the CXCR4 concentration-dependent migration, MSCs were mixed with 100 μg of 
the DMPE-PEG-SDF-1 and seeded in the inserts of transwell system at a density of  
2×104 cells in complete culture media. The lower reservoirs were filled with complete 
culture media containing 0, 50, 100, 200, or 300 ng/mL of CXCR4. After 24 hours of 
incubation, cells remaining on the topside of the insert were removed, and cells that had 
migrated to the bottom of the insert were also counted by MTT assay.   
 
2.3.7. Tests in Various Cell Lines 
DMPE-PEG-FITC was added directly to various cell lines, including 293T, Jurkat, 
A549, BT-474, MCF-7, MDA-MB-231, and SK-BR-3. After 10 minutes of incubation, 
cells were harvested, washed, and suspended in HBSS for confocal microscopy and FACS 
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analysis. The modified cells were seeded on 24-well plates and incubated for 18 hours. The 
cell adhesion and the morphology of the cells were observed using an optical microscope 
(Olympus IX51, Olympus, Japan).  
 
2.3.8. Modification with Tracking Agents 
Carboxyl-terminated SPION-FITCS were attached to DMPE-PEG-NH2 through 
NHS/EDC conjugation chemistry. Briefly, 5 mg of EDC and 10 mg of sulfo-NHS were 
reacted with 1 mL of SPION-FITC containing 2 mg of iron in MES buffer (pH 6.0) for  
30 minutes at room temperature. After EDC and sulfo-NHS were removed using a spin 
column (MWCO: 10 kDa), the NHS-activated SPIONs were mixed with 20 mg of  
DMPE-PEG-NH2 to saturate the NHS-activated sites for 2 hours at room temperature. The 
DMPE-PEG-SPION-FITC was dialyzed (MWCO: 10 kDa) against PBS (pH 7.4) for  
24 hours. For a negative control, PEG-conjugated SPIONs (5 kDa) were generated in the 
same way. Amounts of the DMPE-PEG-SPION-FITC ranging from 10 μL to 200 μL were 
used tomodify 7.5×105 Jurkat cells. SPION-modified Jurkat cells were analyzed by 
confocal microscopy and FACS analysis. Jurkate cells labeled with PEG-SPIONs were 
analyzed with FACS analysis. Viability and proliferation of SPION-modified Jurkat cells 
were analyzed by the CCK-8 assay. 
 
2.3.9. MRI 
For MRI imaging, 7.5×105 Jurkat cells were modified with 50, 100, or 200 μL of the 
DMPE-PEG-SPION-FITC. One hundred thousand SPION-modified or unmodified Jurkat 
cells were seeded into a premolded agar gel prepared in an 8-chamber coverglass with  
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0.5% (w/v) of low melting agarose in PBS. Before the gel completely solidified, cooled 
0.5% agarose solution was added on the top of the seeded cells and kept at 4°C to solidify. 
Agar phantom-containing unmodified or SPION-modified Jurkat cells were examined with 
a Bruker 7T scanner (Bruker Biospin; Ettlingen, Germany). Samples were analyzed using 
T2*-weighted sequences (TR/TE/flip-angle = 323 ms/7.5 ms/30 degrees) with fast  
low-angle shot (FLASH). Images were taken in 25 slices (slice thickness = 0.5 mm) in 
plane resolution 0.195 mm x 0.195 mm. 
 
2.3.10. Statistical Analysis 
All data are presented as the mean ± standard deviation (n=3). Results, including the 
images and plots, were reported from one of two independent experiments. Statistical 
analysis was performed with Student’s t-test, and the threshold value was set at #P<0.01.  
 
2.4. Results 
2.4.1 Modification of MSCs with a Homing Peptide 
To determine the minimal amount of DMPE-PEG-conjugated peptide necessary to 
achieve homogeneous coating of the cell surface, DMPE-PEG-CRPPR-FITC was added 
incrementally to a constant number of MSCs. DMPE-CRPPR-FITC was incorporated 
homogeneously into the surface of MSCs; the degree of modification was directly 
proportional to the amount of added conjugates up to 30 μg (Figure 2.1a, b). When the 
amount of DMPE-PEG-CRPPR-FITC exceeded 60 μg, the fluorescence intensity in the 
cytosol increased significantly, indicating that the internalization had occurred. As little  





















Figure 2.1. MSCs modified with a homing peptide. (a) Confocal micrograph (60×) showing the modified MSCs with  
DMPE-CRPPR- FITC. FICT was excited at 495 nm and emission was recorded at 520 nm. Images were selected from three independent 
experiments. (b) The mean fluorescence intensity (MFI) of the modified MSCs determined by FACS analysis  





To determine the effect of surface modification on cell viability and proliferation, 
CRPPR-modified MSCs and unmodified MSCs were plated and cultured for 48 hours. The 
viabilities and proliferation rates were measured at 24 hours and 48 hours post-seeding. No 
differences in cell viability and proliferation were observed between the modified MSCs 
and the unmodified MSCs (Figure 2.2a, b), verifying that the modified MSCs retained the 
ability to proliferate. These results confirmed that our cell surface engineering technology 
does not hinder cell growth. 
 
2.4.2. Modification of MSCs with a Protein 
SDF-1 was chosen to modify MSCs through hydrophobic interaction seeing that the 
CXCR4/SDF-1 axis is a well-established chemotaxis signal for MSC migration. The MSCs 
were modified to anchor SDF-1 on the cell surface in order to verify uniform cell 
modification with a protein and reconfirm the enhanced migration that we observed in the 
prior study.13 Although 5 μg of DMPE-PEG-SDF-1 was sufficient to modify the given 
number of cells, the degree of modification was increased with an increasing amount of 
added DMPE-PEG-SDF-1 in comparison to the control group and the 0 μg-treated group 
(nonmodified cells incubated with anti-SDF-1 antibody) (Figure 2.3a, b). 
 
2.4.3. Migration of Modified MSCs 
Migration of MSCs modified with DMPE-PEG-CRPPR or DMPE-PEG-SDF-1 
toward their complementary homing signals was verified. First, MSCs were modified with 
increasing amounts of DMPE-PEG-CRPPR to investigate the effect of dosing on  
























Figure 2.2. Viability (a) and proliferation rate (b) of MSCs after the modification with 
DMPE-PEG-CRPPR-FITC. Each condition was tested in triplicate and one representative 
experimental result is presented. No significant difference in cell viability (a) and 
proliferative activity (b) was observed between the unmodified MSCs and the MSCs 
























Figure 2.3. Confocal micrograph and FACS analysis of the SDF-1-modified MSCs. (a) MSCs presenting SDF-1 on the surface  
observed by confocal microscopy (60). (b) The degree of modification determined by the FACS analysis.  
FITC-labeled SDF-1 on MSC surface were excited 495 nm and emission was recorded at 520 nm. One representative result from three 






CRIP2 protein—the molecular target of the CRPPR peptide. The number of MSCs 
migrating towards CRIP2 was significantly increased compared to that of the  
nonmodified MSCs (Figure. 2.4a). The extent of migration was observed to be  
directly proportional to the amount of embedded DMPE-PEG-CRPPR on the  
surface of the MSCs. Todemonstrate the CRIP2 gradient-dependent increase  
in migration, MSCs modified with 60 μg of DMPE-PEG-CRPPR were exposed to 
increasing concentrations of CRIP2.The migration of the modified MSCs  
increased in a CRIP2 dose-dependent manner (Figure. 2.4b). As shown in Figure 2.5, 
migration of the modified MSCs with the DMPE-PEG-SDF-1 increased  
toward CXCR4, which is the target receptor for SDF-1. 
 
2.4.4. Normalization 
In order to demonstrate the feasibility of our surface engineering technology to  
serve as a platform that can be applied to the modification of a wide variety of cells,  
293T, Jurkat, A549, BT-474, MCF-7, MDA-MB-231, and SK-BR-3 cells were modified 
with DMPE-PEG-FITC through the optimized method and then observed by confocal 
microscopy. DMPE-PEG-FITC was detected on the surface of the cells (Figure 2.6). 
Although the degree of the surface modification varies by cell type, 100% of the  
given cell population was modified with DMPE-PEG-FITC. The modified cells  
were seeded on a cell culture plate to evaluate the ability of the modified cells to  
adhere to the plate. There was no difference in cell adhesion between the modified  
cells and the nonmodified parent cells (Figure 2.7). Jurkat cells showed proliferative 

























Figure 2.4. Migration of CRPPR modified MSCs towards CRIP2. (a) Migration of the 
MSCs modified with increasing amounts of DMPE-PEG-CRPPR toward CRIP2 (#P<0.01). 
(b) Migration of the MSCs modified with DMPE-PEG-CRPPR toward CRIP2  
gradient (#P<0.01). Data were selected from three independent experiments. All 
























Figure 2.5. Migration of the MSCs modified with DMPE-PEG-SDF-1 toward CXCR4 
gradient (n=3, #P<0.01). MSCs modified with 100 g of DMPE-PEG-SDF-1 were able to 
migrate across the transwell membrane when they were exposed to increasing 



















Figure 2.6. Surface modification of various cell types. Confocal micrographs (60) of DMPE-PEG-FITC modified cell surface of 
different cell types. FITC-surface modified cells were excited at 495 nm and fluorescence emission was detected at 520 nm. Images 



















Figure 2.7. Adhesion of different types of cells on a tissue culture plate after the surface modification with DMPE-PEG-FITC. No 
difference in cell adhesion pattern was observed between unmodified cells and DMPE-PEG-FITC modified cells. Also, behavior of 





2.4.5. Modification with Tracking Agents 
To test whether or not our surface engineering technology can be used to label cells 
with tracking agents, Jurkat cells were modified with DMPE-PEG-SPION-FITC. Jurkat 
cells modified with increasing amounts of DMPE-PEG-SPION-FITC showed fluorescent 
emission on the cell surface, but not in the cytosol (Figure. 2.8), while FITC emission was 
not observed in the unmodified Jurkat cells. Jurkat cells showed a high degree of 
modification when surface-engineered with DMPE-PEG-SPION-FITC; however, 
considerably low fluorescent intensity was observed when Jurkat cells were treated with 
PEG-SPION-FITC (Figure 2.9a, b). This observation confirmed that the conjugated  
lipids allowed SPION incorporation into the cell surface. As shown in Figure 2.10,  
SPION-modified Jurkat cells were detectable by MRI and displayed a positive MRI  
signal; the signal intensity increased as the dosage of SPION increased. Modification of 
Jurkat cells with DMPE-PEG-SPION had no influence on cell viability or proliferative 
capacity of the cells (Figure 2.11a, b). These results demonstrate that surface engineering 
technology can be employed to embed tracking agents in the surfaces of cells without the 
creation of covalent bonds or internalization of imaging agents. 
 
2.5. Discussion 
Surface modification through hydrophobic interaction requires preconjugation of 
lipid-PEG with the desired biological molecule prior to cell incubation. This method 
generates modified cells more quickly, reduces the amount of conjugate required, increases 
the yield of modified cells, improves cell viability, and minimizes any adverse effects on  




















Figure 2.8. Confocal images (60) of Jurkat cells modified with DMPE-PEG-SPION-FITC. 
FITC-labeled SPIONs were excited at 495 nm and emission was detected at 520 nm. 
Internalization of SPIONs was not observed after the modification. Images were selected 
from three independent experiments.   
 
 




























Figure 2.9. Degree of Jurkat cell modification with SPIONs. (a) FACS analysis of Jurkat 
cells modified with DMPE-PEG-SPION-FITC. (b) FACS analysis of Jurkat cells modified 
with PEG-SPION-FITC. FITC-labeled SPIONs on the Jurkat cell membrane was excited 
at 495 nm and fluorescent emission was recorded at 520 nm. One representative result from 




























Figure 2.10. MRI of agar phantoms containing Jurkat cells modified with different amounts 
of DMPE-PEG-SPION-FITC. Each agar phantom was seeded with 1105 SPION-modified 



























Figure 2.11. Viability (a) and cell proliferation (b) of Jurkat cell after modification with 
DMPE-PEG-SPION-FITC. No significant difference was observed in cell viability (a) or 
proliferative activity (b) between unmodified Jurkat cells and SPION-modified Jurkat cells. 
All experiments were conducted in triplicate. The results were selected from three 






modification with hydrophobic interaction is therefore broadly applicable to many types of 
cell therapy.  
The percentage of MSCs engrafted into a target organ following systemic injection 
is typically very low. For example, generally only 1% of injected MSCs that have been 
expanded ex vivo reach the acutely infarcted myocardium.14 Although MSC-based cell 
therapies have shown promising outcomes in several clinical settings,1,15 the homing of 
injected MSCs to their target tissues must improve. To this end, polymeric scaffolds, 
microspheres, and hydrogels have been tested. The results, however, have been 
unsatisfactory due to reduced activity, viability, and differentiation potential of the MSCs 
following ex vivo expansion.16,17 This proposes the need for tremendous numbers of MSCs 
to be administered in order to achieve a therapeutic benefit.18 On the other hand, the surface 
modification of MSCs using the lipid-PEG platform has minimal effects on the intrinsic 
activity of cells and a high recovery yield, regardless of the type of bioactive molecule 
planted on the cell surface. More importantly, MSCs modified by this method can migrate 
toward the gradients of their corresponding ligands. Consequently, modification of the cell 
surface of MSCs with homing molecules provides a safe means to improve the migration 
of MSCs toward their target tissues, resulting in enhanced efficacy of cell therapy. 
Given their ability to produce a sharp contrast with MRI, SPIONs have become  
well-established imaging agents for a variety of biomedical applications.19,20 SPION-based 
imaging provides real-time noninvasive tracking of cells to monitor their distribution 
throughout the living body. There are a number of methods currently in use to label cells 
with SPIONs. Cellular uptake of imaging agents has been the most commonly used labeling 




cells at high concentrations.21,22 Even though surface-coated SPIONs are generally 
regarded as safe, adverse effects associated with the internalized SPIONs have been 
observed. Within a cell, SPIONs are often found in the acidic environments of 
lysosomes23,24 that can promote the degradation of both the protective coat and  
iron oxide core of the SPIONs to release iron ions,21,25 which in turn can  
disrupt cell homeostasis and lead to cytotoxicity.21,26 Recent studies suggest that the  
long-term adverse effects of SPIONs should not be neglected, especially when stem cells  
or immune cells are labeled and administered for therapeutic purposes.24,27 Cationic 
polyelectrolyte-stabilized SPIONs appear to stay bound to the cell surface.28 The 
cytotoxicity of cationic SPIONs is generally higher than that of neutral or  
slightly negatively charged SPIONs.29,30 Thus, a method that can noninvasively  
and rapidly label cells without the use of positively charged SPIONs would offer  
significant advantages.  
Labeling cells with SPIONs using a lipid-PEG platform offers several  
advantages over the methodologies discussed above. The generation of lipid-PEG-
conjugated SPIONs is inexpensive and straightforward. A variety of target cells  
can be instantly functionalized using lipid-PEG-SPIONs without employing a  
complicated modification process. Cell-surface modification with lipid-PEG-SPIONs  
is biocompatible because the modification is transient, the degree of modification  
is controllable by adjusting the dosage, cell viability is unaffected, and the  
internalization of SPIONs is substantially reduced. Hence, cell surface modification  





Although cell surface modification with hydrophobic interaction using  
lipid-conjugated exogenous materials provides a noninvasive and rapid generation of 
therapeutic cells, the surface retention time of biomaterials embedded in the cell membrane 
should be taken into account when evaluating for potential in vivo studies and clinical 
applications. Many factors, such as physical shape, size, surface charge of the bioactive 
molecules, and their patterns of chemical conjugation with the lipid molecules, can affect 
the surface retention time.10 Previously, our group reported that DMPE-PEG-FITC on the 
cell surface could be detected up to 3 hours in the presence of 20% serum.13  
Lipid-conjugated antibody examined in Chapter 3 of this dissertation displayed 48-hour 
long surface retention time on NK cells. Moreover, Deno et al. showed the detection of 
vitamin E-loaded liposomes (118 ± 12 nm) on the surface of HUVEC cells in the presence 
of serum for up to 72 hours.31 These liposomes were modified with 20-mer of 
deoxyadenylic acid and immobilized on the HUVEC cell surface modified with lipid 
conjugated 20-mer of complementary deoxythymidylic acid though DNA hybridization. 
Cell surface-embedded CRPPR peptides, SDF-1 proteins, and SPIONs may display surface 
retention times similar to FITC dyes, antibodies and liposomes, respectively. Surface 
retention time, dissociation mechanism, and the fate of dissociated biomaterials should be 
further studied for the designed therapeutic purpose.   
 
2.6. Conclusion 
In conclusion, this study has explored the applicability of cell surface engineering to 
embed various types of bioactive molecules in the surfaces of a variety of cell types. Using 




noninvasively and transiently on the surface of a cell membrane without adversely affecting 
the cell or compromising cell function. Therefore, cell surface engineering can improve 
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ADC-EMBEDDED NK92 CELLS TO COMBINE CHEMOTHERAPY  
AND IMMUNOTHERAPY IN A SINGLE CELL 
 
3.1 Abstract 
Conventional combinatorial therapy of chemotherapy and immunotherapy has shown 
promising outcomes; still, a significant interest in developing new methods to reinforce  
the efficacy of chemoimmunotherapy persists for the purpose of effective cancer  
therapy. These potential chemoimmunotherapeutic strategies focus on attaining the 
following: incorporating a strong chemotherapy that is nontoxic to immune cells, targeted 
delivery of potent chemotherapeutic agents to avoid adverse effects, enhancing stimulation 
of the host immune cells to mobilize towards the tumor sites, and preserving the intense 
cytotoxic activities of immune cells against tumor cells. Unfortunately, efforts to achieve 
these objectives with the current combinatorial therapies are often frustrated by the  
health and medical conditions of cancer patients. To overcome this challenge, an  
antibody-drug conjugate (ADC), T-DM1, was embedded in the membrane of NK92  
cells through hydrophobic interaction to produce a single-cell formulation of  
targeted chemoimmunotherapy. These surface-engineered NK92 cells with T-DM1  
(SE-NK/T-DM1 cells) were able to specifically recognize and destroy the target cancer 
cells. With the combined anti-cancer effects of targeted deliveries of chemotherapeutic  
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agents and cytolytic NK92 cells, SE-NK/T-DM1 cells significantly suppressed the tumor 
growth in mice bearing Her2-postive tumors compared to the NK92 cells co-treated with  
T-DM1. These results suggest that ADC-embedded NK92 cells provide therapeutic 
advantages as new chemoimmunotherapeutic agents that can simultaneously deliver 
antibodies, cytotoxic agents, and immune effector cells to their target tissues. 
 
3.2 Introduction 
It has been widely acknowledged that the combinatorial therapy of chemotherapy 
and immunotherapy is beneficial for the treatment of many clinical cancers.1,2 
Conventional chemoimmunotherapy typically utilizes the ability of the host immune 
system to recognize the immunogenic apoptotic cancer cells induced by chemotherapy.3,4 
For better outcomes, chemoimmunotherapy requires both the immunomodulating ability 
of chemotherapy and the recruitment of a sufficient number of immune effector cells to the 
tumor site.5,6 However, the immunomodulatory effects of cytotoxic agents appear only 
when patients are exposed to low-dose chemotherapy because high-dose chemotherapy can 
simultaneously shatter the host immune cells and destroy the cancer cells.7-10 Although the 
host immune system is involved in the suppression of abnormal tumor growth, cytolytic 
activity of these immune cells is inhibited by the evasive mechanism of tumor cells to 
bypass the immune surveillance.11,12 In order for chemoimmunotherapeutic agents to be 
effective, the following criteria should be satisfied: (1) chemotherapeutic agents should be 
able to induce cancer cell death, (2) components must signal the host immune system to 
discharge immune effector cells at the tumor site, (3) the chemotherapeutic agent should 
be nontoxic to immune cells or targeted delivery of cytotoxic drugs should be incorporated 
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to avoid off-tumor toxicity, and (4) immune effector cells must maintain their cytolytic 
activity against the cancer cells.1,13,14  
The adoptive cell transfer of ex vivo expanded immune cells is a clinically proven 
method to provide large amounts of effector cells to boost the anti-cancer immunity. Recent 
fatal adverse effects reported from clinical studies on chimeric antigen receptor T  
(CAR-T) cells have contributed to the increased interest in using natural killer (NK) cells 
as an alternative to T cells.12,15,16 However, obtaining a sufficient amount of autologous 
NK cells seems difficult because the number of autologous NK cells that can be isolated 
from a patient is limited.12 Allogeneic NK cells have demonstrated advantages over 
autologous NK cells in terms of convenient ex vivo expansion and consistent cytolytic 
activity.11,12,16 Among the various types of allogeneic NK cells, NK92 cells constitute the 
only cell line that is currently being tested in patients with solid organ malignancies, but 
the clinical outcomes have been disappointing.11,12,17,18 Genetic modification to express 
CARs, CD16, or NKG2D—in the interest of empowering NK92 cells—is continuously 
being studied to improve the anti-cancer activity of NK92 cells.12,19,20 
Monoclonal antibodies (mAbs) have been established as the mainstream mode of 
immunotherapy in clinical oncology as well as excellent vehicles for targeted delivery of 
cytotoxic agents.21-23 Antibodies can induce cancer cell death through their direct activity, 
antibody-dependent cellular cytotoxicity (ADCC), and/or complement-dependent 
cytotoxicity (CDC).21 As immunomodulators, antibodies bind to the target cancer cells, 
initiating the migration of many effector cells—including NK cells, DCs, cytotoxic T cells, 
and tumor-associated macrophages—towards the tumor tissue.11,13,14 Nevertheless, the fact 
that mAbs must be used in combination with standard chemotherapy in order to produce 
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more potent anti-cancer effects indicates the weak therapeutic efficacy of mAb treatment 
as a monotherapy.24-26 The need to amplify the anti-cancer effects of mAb has encouraged 
the development of antibody-drug conjugates (ADCs).21,27,28 
ADCs exert anti-cancer activity through dual functions: mAbs act as 
immunomodulators to stimulate the host immune system, and chemotherapeutic agents 
directly induce cancer cell death.22,23 ADCs lower the dosage of chemotherapeutic agents 
and reduce the adverse effects on both normal tissues and immune cells, making ADCs 
ideal therapeutic agents for chemoimmunotherapy. Unfortunately, the efficacy of ADCs 
may be reduced due to the distribution of host immune cells and ADCs in the body. It has 
been shown that the number of active immune cells in tumor tissues is not significantly 
different from that in normal tissues.29 Also, poor accumulation of ADCs in the tumor sites 
has been reported.30 Consequently, the host immune system may be unable to detect the 
ADCs bound to cancer cells for ADCC; future studies should address these critical 
challenges. Integrating the ability of ADCs to deliver cytotoxic agents to the target cancer 
cells with the cytolytic activity of NK cells is therefore of great interest, especially when 
considering an innovative strategy to combine ADCs and NK cells in a single formulation.  
We have developed a cell surface engineering technology that enables the 
embedment of a variety of biomaterials in the cell surface.31,32 In this study,  
NK92 cells were engineered to carry ADCs on their membrane in order to generate  
surface-engineered NK92 cells capable of homing toward target tumor tissues and exerting 
enhanced anti-cancer effects through chemoimmunotherapy. We hypothesized that  
(1) ADC-embedded NK92 (SE-NK/ADC) cells would specifically migrate towards the 
target tumor site through the recognition of tumor antigens by ADCs, (2) ADCs would 
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induce apoptosis in the target cancer cells, (3) NK92 cells concurrently delivered at the 
tumor tissues with ADCs would recognize the apoptotic cancer cells, and (4) NK92 cells 
would further destroy the dying cancer cells through direct cytolytic activities. We have 
generated the surface-engineered NK92 cells with a model ADC, Trastuzumab-DM1  
(T-DM1; SE-NK/T-DM1 cells), and investigated the potential therapeutic benefits as a 
novel means of chemoimmunotherapy. 
 
3.3. Materials and Methods 
3.3.1 Study Design 
We hypothesized that the NK92 cells modified with ADCs would migrate toward the 
antigen-expressing target cancer cells via antigen-specific binding. Following the 
migration toward the tumor, ADCs would induce cancer cell death, and NK92 cells would 
destroy the apoptotic cancer cells through a number of mechanisms. All in vitro studies 
were performed at least twice in triplicate. In vivo experiments were designed to 
demonstrate the tumor-targeted efficacy of SE-NK/T-DM1 cells, which would be difficult 
to determine in the in vitro models. NOD scid gamma (NSG, NOD-scid IL2Rgnull) mice 
were selected because they lack mature T cells, B cells, and NK cells that can interact and 
eliminate the infused allogeneic cells. In order to isolate the therapeutic effects of  
SE-NK/T-DM1 cells, interference from the murine immune system had to be minimized. 
The in vivo study sample size was calculated from a similar study reported in a literature 
demonstrating the efficacy of Her2-specific CAR-NK cells.20 Efficacy studies and 
biodistribution studies were completed with four mice per group (three mice for the control 
group in Her2-negative MDA-MB-231 models) and three mice per group, respectively. 
  
78 
Animals were injected once per week for 3 weeks, and tumor growth was monitored for  
21 days. To compensate for the different growth rates of inoculated tumors, the initial 
volume normalized the recorded tumor volume. Animal experiments were terminated when 
the tumor volume reached 1,500 mm3 according to the IACUC-approved protocol. 
Biodistribution was also normalized by counting 1×105 cells using flow cytometry from 
the total cell suspension prepared for each harvested organ. Data analysis was not blinded, 
but rather crosschecked by all lab members, and outliers were not excluded. 
 
3.3.2. Materials 
Trastuzumab (Herceptin® ) and ado-trastuzumab emtansine (Kadcyla® ) were 
purchased from Genentech (San Francisco, CA). Plasmid DNA-encoding trastuzumab, 
pVITRO1-Trastuzumab-IgG1/K, was obtained from Addgene (plasmid # 61883 deposited 
by Andrew Beavil). A DNA isolation kit was purchased from Clonetech (Mountain  
View, CA). Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate linked  
DM1 (SMCC-DM1) was acquired from MedKoo Bioscience (Morrisville, NC).  
1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)-NHS (DMPE-
PEG-NHS, MW= 5 kDa) was purchased from Nanocs (New York, NY). All other materials 
were purchased from Thermo Fisher Scientific (Waltham, MA). All cancer cell lines and 
NK92 cells were purchased from ATCC (Manassas, VA). X-VIVO 15 and IL-2 were 
purchased from Lonza (Walkersville, MD) and Peprotech (Rocky Hill, NJ), respectively. 
Cell counting kit (CCK-8) was obtained from Dojindo Molecular Technologies 
(Kumamoto, Japan). Cell activation cocktail, brefeldin A, and monensin were acquired 
from Biolegend (San Diego, CA). All other cell culture products were purchased from 
 Thermo Fisher Scientific (Waltham, MA). All antibodies were acquired from Miltenyi 
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Biotec (Bergisch Gladbach, Germany), except for the Alexa 488-conjugated goat  
anti-human IgG (H+L) antibody (Thermo Fisher). Human IgG total ELISA kit and human  
IFN-γ ELISA kit were acquired from eBioscience (San Diego, CA) and R&D Systems 
(Minneapolis, MN), respectively. Matrigel™ Matrix HC was obtained from Fisher 
Scientific (Bedford, MA). Tissue dissociation kit, gentleMACS Dissociator, and associated 
materials were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). 
 
3.3.3. Cell Culture 
Human SK-BR-3 and MDA-MB-231 breast cancer cells were maintained in 
McCoy’s 5A media and RPMI 1640 media, respectively. Human Calu-3 lung cancer cells 
were maintained with RPMI 1640 media. Jurkat cells were grown in RPMI 1640. Cancer 
cell and Jurkat cell media were supplemented with 10% FBS, 100 U/mL penicillin,  
and 100 μg/mL streptomycin. Human NK92 cells were maintained in X-VIVO 15,  
containing 500 U/mL IL-2, 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.  
FreeStyle™ 293-F cells were grown in a shaker incubator with FreeStyle™ 293 expression 
media according to the manufacturer’s instructions.  
 
3.3.4. Generation of Recombinant Trastuzumab 
Freestyle™ 293-F cells were transfected with pVITRO1-Trastuzumab-IgG1/K under 
the conditions specified by the Expi293 expression kit (Thermo Fisher Scientific). 
Transfected cells were grown over 72 hours, and the culture media—containing secreted 
trastuzumab (TZ)—was collected. The culture media was dialyzed against PBS for  
24 hours at 4°C, passed through 0.22 μm filter, and purified by FPLC (NGC Scout™ System, 
Bio-Rad, Hercules, CA) equipped with a protein G affinity column (Thermo Fisher 
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Scientific). FPLC-purified TZ was dialyzed against PBS at 4°C using a Slide-A-Lyzer G2 
dialysis cassette (MWCO 20 kDa) and stored at -80°C until use.  
 
3.3.5. Synthesis of T-DM1 
T-DM1 was prepared by conjugating SMCC-DM1 to TZ. SMCC-DM1 was 
dissolved in DMSO at a concentration of 2 mg/mL, and a 5, 10, or 15 molar excess of  
SMCC-DM1 was added to 2 mg of TZ dissolved in PBS. The reaction mixture was stirred 
for 2 hours at room temperature. Unconjugated SMCC-DM1 was removed via overnight 
dialysis (MWCO 20 kDa) against PBS at 4°C. The resulting T-DM1 was further purified 
by FPLC using a protein G affinity column followed by an additional dialysis  
(MWCO 20 kDa). Samples of T-DM1 were submitted to the University of Utah Mass  
Spectrometry & Proteomics Core, and the drug-to-antibody ratio (DAR) of each 
synthesized T-DM1 was calculated from the LC-ESI/MS spectrum. DAR was calculated 
with Equation 3.1. 
 
DAR = ∑ (number of drugs × AUC) / Total AUC                     (3.1) 
 
3.3.6. Antibody Activity 
Her2-binding was determined for TZ and T-DM1 synthesized with different molar 
ratios. All antibodies and ADCs were labeled with FITC. SK-BR-3 cells and MDA-MB-
231 cells were incubated with 5 μg of FITC-conjugated TZ, T-DM1, Herceptin® , and 
Kadcyla®  and the resulting fluorescent signal was measured by flow cytometry 
(FACSCanto™, BD Bioscience). Collected data were analyzed by FlowJo software. 
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3.3.7. Cytotoxicity of T-DM1 
Cytotoxicity of all synthesized T-DM1 was compared to Kadcyla® . Her2-positive 
SK-BR-3 cells and Her2-negative MDA-MB-231 cells—1×104 cells/well—were seeded 
on a 48-well plate, and serially diluted T-DM1 or Kadcyla®  was added to the media. After 
48-hour incubation, the resulting cancer cell death was analyzed by MTT assay. Data were 
analyzed with GraphPad Prism 6 software using a four-parameter logistic nonlinear 
regression model. Subsequent studies used the T-DM1 prepared with a molar ratio of 10. 
 
3.3.8. Surface Engineering of Jurkat Cells and NK92 Cells 
Lipid-PEG-conjugated TZ (DMPE-TZ) or T-DM1 (DMPE-T-DM1) was prepared by 
mixing 2 mg of TZ or T-DM1 dissolved in PBS with 15 molar excess of  
DMPE-PEG-NHS dissolved in DMSO. The reaction mixture was stirred at room 
temperature for 2 hours. Unconjugated DMPE-PEGs were removed via overnight dialysis 
(MWCO: 20 kDa) against PBS at 4°C. Jurkat cells and NK92 cells were modified with 
DMPE-TZ and DMPE-T-DM1 to generate SE-JK/TZ cells, SE-JK/T-DM1 cells,  
SE-NK/TZ cells, and SE-NK/T-DM1 cells. Briefly, 5×105 Jurkat cells or NK92 cells were 
incubated with different amounts of DMPE-TZ or DMPE-T-DM1 in 100 μL PBS at room 
temperature for 15 minutes. After the modification, cells were washed twice  
with 1 mL PBS.  
 
3.3.9. Characterization of Surface-Engineered Effector Cells 
Jurkat cells and NK92 cells were modified with FITC-labeled DMPE-TZ and 
DMPE-T-DM1 according to the procedure described above. Surface-engineered effector 
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cells were visualized by confocal microscopy (Nikon A1R, Nikon). Collected images were 
processed with ImageJ software. Changes in cell viability and proliferative functions after 
the modification were determined using CCK-8. Changes in absorbance were recorded 
over 48 hours. Surface retention times of TZ and T-DM1 on the cells membrane were 
measured using Alexa 488-conjugated goat anti-human (H+L) antibodies  
(Ex/Em= 495/520 nm). The SE-JK/TZ cells and SE-NK/T-DM1 cells were incubated in 
complete media. At each time point, a portion of cells were withdrawn and labeled with  
10 μg of Alexa 488-conjugated goat anti-human (H+L) antibodies. Fluorescent signal was 
measured by flow cytometry and analyzed by FlowJo software. 
The amount of T-DM1 embedded on the cell membrane was determined using a 
Human IgG total ELISA kit (detection limit: 15.6 - 1,000 pg/mL). Proteins from  
1×105 SE-NK/T-DM1 cells or SE-JK-T-DM1 cells prepared with different amounts of  
T-DM1 were extracted through differential lysis, and the lysate collected from the 
membrane fraction was analyzed. The amount of human IgG was calculated using the  
T-DM1 standard curve. NK92 cells and Jurkat cells were modified with 100 μg DMPE-TZ 
or DMPE-T-DM1 in all subsequent studies. The amounts of TZ and T-DM1 were scaled 
up according to the effector-to-target (E:T) ratio for each experimental condition involving 
single or co-treatment.   
 
3.3.10. Selective Binding and Transfer of TZ and T-DM1 from  
Surface-Engineered Effector Cells to Cancer Cells 
To test the selective binding of surface-engineered effector cells, SK-BR-3 cells, 
Calu-3 cells, and MDA-MB-231 cells were labeled with 2 μM of CellTracker™ Red 
CMTPX (Ex/Em= 577/602 nm). Cancer cells— 4×104 cells/well—were seeded 24-well 
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plate. Jurkat cells and NK92 cells were labeled with 1 μM of CellTracker™ Blue CMAC 
(Ex/Em= 353/466 nm) prior to modification. Cancer cells were co-incubated with  
SE-JK/TZ cells, SE-NK/T-DM1 cells, Jurkat cells with TZ co-treatment (TZ+Jurkat cells), 
NK92 cells with T-DM1 co-treatment (T-DM1+NK92 cells), unmodified Jurkat cells, and 
unmodified NK92 cells at E:T ratio of 5:1 or 10:1. After 2 hours, unbound Jurkat cells and 
NK92 cells were removed, and all remaining cells were collected. The number of effector 
cells was quantified per 1×104 cancer cells by flow cytometry and the remaining E:T ratio 
was calculated.    
An experimental approach similar to the selective binding study has been used to 
demonstrate the transfer of TZ and T-DM1 from the surface-engineered effector cells to 
target cancer cells. SK-BR-3 cells, Calu-3 cells, and MDA-MB-231 cells were labeled  
with 2 μM of CellTracker™ Red CMTPX and seeded on a Lab-Tek™ II 8-chambered 
coverglass at a density of 1×104 cells/well. Jurkat cells and NK92 cells were labeled  
with 1 μM of CellTracker™ Blue CMAC and subsequently modified with 100 μg of 
DMPE-TZ-FITC and DMPE-T-DM1-FITC. After the modification, 1×105 effector cells 
were incubated with the cancer cells for 30 minutes at room temperature and washed twice 
to remove the unbound effector cells. Co-incubated cells were imaged by confocal 
microscopy (60) and collected images were processed by ImageJ software. 
 
3.3.11. Internalization of Transferred T-DM1 into Cancer Cells 
Cancer cells were seeded on a Lab-Tek™ II 8-chambered coverglass at a density  
of 1×104 cells/well and labeled with NucBlue®  Live ReadyProbe Reagent  
(Ex/Em= 360/460 nm). Cancer cells were treated with T-DM1-FITC or CMPTX-labeled 
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SE-NK/T-DM1-FITC cells at E:T ratio of 10:1. Unbound T-DM1-FITC and  
SE-NK/T-DM1-FITC cells were removed after 30 minutes. As a positive control, 
geldanamycin (GA) was added to the wells treated with T-DM1-FITC at a final 
concentration of 3 μM. Internalization of T-DM1-FITC (Ex/Em= 495/520 nm) was imaged 
by confocal microscopy (60) at the initial time point and 6 hours later. Collected images 
were processed with ImageJ software.   
 
3.3.12. Cytotoxicity Assay 
SK-BR-3 cells, Calu-3 cells, and MDA-MB-231 cells were labeled with 
CellTracker™ Blue CMAC and seeded at 1×104 cells/well on a 48-well plate 24 hours 
before the treatment. Cancer cells were co-incubated with SE-JK/TZ cells, SE-JK/T-DM1 
cells, SE-NK/TZ cells, and SE-NK/T-DM1 cells at E:T ratio of 5:1 or 10:1 in 600 μl of 
complete media. As control treatments, cancer cells were co-incubated with unmodified 
Jurkat cells, unmodified NK92 cells, TZ, T-DM1, TZ+Jurkat cells, Jurkat cells with  
T-DM1 co-treatment (T-DM1+JK cells), T-DM1+NK92 cells, or NK92 cells with TZ 
 co-treatment (TZ+NK92 cells). All cells were harvested, labeled with the Annexin V 
Alexa Fluor®  488 and propidium iodide (Annexin V/PI) kit, and analyzed by flow 
cytometry after 24 hours of co-incubation. To determine the targeted anti-cancer efficacy, 
all treatments were washed 2 hours after the co-culture, and the remaining cancer-bound 
effector cells were further incubated for 24 hours. All cells were collected and labeled with 
the Annexin V/PI kit. Cancer cell death was analyzed by flow cytometry. To distinguish 
the effects of T-DM1 and NK92 cells, cancer cells were co-incubated with SE-JK/TZ cells,  
SE-JK/T-DM1 cells, SE-NK/TZ cells, SE-NK/T-DM1 cells, and other corresponding 
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control treatments for 6 hours. Resulting cancer cell death was identified with the Annexin 
V/PI kit under flow cytometry. All collected results were analyzed by FlowJo software.  
 
3.3.13. Mechanistic Studies 
SK-BR-3 cells were labeled with CellTracker™ Blue CMAC and seeded at  
1×104 cells/well on a 48-well plate. SK-BR-3 cells were co-incubated with SE-NK/T-DM1 
cells, NK92 cells, T-DM1, and T-DM1+NK92 cells in the presence or absence of 50 U/mL 
of IL-2 at E:T ratio of 10:1. After 2 hours, unbound effector cells were removed, and the 
remaining cells were continuously incubated for 24 hours. Cancer cell death induced by 
each treatment was analyzed by flow cytometry as described above. Culture media from 
each well was applied to a human INF-γ ELISA to determine the level of secreted INF-γ. 
Expression of CD107a was detected by co-incubating the effector cells with  
SK-BR-3 cells, Calu-3 cells, or MDA-MB-231 cells. Cancer cells were seeded on  
a 96-well plate at a density of 2×104 cells/well; SE-NK/T-DM1 cells, NK92 cells  
and T-DM1+NK92 cells were added to each well at E:T ratio of 10:1. Unmodified  
NK92 cells stimulated with cell activation cocktail containing phorbol-12-myristate-13-
acetate (PMA) and ionomycin were included as a positive control. Anti-CD107a-FITC 
antibodies (Clone: H4A3), 10 µg, were added directly into each well. After the cells  
were incubated at 37°C for 1 hour, brefeldin A and monensin were added to each  
well according to the manufacturer’s protocol and incubated for an additional 5 hours.  
All cells were collected, stained with anti-CD56-APC antibodies (clone: REA196) to 
identify NK92 cells, and examined by flow cytometry. Collected results were analyzed 
with FlowJo software. 
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3.3.14. In Vivo Tumor Efficacy Study 
In vivo studies were conducted with 6-week-old female NSG mice. Each mouse was 
inoculated with 1×107 cells of Her2-positive Calu-3 cells or Her2-negative MDA-MB-231 
cells suspended in PBS with 10% (v/v) Matrigel™. Tumor-inoculated mice were randomly 
assigned to each experimental group upon tumor establishment. The control group  
(n=4 for Calu-3 model and n=3 for MDA-MB-231 model) received no treatment, but the 
study groups (n=4 per group) were administered weekly with 0.21 mg of T-DM1,  
1×107 NK92 cells, 0.21 mg of T-DM1+1×107 NK92 cells, 5×106 SE-NK/T-DM1 cells, or 
1×107 SE-NK/T-DM1 cells via tail vein infusion. The tumor size was measured three times 
per week, and the tumor volume was calculated using Equation 3.2: where a is the long 
diameter, and b is the short diameter of the tumor. Tumor progression was monitored for  
 
V= 0.5ab2     (3.2) 
 
21 days, and the relative tumor volume was calculated by dividing the recorded volumes 
with the initial volume.  
 
3.3.15. Biodistribution 
Biodistribution of SE-NK/T-DM1 cells was analyzed using a flow cytometry 
technique that quantifies organ-trafficking cells.20,33-35 This approach provides an  
analysis that agrees well with image-based biodistribution analyses, such as  
radiolabeling and bioluminescent imaging.33,34 NSG mice bearing Calu-3 tumors  
were randomly assigned to each experimental group. The control group (n=3)  
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received no treatment, and the study groups (n=3) were treated with 1×107 NK92 cells, 
0.21 mg of T-DM1+1×107 NK92 cells, or 1×107 SE-NK/T-DM1 cells via tail vein  
infusion. Animals were sacrificed 24 hours after the injection, and the heart, kidneys, 
 liver, lungs, spleen, and tumor were harvested. Single-cell suspension of each  
harvested organ was prepared using the gentleMACS dissociator and tissue dissociation 
kits. Half of each cellmixture was incubated with 30 μg of an anti-CD56-APC  
antibody (clone: REA196,Ex/Em= 650/660 nm) for 30 minutes at 4°C. Cells were  
washed twice with coldPBS, and the presence of NK92 cells was detected by counting 
1×105 total cells using flow cytometry. Collected results were analyzed by FlowJo. 
 
3.3.16. Statistical Analysis 
Statistical analysis was performed using Graphpad Prism 6. All data are  
presented in mean ± SD. All data were analyzed with one-way ANOVA with Tukey  
post-hoc tests or two-way ANOVA with Bonferroni post-hoc tests. Statistical significance  
threshold of each test was set at P < 0.05: ns = not significant; P > 0.05; *, P < 0.05; **,  
P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
 
3.3.17. Animal Ethics 
All animal experiments were approved by the University of Utah Institutional 
Animal Care and Use Committee. Described animal procedures were conducted  




3.4.1. Design of SE-NK/ADC Cells as Chemoimmunotherapy 
We recently described that bioactive molecules including proteins, peptides, and 
imaging agents could be incorporated into the cell surface for targeted delivery or in vivo 
real-time tracking.31,32 With this understanding, we have generated the SE-NK/ADC cells 
to combine targeted chemotherapy and cell-based immunotherapy in a single formulation 
(Figure 3.1). Allogeneic NK92 cells that expand to a large population in ex vivo conditions 
can be rapidly transformed into SE-NK/ADC cells. These surface-engineered NK92 cells 
with ADCs can induce a combinatorial anti-cancer efficacy at the tumor site through the 
cytotoxicity of ADCs and direct cytolytic activity of NK92 cells. 
 
3.4.2. Synthesis of T-DM1 
SMCC-DM1 was conjugated to the recombinant anti-Her2 mAb (Trastuzumab, TZ) 
at molar ratios (SMCC-DM1/TZ) of 5, 10, or 15 (Figure 3.2). FPLC purification profiles 
of TZ and T-DM1 products are shown in Figure 3.3. The resulting species of T-DM1 were 
analyzed using ESI/MS to calculate the drug-to-antibody ratios (DARs) (Figure 3.4, 3.5, 
3.6). The calculated DARs for T-DM1 R=5, R=10, or R=15 were 1.04, 2.18, or 3.18, 
respectively. Synthesized T-DM1 and Kadcyla®  induced cell death in SK-BR-3 cells, but 
not in MDA-MB-231 cells (Figure 3.7, 3.8). The LC50 of T-DM1 R=5, 10, and 15 were 
0.275 μg/mL, 0.044 μg/mL, and 0.024 μg/mL, respectively, on SK-BR-3 cells. T-DM1 
R=10 demonstrated comparable anti-cancer activity to Kadcyla® , whose LC50 was  
0.040 μg/ml in SK-BR-3 cell T-DM1 R=10 was therefore selected for the cell surface 



















Figure 3.1. Illustration of SE-NK/ADC cells and their mechanism of actions. As a model ADC, T-DM1 specific for Her2 has been 
selected. The lipid-PEG-conjugated ADCs are prepared as a ready-to-use formulation while allogeneic NK92 cells are available from a 
cell bank. The surface-engineered NK92 cells engrafted with ADCs migrate toward the target tumor site guided by the recognition of 
target antigen. In the target tumor tissues, ADCs induce apoptosis in cancer cells and NK92 cells present in proximity destroy the 





















Figure 3.2. Synthesis of T-DM1, DMPE-TZ, and DMPE-T-DM1. (a) Different molar 
excess of SMCC-DM1 reconstituted in DMSO was added to TZ dissolved in PBS. 
Mixtures were continuously stirred at room temperature for 2 hours. Product was dialyzed 
(MWCO 20 kDa) overnight against PBS at 4°C and further purified by FPLC using a 
protein G affinity column. FPLC-purified T-DM1 was dialyzed (MWCO 20 kDa) 
overnight against PBS at 4°C. (b, c) TZ or T-DM1 was mixed with 15 molar excess of 
DMPE-PEG-NHS dissolved in DMSO. Each mixture was stirred at room temperature for 








































































































































Figure 3.7. Cytotoxicity of Kadcyla®  and T-DM1s synthesized with different ratio of 
SMCC-DM1 in SK-BR-3 cells. The LC50 of T-DM1 R=5, R=10, R=15, and Kadcyla®  
were 0.275 μg/ml, 0.044 μg/ml, 0.024 μg/ml, and 0.040 μg/ml, respectively. Data presented 























Figure 3.8. Cytotoxicity of Kadcyla®  and T-DM1s synthesized with different ratio of 
SMCC-DM1 in MDA-MB-231 cells. Kadcyla®  and T-DM1s only induced nonspecific 




ADCs with high DARs tend to form aggregates, which can cause rapid clearance from the 
body due to the increased hydrophobicity.36 The binding activity of recombinant TZ and 
the synthesized T-DM1 R=10 was compared to that of Herceptin®  and Kadcyla®  in  
Her2-positive SK-BR-3 cells and Her2-negative MDA-MB-231 cells, respectively. TZ and 
T-DM1 prepared in our laboratory showed the same antibody binding activity as 
Herceptin®  and Kadcyla®  (Figure 3.9). 
 
3.4.3. Generation of Surface-Engineered Cells 
To precisely demonstrate the combined anti-cancer activity of SE-NK/T-DM1 cells, 
the effects of individual components—DM1, TZ, and NK92 cells—must be identified. 
Since Jurkat cells are CD3- and CD4-positive T cells that do not have direct cytolytic 
activities, this cell line was selected as a surrogate negative control for NK92 cells. We 
therefore prepared Jurkat cells modified with TZ (SE-JK/TZ) or T-DM1 (SE-JK/T-DM1) 
and NK92 cells modified with TZ (SE-NK/TZ) or T-DM1 (SE-NK/T-DM1) in addition to 
the unmodified cells. 
Jurkat cells were uniformly modified with various amounts of DMPE-TZ to generate 
the SE-JK/TZ cells (Figure 3.10). The cell viability and proliferation of Jurkat cells were 
not affected upon modification (Figure 3.11a, b). To investigate the retention time of TZ 
on the cell membrane in the presence of serum, FITC-labeled goat anti-human (H+L) 
antibody was used to detect TZ on the SE-JK/TZ cells. Even though the fluorescence 
intensity decreased partly due to cell proliferation and loss of TZ to the media over time, 
TZ was detected on the modified cells incubated in the complete growth media over  



















Figure 3.9. Antigen-specific binding of TZ and T-DM1. Antibody binding activities of TZ, T-DM1 R=10, Herceptin® , and Kadcyla®  
















Figure 3.10. Confocal images of SE-JK/TZ cells. Jurkat cells, 5×105 cells, were modified 



















Figure 3.11. Cell viability (a) and cell proliferation (b) of SE-JK/TZ cells compared to 























Figure 3.12. Retention time of TZ on the surface of SE-JK/TZ cells in the presence of 10% serum. SE-JK/TZ cells, 1×105 cells, were 
collected at each time point and mixed with FITC-labeled goat anti-human antibodies. Fluorescent intensity was measured by flow 





challenge, this result suggests that the modified cells may circulate in the body long enough 
to bind to the target tumor tissues. The optimal amount of DMPE-TZ required for reliable 
modification of 5×105 cells was determined to be 100 μg. Jurkat cells and NK92 cells  
were further modified with DMPE-T-DM1 to generate the SE-JK/T-DM1 cells and  
SE-NK/T-DM1 cells, respectively (Figure 3.13). Despite the fact that T-DM1 may lead to 
NK92 cell death, the surface engineering with DMPE-T-DM1 had no influence on the 
NK92 cell viability and proliferation (Figure 3.14a, b). Unlike other subtypes of NK cells, 
NK92 cells lack CD16, CD32 and CD64 IgG receptors that can initiate antibody 
internalization and antibody-dependent cellular cytotoxicity (ADCC).37 This characteristic 
receptor expression protects NK92 cells from the membrane-embedded ADCs. Retention 
time of T-DM1 on the SE-NK/T-DM1 cells was tested beyond 24 hours (Figure 3.15). This 
result confirms that TZ or T-DM1 could reside on the cell surface for 48 hours. Surface 
engineering of Jurkat cells or NK92 cells with TZ or T-DM1 was well-tolerated because 
the TZ or T-DM1, embedded in the cell membrane through the lipid-PEG, did not 
internalize into the cells.38  
NK cell-specific receptors should still be available following the surface 
modification. NK92 cells express a broad spectrum of activating receptors, including 
NKp30, NKp46, 2B4, NKG2D, NKG2E, and CD56.39 We observed the availability of two 
NK cell markers, CD56 and 2B4, on the surface of the SE-NK/T-DM1 cells because those 
receptors are necessary for cytolytic activity, cell adhesion, and NK92 cell activation.39 
CD56 and 2B4 were available on the SE-NK/T-DM1 cells (Figure 3.16), indicating that 
the surface engineering of NK92 cells did not interfere with the receptor accessibility and 

























Figure 3.13. Confocal images of SE-JK/T-DM1 cells and SE-NK/T-DM1 cells. NK92  
cells or Jurkat cells were modified with 100 µg of DMPE-T-DM1-FITC. Immediately after 
the washing, cells suspended in HBSS were observed under confocal microscope. Scale 



























Figure 3.14. Influence of surface modification with T-DM1 on NK92 cell viability  
and proliferation. (a) Cell viabilities of the SE-NK/T-DM1 cells and unmodified  
NK92 cells. Data represent mean ± SD. (b) Proliferation of the SE-NK/T-DM1 cells  
and unmodified NK92 cells. The SE-NK/T-DM1 cells were generated with 50 μg, 100 μg, 
or 200 μg of DMPE-PEG-T-DM1 and compared to unmodified NK92 cells. Data presented 

























Figure 3.15. Retention time of T-DM1 on the surface of SE-NK/T-DM1 cells. The  
SE-NK/T-DM1 cells were incubated in the presence of 10% serum. At each time point, 
1×105 SE-NK/T-DM1 cells were collected and mixed with FITC-labeled goat anti-human 
























Figure 3.16. Expression of NK92 cell receptors. The availability of CD56 and 2B4 on the 
cell membrane of SE-NK/T-DM1 cells prepared with 100 μg of DMPE-T-DM1-FITC was 




3.4.4. Selective Binding and Transfer of TZ and T-DM1 
To demonstrate the specific binding of modified immune cells to Her2-positive 
cancer, the SE-JK/TZ cells or unmodified Jurkat cells were co-incubated with  
Her2-positive SK-BR-3 cells or Her2-negative MDA-MB-231 cells at E:T ratio of 5:1 for 
2 hours and thoroughly washed to remove unbound Jurkat cells. The ratio of remaining  
SE-JK/TZ cells to SK-BR-3 cells was significantly higher than that of unmodified Jurkat 
cells after the washing. No difference was observed between the SE-JK/TZ cells and 
unmodified Jurkat cells in MDA-MB-231 cells (Figure 3.17a). To expand on this finding, 
we determined the amount of remaining NK92 cells after co-incubation of SK-BR-3 cells 
with unmodified NK92 cells, T-DM1+NK92 cells, or SE-NK/T-DM1 cells at E:T ratio 
10:1. The remaining E:T ratios of SE-NK/T-DM1 cells, T-DM1+NK92 cells, and 
unmodified NK92 cells after the removal of unbound cells were approximately 3.8, 0.5, 
and 0.3, respectively (Figure 3.17b). When the SE-NK/T-DM1 cells were treated at E:T 
ratio of 5:1, the remaining E:T ratio of SE-NK/T-DM1 cell to SK-BR-3 cells was 1.4. 
Consistently, negligible numbers of NK92 cells remained bound on Her2-negative  
MDA-MB-231 cells. These results confirm the specific binding capability of the  
surface-engineered immune effector cells—modified with TZ or T-DM1—to the target 
cancer cells. 
T-DM1 should transfer from the SE-NK/T-DM1 cells to the target cells in order to 
exert its anti-cancer activity on cancer cells. The SE-JK/TZ-FITC cells, SE-NK/TZ-FITC 
cells, SE-NK/T-DM1-FITC cells, unmodified Jurkat cells, or unmodified NK92 cells  
were co-incubated with SK-BR-3 cells or MDA-MB-231 cells; the transfer of TZ-FITC  






















Figure 3.17. TZ and T-DM1 on the surface of SE-JK/TZ cells and SE-NK/T-DM1 cells, 
respectively, increased the number of cancer-bound Jurkat and NK92 cells. (a) Remaining 
E:T ratio of cancer-bound Jurkat cells. Higher number of SE-JK/TZ cells remained bound 
to SK-BR-3 cells. (b) Remaining E:T ratio of cancer-bound NK92 cells. The number of 
cancer cells-bound NK92 cells was increased when the SE-NK/T-DM1 cells were  
co-incubated with SK-BR-3 cells. Binding of surface-engineered immune cells to  
MDA-MB-231 cells was not observed in either study. After the removal of unbound 
effector cells, the remaining Jurkat cells and NK-92 cells were counted per 1×104 cancer 
cells by flow cytometry. Data presented as mean ± SD (ns, no significant; ****P<0.0001, 
























Figure 3.18. Confocal images showing the binding of SE-JK/TZ-FITC cells,  
SE-NK/TZ-FITC cells, or SE-NK/T-DM1-FITC cells to SK-BR-3 cells or MDA-MB-231 
cells. CMTPX-labeled cancer cells (red) were co-incubated with CMAC-labeled effector 
cells (blue). These fluorescently labeled cells were co-incubated at E:T ratio of 10:1. 
Unbound effector cells were washed after 30 minutes of co-incubation and the cells were 
observed under confocal microscopy. Localization of TZ (green) and T-DM1 (green) at the 
effector cell-to-cancer cell junction is indicated with white arrows. Scale bars, 10 μm. All 





surface-engineered immune cells to the target cancer cells (Figure 3.18), TZ and T-DM1 
migrated toward the contact area, formed clusters at the effector cell-to-cancer cell junction 
(Figure 3.18, white arrows), and subsequently transferred to the target cancer cells. This 
observation suggests the lipid raft involvement of DMPE-TZ and DMPE-T-DM1 anchored 
on the cell membrane.40 In contrast, these events did not occur with MDA-MB-231 cells 
(Figure 3.18). These results reveal that the SE-NK/T-DM1 cells or SE-NK/TZ cells are 
able to specifically recognize and bind to Her2-positive cancer cells; thereafter, T-DM1 
embedded on the surface of NK92 cells can relocate onto the cancer cell membrane. 
Internalization of T-DM1, which may occur through receptor-mediated and clathrin-
dependent endocytosis, is critical for the anti-cancer efficacy of T-DM1 because DM1 acts 
on intracellular targets in cancer cells.23,41 With the knowledge of previously reported 
observations on cellular uptake of T-DM1, trafficking of T-DM1 to lysosomes, and release 
of DM1,42 we have focused on confirming the internalization of T-DM1 that has been 
transferred from the SE-NK/T-DM1 cells. Distinct fluorescent dots representing the 
internalized T-DM1 following the transfer from the SE-NK/T-DM1 cells were detected in 
the cytoplasm (Figure 3.19). To confirm that the fluorescence intensity represents T-DM1, 
cancer cells—used as a positive control—were co-treated with T-DM1 and geldanamycin 
(GA), the latter of which is a Hsp90 inhibitor that induces rapid internalization of TZ bound 
to Her2.43 The T-DM1 internalization was facilitated in the presence of GA in SK-BR-3 
cells as expected (Figure 3.19). Although the fluorescent intensity was low, we confirmed 
that the fluorescence pattern of T-DM1 observed in the cytosol of cancer cells upon the 
transfer from the SE-NK/T-DM1 cells was similar to the internalized T-DM1 induced by 






















Figure 3.19. Internalization of transferred T-DM1 into Her2-positive SK-BR-3 cells. 
Cancer cells were labeled with Nucblue®  nuclear stain (blue) and NK92 cells were labeled 
with CMTPX (red). Cancer cells were treated with 5 μg of T-DM1-FITC or  
SE-NK/T-DM1-FITC cells at E:T ratio of 10:1. Unbound effector cells were removed after 
30 minutes of incubation. As a positive control, GA was added at a final concentration of  
3 μM. Cells were imaged immediately after removing unbound cells and after 6 hours of 
incubation by confocal microscopy. Scale bars, 10 μm. All images are representative of 





with the identical conditions used in SK-BR-3 cells (Figure 3.20), confirming the 
insignificant anti-cancer activity of SE-NK/TZ cells and SE-NK/T-DM1 cells against 
Her2-negative cancer cells.  
 
3.4.5. Anti-Cancer Activity of SE-NK/T-DM1 Cells 
To demonstrate the therapeutic benefits of SE-NK/T-DM1 cells over the  
co-treatment of NK92 cells with T-DM1 (T-DM1+NK92 cells), we compared the  
anti-cancer activity of SE-NK/T-DM1 cells to that of T-DM1+NK92 cells. For accurate 
comparison, we first quantified the amount of T-DM1 on the membrane of  
surface-engineered cells. The SE-JK/T-DM1 cells or SE-NK/T-DM1 cells were 
fractionated by differential lysis, and the amount of T-DM1 in the cell membrane fraction 
was measured (Figure 3.21a, b). Preparation of 1×105 SE-NK/T-DM1 cells with 50 μg,  
100 μg, 200 μg of DMEP-T-DM1 contained approximately 1.2 μg, 2.1 μg, or 3.3 μg of  
T-DM1, respectively, on the membrane (Figure 3.21a). Identical numbers of  
SE-JK/T-DM1 cells modified with 50 μg, 100 μg, or 200 μg of DMEP-T-DM1 contained 
approximately 1.0 μg, 1.6 μg, or 2.2 μg of T-DM1, respectively, on the membrane (Figure 
3.21b). In the subsequent experiments, the amount of TZ or T-DM1 for the co-treatment 
groups was determined to be 2.1 μg per 1×105 surface-engineered effector cells, which is 
equivalent to the amount of T-DM1 contained on the surface of 1×105 SE-NK/T-DM1 cells 
prepared by 100 μg of DMPE-T-DM1. To confirm if the SE-NK/T-DM1 cells and  
T-DM1+NK92 cells induce the same levels of cancer cell death, cancer cells were 
continuously exposed to each formulation for 24 hours. Both SE-NK/T-DM1 cells and  






















Figure 3.20. Internalization of transferred T-DM1 into Her2-negative MDA-Mb-231 cells. 
Cancer cells were labeled with Nucblue®  nuclear stain (blue) and NK cells were labeled 
with CMTPX (red). MDA-MB-231 cells were treated with 5 μg of T-DM1-FITC or  
SE-NK/T-DM1-FITC cells at E:T ratio of 10:1. Unbound effector cells were removed after 
30 minutes of incubation. As a positive control, GA was added at a final concentration of  
3 μM. Cells were imaged immediately after removing unbound cells and after 6 hours of 
incubation by confocal microscopy. No intracellular uptake of T-DM1 was observed. Scale 



























Figure 3.21. Amounts of T-DM1 embedded on the cell membrane. The SE-NK/T-DM1 
cells or SE-JK/T-DM1 cells were generated with 50, 100, and 200 μg of DMPE-T-DM1. 
The membrane faction of cell lysate was collected by the differential lysis of  
SE-NK/T-DM1 cells or SE-JK/T-DM1 cells (1×105 cells). The amount of T-DM1 in the 
cell membrane fraction of (a) SE-NK/T-DM1 cells or (b) SE-JK/T-DM1 cells was 
quantified by a human IgG ELISA. Number represents the average amount of T-DM1 on 
































Figure 3.22. Long-term incubation of SE-NK/T-DM1 cells with (a) Her2-positive  
SK-BR-3 cells or (b) Her2-negative MDA-MB-231 cells. Cancer cells labeled with CMAC 
were co-incubated with SE-NK/T-DM1 cells, NK92 cells, T-DM1, or T-DM1+NK92 cells 
at E:T ratio of 5:1 or 10:1. After 24 hours, all cells were collected and Annexin V/PI assays 
were performed using flow cytometry. Data presented as mean ± SD (ns, not significant, 







indicating that there was no difference in the exposed amount ofT-DM1 between groups  
treated with the SE-NK/T-DM1 cells and those co-treated with T-DM1+NK92 cells. This 
observation also implied that continuous exposure to the T-DM1+NK92 cells treatment 
would allow enough time for NK92 cells to identify dying cancer cells affected by T-DM1 
in a confined well system. In MDA-MB-231 cells, only the anti-cancer activity of NK92 
cells was observed in both treatment groups (Figure 3.22b). 
Second, cancer cells were incubated with the effector cells for 2 hours; subsequently, 
the unbound effector cells were thoroughly removed in order to mimic the in vivo cancer 
homing effect. The remaining cancer-bound effector cells were further incubated with the 
target cells for 24 hours, and the resulting cancer cell death was recorded. In SK-BR-3 cells, 
we found that the level of cancer cell death induced by the SE-NK/T-DM1 cells was higher 
than that induced by the NK92 cell and T-DM1+NK92 cells (Figure 3.23a). This is due to 
the fact that a higher number of SE-NK/T-DM1 cells remained bound to SK-BR-3 cells, 
resulting in an augmented anti-cancer activity. Again, no significant cell death was noticed 
in MDA-MB-231 cells (Figure 3.23b). 
Third, we assessed the effect of chemotherapeutic agents on the surface-engineered 
effector cells on cancer cell viability. The effector cells and cancer cells were co-incubated 
for 6 hours, and the cancer cell viability was measured. Levels of cancer cell death induced 
by the SE-JK/TZ cells and SE-JK/T-DM1 cells were compared to identify the anti-cancer 
effect of DM1. As expected, T-DM1 exhibited a greater cytolytic effect against SK-BE-3 
cells than TZ (Figure 3.24a). The resulting cancer cell death was due to the addition  
of DM1 and Jurkat cells—lacking cytolytic effects—and did not show supportive effects. 










































Figure 3.23. Short-term incubation of SE-NK/T-DM1 cells with (a) SK-BR-3 cells and  
(b) MDA-MB-231 cells demonstrated targeted anti-cancer activity. Cancer cells labeled 
with CMAC were co-incubated with SE-NK/T-DM1 cells, NK92 cells, or T-DM1+NK92 
cells at E:T ratio of 5:1 or 10:1. Unbound cells were thoroughly removed 2 hours after the 
treatment and the remaining cell mixtures were incubated for additional 24 hours. The 
cancer cell death was measured by the Annexin V/PI kit and flow cytometry. Data 


























Figure 3.24. Effects of DM1 on cancer cell death. The targeted anti-cancer activity of  
T-DM1 was isolated by comparing the cancer cell death induced by the treatment of  
SE-JK/TZ cells and SE-NK/T-DM1 cells in (a) SK-BR-3 cells or (b) MDA-MB-231 cells. 
All effector cells were co-incubated with CMAC-labeled cancer cells at E:T ratio of 10:1 
and the amount of TZ or T-DM1 co-treated with Jurkat cells was equivalent to the T-DM1 
amount embedded on the SE-NK/T-DM1 cells as shown in Figure 3.20. All cells were 
collected after 6 hours of co-incubation. Cancer cell death was determined by the flow 
cytometry-based Annexin V/PI analysis. Data presented as mean ± SD (ns, not significant, 







MDA-MB-231 cells (Figure 3.24b). After changing the effector cells from Jurkat cells to 
NK92 cells, the SE-NK/TZ cells showed augmented cancer cell deaths in comparison to 
TZ alone, TZ+NK92 cells, and unmodified NK92 cells (Figure 3.25a). The treatments 
involving T-DM1 further enhanced the anti-cancer activity against Her2-positive cancer 
cells, and the SE-NK/T-DM1 cells exhibited a superior anti-cancer activity over all 
treatments (Figure 3.25a). We postulated that DM1 contained in T-DM1 had induced an 
increase of approximately 20% in the death of Her2-positive cancer cells. Except for the 
nonspecific cytolytic activity of NK92 cells, none of the treatments induced significant 
cytotoxicity in MDA-MB-231 cells (Figure 3.25b). It is thus acceptable to state that the 
anti-cancer activity of SE-NK/TZ cells or SE-NK/T-DM1 cells against MDA-MB-231 
cells is confined to the innate cytolytic functions of NK92 cells with negligible effects from 
TZ or T-DM1. 
Finally, we have identified the cytolytic activity of NK92 cells by comparing the  
SE-JK/TZ cells to SE-NK/TZ cells and the SE-JK/T-DM1 cells to SE-NK/T-DM1 cells. 
Unlike Jurkat cells, NK92 cells showed cytolytic activity in SK-BR-3 cells (Figure 3.26a). 
Comparing the TZ+Jurkat cells to TZ+NK92 cells, NK92 cells were observed to induce 
roughly 25% more cancer cell death. With surface engineering, the SE-NK/TZ cells 
showed approximately 47% higher cancer cell death than the SE-JK/TZ cells. In contrast, 
only the cytolytic activity of NK92 cells was observed when MDA-MB-231 cells  
(Figure 3.26b) were exposed to the same treatment stated in Figure 3.25a. Similarly,  
T-DM1+NK92 cells caused nearly 27% more cancer cell death compared to  
T-DM1+Jurkat cells (Figure 3.27a). The SE-NK/T-DM1 cells induced approximately  






















Figure 3.25. Anti-cancer activity of T-DM1 contained in the SE-NK/T-DM1 cells against 
(a) SK-BR-3 cells and (b) MDA-MB-231 cells. All effector cells were co-incubated with 
CMAC-labeled cancer cells at E:T ratio of 10:1. The amount of TZ or T-DM1 used for the 
co-treatment with NK92 cells was identical to the amount T-DM1 found in SE-NK/T-DM1 
cells as shown in Figure 3.20. After 6 hours of incubation, all cells were collected and the 
cancer cell death was analyzed by the flow cytometry-based Annexin V/PI analysis. Data 
presented as mean ± SD (ns, not significant, ****P<0.0001, by one-way ANOVA followed 






































Figure 3.26. Cancer cell death induced by SE-NK/TZ cells and SE-JK/TZ cells in  
(a) SK-BR-3 cells and (b) MDA-MB-231 cells. All effector cells were co-incubated with  
CMAC-labeled cancer cells at E:T ratio of 10:1. The amount of TZ co-treated with Jurkat 
cells or NK92 cells was identical to the amount of T-DM1 found on the SE-NK/T-DM1 
cells as shown in Figure 3.20. After 6 hours of incubation, all cells were collected and the 
cancer cell death was analyzed by the flow cytometry-based Annexin V/PI analysis. Data 
presented as mean ± SD (ns, not significant, **P<0.01, ****P<0.0001, by one-way 
























Figure 3.27. Anti-cancer effects of SE-NK/T-DM1 cells and SE-JK/T-DM1 cells against 
(a) SK-BR-3 cells and (b) MDA-MB-231 cells. All effector cells were co-incubated with 
CMAC-labeled cancer cells at E:T ratio of 10:1. The amount of T-DM1 co-treated with 
Jurkat cells or NK92 cells was identical to the amount of T-DM1 found on the  
SE-NK/T-DM1 cells as shown in Figure 3.20. After 6 hours of incubation, all cells were 
collected and the cancer cell death was analyzed by the flow cytometry-based Annexin 
V/PI analysis. Data presented as mean ± SD. (ns, not significant, **P<0.01, ****P<0.0001, 






Consistently, no significant differences in cell death beyond the NK92 cell activity were 
shown in MDA-MB-231 cells (Figure 3.27b). These results confirm that the individual 
components contained in the SE-NK/T-DM1 cells contributed to the combinatorial  
anti-cancer effect. Moreover, embedding ADCs in NK92 cells through surface engineering 
enhanced the anti-cancer efficacy beyond the provided benefits of T-DM1 alone, NK92 
cells alone, or T-DM1+NK92 cells.  
 
3.4.6. Mechanistic Studies 
To determine whether or not cytokine release plays a crucial role in the combined 
anti-cancer activity of SE-NK/T-DM1 cells, we assessed the levels of interferon-γ (IFN-γ) 
released in the presence or absence of IL-2, a key component in retaining the activity of 
NK92 cells.44 IL-2 appeared to be essential in enhancing the cytolytic activity of 
unmodified NK92 cells (Figure 3.28a). However, IL-2 had no influence on the anti-cancer 
activity of SE-NK/T-DM1 cells. Moreover, the level of IFN-γ released was low throughout 
all treatment groups in the absence of IL-2 (Figure 3.28b). These findings reveal that IL-2 
is not critical for the combined anti-cancer activity of SE-NK/T-DM1 cells. 
To elucidate the mechanism of action of SE-NK/T-DM1 cells, expression of CD107a, 
a marker expressed with the degranulation of NK cells,45,46 was examined in the  
SE-NK/T-DM1 cells and unmodified NK92 cells upon interaction with cancer cells. As a 
positive control, the degranulation of NK92 cells was observed by detecting the appearance 
of CD107a after the PMA/Ionomycin stimulation (Figure 3.29a). The NK92 cells and  
T-DM1+NK92 cells expressed CD107a at the basal level when co-incubated with  


















Figure 3.28. Effects of IL-2 on the anti-cancer activity of SE-NK/T-DM1 cells.  
(a) CMAC-labeled SK-BR-3 cells were co-incubated with SE-NK/T-DM1 cells, T-DM1, 
NK92 cells, or T-DM1+NK92 cells at E:T ratio of 10:1. NK92 cells were maintained in 
the absence of IL-2 for 48 hours prior to the surface modification. Unbound cells were 
removed and the remaining cell mixtures were incubated for 24 hours. Annexin V/PI kit 
was used to determine the dead cancer cells by Flow cytometry. (b) Level of IFN-γ released 
from SE-NK/T-DM1 cells. The culture media was sampled from the cytotoxicity study  
(a) and the amount of IFN-γ in each collected sample was measured using the human  
IFN-γ ELISA kit (detection limit: 15.6 - 1,000 pg/mL). Bars represent mean ± SD (*P<0.05, 





























Figure 3.29. Degranulation of NK92 cells. (a) CD107a expression in NK92 cells grown in 
culture condition or under PMA/Ionomycin stimulation. CD107a expression on NK92 cells, 
T-DM1+NK92 cells, or SE-NK/T-DM1 cells co-incubated with (b) SK-BR-3 cells or  
(c) MDA-MB-231 cells. Flow cytometry was conducted to detect the CD107a expression 
from NK92 cells that have been identified by CD56 expression. Plots were selected from 








cancer cells, the CD107a expression was amplified in the SE-NK/T-DM1 cells  
co-incubated with SK-BR-3 cells at E:T ratio 10:1 (Figure 3.29b); this increase was absent 
in MDA-MB-231 cells (Figure 3.29c). We concluded that the degranulation of NK92 cells 
stimulated by the binding of SE-NK/T-DM1 cells to the target cancer cells is a favorable 
mechanism of action of the combined anti-cancer activity of SE-NK/T-DM1 cells. 
 
3.4.7. In Vivo Efficacy Studies 
Because generating Her2-positive breast cancer xenograft models using  
SK-BR-3 cells is very difficult,47 we instead developed a Her2-positive lung cancer model 
with Calu-3 cells. Before initiating the in vivo efficacy studies with this animal  
model, we had verified the in vitro anti-cancer activity of SE-NK/T-DM1 cells  
against Calu-3 cells. Briefly, T-DM1 activity against Calu-3 was determined (Figure 3.30). 
The SE-NK/T-DM1 cells were able to specifically bind to Calu-3 cells (Figure 3.31). 
Following the binding event, the fluorescence cluster formation was observed at the 
effector cell-to-cancer cell junctions, and T-DM1 was transferred from the  
SE-NK/T-DM1 cells into internal compartments of Calu-3 cells (Figure 3.32). Comparable 
levels of cancer cell death were observed when Calu-3 cells were continuously exposed to  
T-DM1+NK92 cells and SE-NK/T-DM1 cells for 24 hours (Figure 3.33). The number of 
NK92 cells bound to Calu-3 cells increased when cancer cells were co-incubated with the 
SE-NK/T-DM1 cells for a short period (Figure 3.34). Increased numbers of SE-NK/T-DM1 
cells bound to Calu-3 cells resulted in an enhanced anti-cancer activity (Figure 3.35). The 
SE-NK/T-DM1 cells expressed CD107a upon encountering Calu-3 cells, indicating the 


















Figure 3.30. Cytotoxicity of Kadcyla®  and T-DM1s synthesized with different ratios of 
SMCC-DM1 in Calu-3 cells. The LC50 of T-DM1 R=5, R=10, R=15, and Kadcyla®  was 






















Figure 3.31. Confocal images showing the binding of SE-JK/TZ cells, SE-NK/TZ cells, or SE-NK/T-DM1 cells to Calu-3 cells. 
CMTPX-labeled Calu-3 cells (red) were co-incubated with CMAC-labeled effector cells (blue). Identical procedure stated in Figure 
2.17 was followed. Localization of TZ (green) and T-DM1 (green) at the effector cell-to-cancer cell junction is indicated with white 



















Figure 3.32. Internalization of transferred T-DM1 into Her2-positive Calu-3 cells. Calu-3 
cells were labeled with Nucblue®  nuclear stain (blue) and NK92 cells were  
labeled with CMTPX (red). Calu-3 cells were treated with 5 μg of T-DM1-FITC or  
SE-NK/T-DM1-FITC cells at E:T ratio of 10:1. Unbound effector cells were removed after 
30 minutes of incubation. GA was added to T-DM1 treated Calu-3 cells at a final 
concentration of 3 μM. Cells were imaged immediately after removing unbound cells and 
after 6 hours of incubation by confocal microscopy. Scale bars, 10 μm. All images are 



























Figure 3.33. Long-term incubation of SE-NK/T-DM1 cells with Calu-3 cells.  
CMAC-labeled Calu-3 cells were co-incubated with SE-NK/T-DM1 cells, NK92 cells,  
T-DM1, or T-DM1+NK92 cells at E:T ratio of 5:1 or 10:1. After 24 hours, all cells were 
collected and Annexin V/PI assays were performed by flow cytometry. Data presented as 




























Figure 3.34. Targeted binding of SE-NK/T-DM1 cells to Calu-3 cells. CMTPX-labeled 
Calu-3 cells were co-incubated with CMAC-labeled effector cells. Calu-3 cells were 
treated with NK92 cells, T-DM1+NK cells, or SE-NK/T-DM1 cells. After 2 hours, 
unbound effector cells were removed and remaining cells were collected. NK92 cells were 
counted per 1×104 Calu-3 cells by flow cytometry. Data presented as mean ± SD 





















Figure 3.35. Short-term incubation of SE-NK/T-DM1 cells with Calu-3 cells demonstrated 
the enhanced anti-cancer activity through targeted binding. Calu-3 cells labeled with 
CMAC were co-incubated with SE-NK/T-DM1 cells, NK92 cells, T-DM1, or  
T-DM1+NK92 cells at E:T ratio of 5:1 or 10:1. Unbound cells were removed after 2 hours 
and the remaining cell mixtures are incubated for 24 hours. All cells were collected and 
Annexin V/PI assay was performed by flow cytometry. Data presented as mean ± SD. 



















Figure 3.36. Expression of CD107a on NK92 cells, T-DM1+NK92 cells, or  
SE-NK/T-DM1 cells following the co-incubation with Calu-3 cells. Flow cytometry was 
conducted to analyze the CD107a expression on NK92 cells that have been identified by 





No significant toxicity was reported on NSG mice injected with 1×107 Her2-specific 
CAR-NK cells; therefore, 1×107 surface-engineered NK92 cells were injected as  
the maximum dose.20 The amount of T-DM1 on 1×107 SE-NK/T-DM1 cells  
(100 μg formulation) was calculated to be 210 μg, which is similar to the recommended 
dose found in the literature for mice models (7-10 mg/kg).48 
We have compared the anti-cancer activity of SE-NK/T-DM1 cells to that of  
T-DM1+NK92 cells using Her2-positive Calu-3 models and Her2-negative MDA-MB-231 
models. In the Her2-positive tumor model, SE-NK/T-DM1 cells exhibited the  
strongest anti-cancer efficacy through the combinatorial effects of TZ, DM1, and NK92 
cells (Figure 3.37a). Unmodified NK92 cells were ineffective in inhibiting the  
tumor growth, while T-DM1 started to suppress the tumor growth after Day 7.  
The T-DM1+NK92 cells also significantly inhibited the tumor growth compared  
to the control. At the end-point of the study, both dosages of SE-NK/T-DM1 cells  
were effective in demonstrating substantially reduced tumor growth compared to  
the T-DM1+NK92 cells. With the benefit of enhanced anti-cancer activity, the 
chemoimmunotherapeutic approach using the SE-NK/T-DM1 cells may reduce 
the time and cost required to obtain sufficient tumor-reactive NK92 cells for patient 
infusion. In the Her2-negative tumor model, no significant tumor growth suppression  
was observed among all treatment groups (Figure 3.38a). At the end-point of the  
study, animals treated with NK92 cells, T-DM1+NK92 cells, and SE-NK/T-DM1 cells 
showed a minor suppression effect on tumor growth compared to the control  
group; however, no statistical significance was attained between the treatment groups.  











































Figure 3.37. In vivo anti-cancerr efficacy of SE-NK/T-DM1 cells in Her2-positive Calu-3 
models. (a) Tumor growth and (b) body weight of Calu-3 models. Female NSG mice (n=4) 
were inoculated with 1×107 cancer cells and the tumor volume was measured. Animals 
received weekly treatment of T-DM1, NK92 cells, T-DM1+NK92 cells, or SE-NK/T-DM1 
cells for 3 weeks. Relative tumor volume was calculated by normalizing the recorded tumor 
volume to the initial tumor volume. Data presented mean ± SD (****P<0.0001, two-way 












































Figure 3.38. In vivo anti-cancer efficacy of SE-NK/T-DM1 cells in Her2-negative  
MDA-MB-231 models. (a) Tumor growth and (b) body weight of MDA-MB-231 models. 
Female NSG mice (n=3 for control, rest n=4) were inoculated with 1×107 cancer cells and 
the tumor volume was measured. Animals received weekly treatment of NK92 cells,  
T-DM1+NK92 cells, or SE-NK/T-DM1 cells for 3 weeks. Relative tumor volume was 
calculated by normalizing the recorded tumor volume to the initial tumor volume. Data 
presented as mean ± SD (ns, not significant, two-way repeated measure ANOVA with 






or MDA-MB-231 models (Figure 3.38b), indicating that no severe toxicity was caused by 
the treatments. 
For the biodistribution study, NSG mice bearing Calu-3 tumors were administered 
unmodified NK92 cells, T-DM1+NK92 cells, or SE-NK/T-DM1 cells. The population of 
NK92 cells migrated to the major organs, including the heart, kidneys, liver, lung, and 
spleen; the tumor was quantitatively analyzed by flow cytometry. No accumulation of 
NK92 cells was observed in the heart, kidneys, or lungs (Figure 3.39). NK92 cells were 
detected in the liver and spleen; however, no significant difference in the number of NK92 
cells was observed among the treatment groups. Compared to the T-DM1+NK92 cells and 
unmodified NK92 cells, a larger number of NK92 cells were spotted in the tumor tissues 
of mice that received SE-NK/T-DM1 cells. 
  
3.5. Discussion 
The anti-cancer activity of SE-NK/T-DM1 cells as chemoimmunotherapy was 
extensively investigated to identify the individual activities of TZ, DM1, and NK92 cells. 
It is clear to note that T-DM1 is more potent to induce cell death than is TZ. The differences 
in the anti-cancer effects between SE-JK/T-DM1 cells and SE-JK/TZ cells originated 
solely from the cytotoxicity of DM1 contained in T-DM1 due to the fact that Jurkat cells 
lack direct cytolytic function.49 More complicated trends were observed in the  
SE-NK/T-DM1 cells. In the target cancer cells, unmodified NK92 cells showed noticeable 
cytolytic activity; however, it was lower than cytotoxicity of T-DM1. The TZ+NK92 cells 
were more effective in eliminating the target cancer cells than T-DM1 alone. Binding of 


















Figure 3.39. Biodistribution of SE-NK/T-DM1 cells in Calu-3 model. Animals (n=3) 
received NK92 cells, T-DM1+NK92 cells, or SE-NK/T-DM1 cells and the vital organs 
were harvested 24 hours after the injection. Single-cell suspensions were generated through 
mechanical and enzymatic digestion of the harvested organs and NK92 cells were detected 
using the anti-CD56 antibody. The NK92 cells were counted among 1×105 total cells. Data 
presented as mean ± SD (ns, not significant; ***P<0.001; ****P<0.0001; two-way 





with PI3K and AKT, both of which are involved in cell cycle arrest and cell apoptosis.50  
NK92 cells recognized and eradicated the target cancer cells undergoing apoptosis, which 
was induced by the inhibition of the downstream signaling pathways resulting from the 
binding of TZ.51,52 SE-NK/TZ cells displayed stronger anti-cancer activities compared to 
the TZ+NK92 cells. The TZ grafted on the surface may have directed SE-NK/TZ cells 
toward the antigen-expressing cancer cells and led to physical contact with the target cancer 
cells, which in turn increased the chance to stimulate the cytolytic function of NK 92 cells. 
The SE-NK/T-DM1 cells achieved the greatest anti-cancer activity; the magnitude of the 
increased anti-cancer efficacy could not be simply explained as the sum of anti-cancer 
effects of three components—DM1, TZ, and NK92 cells.  
The lack of CD16, CD32 and CD64 IgG receptor expression on the surface of  
NK92 cells indicates that ADCC seems to be inappropriate to explain the mechanism  
of action of SE-NK/T-DM1 cells.12,37,39 The NK92 cells that are transferred adoptively  
are typically supplemented with IL-2—an NK cell activating cytokine—which  
stimulates NK92 cells to secrete IFN-γ upon encountering the target cells.53,54  
We investigated the effect of IL-2 on IFN-γ secretion from the SE-NK/T-DM1 cells.  
The NK92 cells and T-DM1+NK92 cells showed increase in targeted cancer cell  
death with IL-2, whereas SE-NK/T-DM1 cells showed the same activity regardless  
of the presence of IL-2. Interestingly, the IFN-γ secretion was only increased in  
the treatment groups supplemented with IL-2. These results demonstrate that although  
IL-2 increases the cytolytic activity of NK92 cells through enhanced release of  
IFN-γ,55,56 the cytolytic activity of SE-NK-T-DM1 cells is independent from IFN-γ 




The next mechanism we examined was the ability of NK92 cells to release perforins 
and granzymes,39 both of which trigger direct killing of foreign, damaged, malignant, and 
infected cells.45,57 The detection of degranulation marker, CD107a, has been a widely  
used method to measure the cytolytic activity of NK cells.45,46 As NK92 cells engage  
the target cells, CD107a co-localizes with perforins and granzymes into the secretory 
lysosomes and translocates to the cell membrane as the lysosomes fuse with the cell 
membrane for perforin and granzyme release.58,59 The unmodified NK92 cells and  
T-DM1+NK92 cells showed basal level of CD107a expression when encountered with the 
target cancer cells. Compared to the other treatment groups, the appearance of CD107a was 
increased in the SE-NK/T-DM1 cells following the recognition of target cancer  
cells; this level of increase in the CD107a expression was found to be similar to the reported 
levels from Alter et al. and Kwant-Mitchell et al.58,60 We postulate that, in the  
SE-NK/T-DM1 cells, T-DM1 pushes target cancer cells towards apoptosis and triggers  
the expression of damage-associated molecular patterns (DAMP).51,61-63 Simultaneously, 
these damaged and/or apoptotic cancer cells are recognized and eliminated by NK92  
cells that have been delivered closer to the target tumor tissues by the targeting ability of 
T-DM1. Finally, the stimulated SE-NK/T-DM1 cells destroy the target cancer cells through 
the perforin and granzyme pathway. Consequently, these findings confidently claim that 
the incorporation of ADCs into the surface of NK92 cells not only allows the cancer 
homing of NK92 cells, but also offers a novel means of combining chemotherapy and 
immunotherapy in a single immune cell.   
Our objective was to demonstrate the therapeutic benefit of ADC-embedded NK92 




define the mechanism of action of the surface-engineered effector cells in detail and, more 
importantly, to facilitate the translation into clinical cancer therapy. Pharmacokinetic 
studies are necessary to determine the circulation times of SE-NK/T-DM1 cells and the 
fate of T-DM1 and NK92 cells once the SE-NK/T-DM1 cells dissociate into individual 
components. Although expression of CD107a provides indirect evidence for the activation 
of NK92 cells, actual levels of perforins and granzymes released from the activated NK92 
cells should be determined. Several supplementary cytokines, such as IL-2, IL-12, IL-15, 
and IL-18, can enhance the innate cytolytic activity of NK cells.64-66 Preactivation or  
co-administration of these activating cytokines can improve the anti-cancer efficacy of  
SE-NK/T-DM1 cells and allow them to be more favorable for clinical application. It is also 
important to perform histological analysis to identify SE-NK/T-DM1 cells trafficked to 
tumors and other organs. Since T-DM1 is approved primarily to treat Her2-positive breast 
cancers, the efficacy of SE-NK/T-DM1 cells should be evaluated in Her2-positive  
patient-derived primary breast cancer models for clinical translation. In addition, as the  
CD19-targeted CAR-T cells have shown impressive results in hematological 
malignancies,67  we plan to investigate the therapeutic efficacy of SE-NK/ADC cells 
generated with anti-CD19 ADCs in B-cell acute lymphoblastic leukemia, chronic 




Surface engineering of active immune cells with ADCs is composed of a clinically 




cell. Our method allows enhanced accumulation of ADCs and active NK92 cells in the 
target tumor tissue. With the active NK92 cells and ADCs co-localized in proximity at the 
tumor tissue, NK 92 cells recognize the damaged cancer cells induced by ADCs. These 
simultaneous anti-cancer activities are the basis for combinatorial anti-cancer efficacy of 
the ADC-embedded NK92 cells. With our strategy, active targeting of any immune  
cells—including T cells, DCs, and macrophages—to different types of cancers is 
achievable through the embedding of various ADCs in the immune cell surface. Currently, 
many antibodies have been generated for specific diseases and target cells. Most of these 
antibodies are candidates of new ADCs, and thus the application of SE-NK/ADCs cells 
may become a readily accessible tool for chemoimmunotherapy. Potent effector cells with 
a specific tumor-homing capability and chemoimmunotherapeutic anti-cancer activity  
can be generated instantly by simply mixing the pre-expanded immune cells from cell  
bank or freshly isolated immune cells from the patients with a ready-to-use  
DMPE-ADC formulation on the bedside. This single-injection therapy using  
ADC-embedded immune cells serves as a new platform to develop tailored 
chemoimmunotherapy for the treatment of many different types of cancers in addition  
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RESULTS, CONCLUSIONS, AND FUTURE STUDIES 
 
4.1. Summary of Chapter 2 
4.1.1. Study Motivation 
Cell surface regulates the behavior of cells toward their surrounding environment. 
As discussed in Chapter 1, cell surface engineering is a powerful tool for cell therapy 
because remodeling of cell surface with biomaterials can change the cell adhesion, 
migration, cellular activities, and cell-to-cell interaction for specific purposes. Indeed, 
genetic modification, which is the most advanced strategy available today, has 
revolutionized the field of cell therapy through the generation of tailor-made therapeutic 
cells. Although a large number of genetically modified cells have entered oncology clinical 
trials in the past decade, smoother clinical transition of these cells has been blocked by 
their stigma related to safety and lengthy production time.1-3 One of the disadvantages of 
genetic engineering is that it can only generate proteins, receptors, and biomolecules  
within the realm of cellular biosynthesis with variable expression efficiency. In other  
words, genetic modification limits the manipulative freedom of modifying cells.  
Therefore, surface modification methods—aside from the genetic engineering discussed in 
Chapter 1—should be applied to incorporate many therapeutic and diagnostic materials, 
including small molecule drugs, polymers, proteins, nanoparticles, fluorescent tags, and  
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imaging agents. In Chapter 2, studies were designed to demonstrate the use of hydrophobic 
interactions to modify cells for enhanced cell migration and improved cell tracking.  
 
4.1.2. Hypothesis 
Cell surface engineering with hydrophobic interaction allows noninvasive and  
nontoxic incorporation of biomaterials into the cell membrane. This technology allows 
homogeneous and rapid modification of the cell membrane. Because any biomaterials 
hydrophobized with lipid conjugation can theoretically be embedded into the cell 
membrane, applications of cell surface engineering through hydrophobic interaction  
would allow cells to be modified with a small protein or a magnetic resonance imaging 
(MRI) contrast agent. 
 
4.1.3. Key Study Results 
Mesenchymal stem cells (MSCs) expressing chemokine receptors CXCR4  
migrate toward the SDF-1 gradient established by injured cardiomyocytes in the  
ischemic heart.4,5 As described in Chapter 1, SDF-1 expression decreases after 4-7 days of 
myocardial infarction (MI). Thus, surface engineering of MSCs with CXCR4, as 
demonstrated by Won et al., can enhance the migration of ex vivo expanded MSCs for  
early cardiac muscle repair.6 As the expression of SDF-1 decreases over time, 
cardiomyocytes in the infarct border zone begin to express CXCR4.7 It has been reported 
that the delivery of cell mixtures containing whole bone marrow mononuclear cells and 
SDF-1 expressing MSCs has improved the cardiac function in MI patients who missed the 
SDF-1 therapeutic window for the delivery of MSCs expressing CXCR4.8 This observation 
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indicated that the surface engineering of MSCs with SDF-1 could be beneficial for homing 
MSCs to the ischemic heart in later stages of acute MI. In order to test the enhanced 
migration, MSCs were first modified with DMPE-PEG-SDF-1. Different amounts of 
DMEP-PEG-SDF-1 uniformly modified the MSCs. Similar to the results reported by Won 
et al., SDF-1 modified MSCs showed enhanced migration when exposed to increasing 
concentrations of CXCR4. 
Next, Jurkat cells were surface-engineered with MRI contrast agents to test the 
possibility of real-time visualization. Superparamagnetic iron oxide nanoparticles (SPIONs) 
are popular imaging agents for MRI due to their ability to produce sharp image contrasts. 
Internalization of surface-coated SPIONs is often required to label therapeutic cells for  
in vivo tracking.9,10 With this approach, the risk of releasing iron ions from the SPION  
core increases as the internalized surface-coated SPIONs undergo endocytosis and 
experience the low pH environment of lysosomal compartments.11,12 Ultimately, 
dismantled surface-coated SPIONs may alter the cell homeostasis and induce 
cytotoxicity.10,13 To overcome this challenge, fluorescently labeled surface-coated  
SPIONs were hydrophobized with DMPE-PEG molecules and subsequently applied  
onto Jurkat cells. Surface modification with DMPE-PEG-SPION-FITC did not affect  
the viability or cell proliferation. Most importantly, Jurkat cells modified with different 
amounts of DMPE-PEG-SPION-FITC showed dosage-dependent MRI signal intensity.       
 
4.1.4. Conclusion  
Cell surface engineering with hydrophobic interaction instantaneously changes the 
properties of cells without sacrificing cell viability and cellular functions. As demonstrated 
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by the SDF-1-embedded MSCs and SPION-modified Jurkat cells, surface modification 
through hydrophobic interaction reliably transforms ordinary cells for enhanced  
target site-homing effects and real-time cell tracking. Many different types of cells can be 
modified with a wide range of biomaterials through hydrophobic interaction, and these 
therapeutic cells with special functions can be employed to improve the therapeutic benefits 
of cell therapy.  
 
4.2. Summary of Chapter 3 
4.2.1. Study Motivation 
Historically, many conventional chemotherapeutic agents have been thought to 
impair host immunosurveillance against tumors. Recent combinational cancer therapies 
have shown that the ability of low dose chemotherapeutic agents to work in concert with 
the host innate and adaptive immune systems is essential to stimulate potent anti-cancer 
activity inducing cancer cell death.14-17 Many combinatorial therapies have introduced 
monoclonal antibodies in order to bridge the anti-cancer activities of chemotherapeutic 
agents with the host immune system; hence chemoimmunotherapy has been in the 
spotlight.18-22 Antibodies are particularly proficient in this role because of their high 
specificities against tumor-associated antigens (TAAs), minimal off-target effects, low risk 
of immunogenicity, high rate of promoting immunologic memory, and circulation 
longevity. Antibodies in action will bind to the TAAs expressed on cancer cells and 
subsequently initiate cell death signaling, antibody-dependent cellular cytotoxicity 
(ADCC), antibody dependent phagocytosis, and complement-dependent cytotoxicity 
(CDC).23 A summary of the immunomodulatory mechanisms of chemotherapeutic agents  
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and antibodies is provided in Table 4.1. The interaction of cytotoxic agents and antibodies 
with the immune system has fueled the development of a delivery strategy that can tie all 
three components together. 
To achieve stronger anti-cancer activity, decades of research aimed to enhance the 
potency of antibodies have successfully conjoined chemotherapy with antibodies to 
generate the antibody-drug conjugates (ADCs).24 In addition to the distinctive 
characteristics of antibodies, these new therapeutic antibodies specifically deliver toxic 
chemotherapeutic agents to certain types of cancer cells for the interest of maximizing  
the therapeutic benefits with low off-target effects. Several ADCs, including  
Trastuzumab-DM1 (T-DM1) and Brentuximab vedotin, are available in the market, and 
other ADCs are currently undergoing clinical investigation.25,26 
Chemotherapeutic agents, antibodies, and ADCs as immunomodulators recruit a 
number of different effector cells—including natural killer (NK) cells, dendritic cells (DCs), 
tumor-specific T cells, and tumor-associated macrophages—to the tumor site as shown in 
Table 4.1.14,15,27 As a crucial component of the innate immune system, NK cells have been 
involved in preventing abnormal neoplastic growth.27 Unfortunately, tumor cells often 
evade the immunosurveillance by establishing a supportive microenvironment for 
undisturbed tumor growth. Cytolytic activity of autologous NK cells is thus suppressed as 
the cells encounter self-MHC expressing tumor cells and weakened by preexisting 
diseases.28 Moreover, patients experiencing a high dose chemotherapy and ionizing 
radiotherapy display a significantly reduced NK cell population.29,30 In order to  
achieve sufficient anti-cancer efficacy, an adequate number of immune effector cells  







Table 4.1 Immunomodulatory functions of chemotherapeutic agents and antibodies 
 
Drug Effect on Tumor Effect on Immune System 
Sunitinib 
• Blocks multiple tumor-associated 
tyrosine kinases, including VEGFR 
and PDGFR  
• Blocks STAT3  
• Decreases numbers and effectiveness of MDSCs and TReg cells 
• Blocks VEGF signaling 
Imatinib 
• Blocks multiple tumor-associated 
tyrosine kinases, including ABL and 
KIT 
• Increases TRAIL expression 
• Blocks IDO 
• Decreases number and effectiveness of TReg cells  
• Promotes DC–NK cell crosstalk 
• Increases the number of B-1 B cells (without memory) 
• Increases the amount of 'natural' anti-cancer carbohydrate antibodies 
Trastuzumab 
• Blocks growth signaling through 
HER2 
• Primes anti-cancer CTLs 
• Boosts NK cell secretion of IFN-γ and ADCC 
Bevacizumab • Blocks angiogenesis 
• Increases DC maturation 
• Promotes DC differentiation toward mature DCs instead of MDSCs 





• Blocks mTOR pathway 
• Enhances CD8+ T cell activation and IFN-γ production,  
• Augments CD8+ T cell differentiation into memory T cells 
• Impairs the homeostasis of TReg cells 
• Decreases IDO expression 
• Augments the responsiveness of TReg cells to antigen 
JAK2 inhibitors 
• Blocks JAK2 signaling in tumor 
cells 
• Enhances DC maturation 
• Bolsters DC-mediated antigen presentation and T cell priming 
• Decreases immunosuppressive STAT3 signaling, decreases IAP 







Table 4.1 (Continued) 
 
Drug Effect on Tumor Effect on Immune System 
HSP90 
inhibitors 
• Blocks HSP90, which increases 
unfolded protein-associated stress in 
tumor cells 
• Increases expression of NKG2D 
ligands 
• Recognition of NKG2D ligand on tumor cells by CTL  
• Decreases cytokine secretion from macrophages and T cells 
• Decreases expression of co-stimulatory molecules on DCs and 
• Decreases antigen presentation by DCs 
PI3K-AKT 
inhibitors 
• Decreases PI3K-AKT signaling in 
tumor cells 
• Decreases prosurvival signaling 
• Decreases tumor-promoting 
inflammation 
• Increases tumor susceptibility to perforin and granzyme-mediated 
lysis by CTLs and NK cells 
IAP inhibitors • Sensitizes tumor cells to apoptosis • Increases T cell, NK cell and NKT cell responses to stimulation 
Gemcitabine 
 
• Antigen presentation 
• Inhibition of MSCs and B cells 
• Increases antigen cross-presentation  
• Partial activation of dendritic cells  
• Priming of APCs for CD40 signal 
• Killing subsets of APC 
• Inhibition of regulatory cells 
Anthracyclines 
• HMGB1 release 
• Cell-surface calreticulin  
• Increases antigen uptake T-cell activation  
• Increases T cell-dependent anti-cancer effects 
Oxaliplatin • HMGB1 release  
• Increases T cell activation  








Table 4.1 (Continued) 
 
Drug Effect on Tumor Effect on Immune System 
5-Fluorouracil • Increases HSP production 
•  Increases local tumor-antigen cross-presentation  
•  T-cell activation 
•  Suppresses TReg cells 
 
Cisplatin 
• Decreases succinate 
dehydrogenase activity 
• Increases CD95 expression 
• Increases local tumor-antigen cross-presentation  
• T-cell activation 
• MDSCs suppression 
Taxanes 
• Inhibition of M2 macrophages 
• Upregulation of mannose-6-
phosphate receptors 
• Inhibition of regulatory cells 
• Perforin and granzyme-mediated lysis by CTLs and NK cells 




• Inhibition of TReg cells Self-
peptide–MHC class I complexes 
• Inhibition of regulatory cells  
• Generation of memory T cells 
• Increases NK cell activation 
 
Abbreviation: 
ADCC, antibody-dependent cellular cytotoxicity; APC, antigen presenting cells; CTL, cytotoxic T lymphocyte; DC, dendritic cell; 
HSP90, heat shock protein 90; IAP, inhibitor of apoptosis protein; IDO, indoleamine-pyrrole 2,3-dioxygenase; JAK2, janus kinase 2; 
MDSC, myeloid-derived suppressor cell; MHC, major histocompatibility complex; mTOR, mammalian target of rapamycin NK, natural 
killer; NKG2D, natural killer group 2, member D; PDGFR, platelet-derived growth factor receptor; PDL1, PD1 ligand 1; STAT3, signal 
transducer and activator of transcription 3; TReg cells, regulatory T cells; TRAIL, tumour-necrosis-factor-related apoptosis-inducing 
ligand; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 
 




graft-versus leukemia (GVL) effects with minimal risk of inducing graft-versus-host 
diseases (GVHD),34 the supply of large amounts of NK cells is limited due to the low  
number of NK cells present in the donor’s blood.28 Fortunately, several NK cell lines, such 
as NK92, HANK-1, KHYG-1, NK-YS, NKG, YT, YTS, and NKL have been  
developed; however, NK92 cells constitute the only cell line approved for testing that 
demonstrates reliable ex vivo expansion and consistent cytotoxicity against target 
cells.27,28,34 Comparisons among T cells, peripheral blood NK cells and NK92 cells are 
shown in Table 4.2. Despite the optimism surrounding NK92 development, clinical studies 
with NK92 have shown at most mild responses in patients with solid tumors.27,28,35-37 
Nevertheless, NK92 cells have increasingly become favorable cell-based 
immunotherapeutic agents while the method of redirecting cytolytic activity of T cells 
using the chimeric antigen receptors (CARs) has continued to show fatal adverse 
effects.28,34,38-40 Currently, genetic modification to express CARs, CD16, and  
NKG2D—in order to empower NK92—has been studied to improve the anti-cancer 
responsiveness of NK92 cells.41-44 These genetically engineered NK92 cells also bear 
limitations—such as inefficient gene transfer efficiency, development of endogenous 
immune responses against the viral components, possibility of mutagenesis, uncontrolled 
persistence of genetically modified NK, inability to administrate repeatedly, and inability 
to achieve systemic dose escalation—that allow us to conclude that preserving the transient  
anti-cancer activity of NK92 cells is much safer than the genetic modification  
approach.34,45-48 Nonetheless, NK92 cells lack functionality to specifically target cancer 
cells; therefore, a new method for cancer targeted delivery of NK92 cells must be 





























ADC technology has certainly revolutionized cancer immunotherapy. Nevertheless, 
it has a critical limitation to be a stand-alone treatment: only a small percentage of 
administrated ADCs localizes at the tumor site.49 The host immune system may not be  
able to recognize and exert anti-cancer effects due to low numbers of antibodies bound  
on cancer cells intended to induce apoptosis. Because the number of tumor-infiltrating  
NK cells has been shown to be indistinguishable from the NK cell population in normal 
tissues,50 the probability of observing the benefits of chemoimmunotherapy using ADCs 
alone may depend on the sensitivity of host immune system. Therefore, an innovative 
strategy to concurrently deliver activated allogenic NK92 cells with ADCs is necessary in 
order to reach the full therapeutic capacity of chemoimmunotherapy. 
 
4.2.2. Hypothesis 
Lipid-conjugated ADCs can modify NK92 cells through hydrophobic interaction  
to generate surface-engineered NK92 cells with ADCs (SE-NK/ADC cells). The  
study was designed to investigate the following hypotheses: (1) SE-NK/ADC cells  
would specifically migrate toward the target tumor site through the recognition of  
target cancer cells by ADCs, (2) ADCs would induce apoptosis in the target cancer  
cells, (3) NK92 cells concurrently delivered at the tumor tissues with ADCs  
would recognize the apoptotic cancer cells, and (4) NK92 cells would further  
destroy the dying cancer cells. In order to test these hypotheses, NK92 cells were  
surface-engineered with T-DM1 (SE-NK/T-DM1 cells), and the in vitro and  





4.2.3. Key Study Results 
T-DM1 was generated by conjugating trastuzumab (TZ) with 10 molar excess of 
linker-conjugated DM1. When tested against Her2-positive SK-BR-3 cells, synthesized  
T-DM1 showed comparable cytotoxicity to Kadcyla®  (ado-trastuzumab emtansine). The 
SE-NK/T-DM1 cells were prepared by incubating NK92 cells with lipid-conjugated  
T-DM1. Incubation of SE-NK/T-DM1 cells or co-treatment of T-DM1 and NK92 cells  
(T-DM1+NK92 cells) with Her2-positive SK-BR-3 cells for 24 hours showed increased 
cancer cell death compared to the individual effects of T-DM1 or NK92 cells. There  
were no differences detected between the treatments of SE-NK/T-DM1 cells and  
T-DM1+NK92 cells when both treatments were incubated for 24 hours. However, when 
SE-NK/T-DM1 cells and T-DM1+NK92 cells were incubated for short period of  
time, washed to remove unbound NK92 cells, and incubated for 24 hours,  
the SE-NK/T-DM1 cells induced a significantly greater number of cancer cell deaths  
than did the co-treatment. This result indicates that the surface embedded T-DM1 was  
able to deliver NK92 cells toward the Her2-positive cancer cells. In Her2-negative  
MDA-MB-231 cells, only the cytolytic activity of NK92 cells was observed. In order to 
examine the individual effects of NK92 cells and T-DM1 on SE-NK/T-DM1cells,  
NK92 cells were modified with TZ (SE-NK/TZ cells), and Jurkat cells were modified with  
TZ (SE-JK/TZ cells) and T-DM1 (SE-JK/T-DM1 cells). Jurkat cells did not show cytolytic 
activity against SK-BR-3 cells or MDA-MB-231 cells. When SE-JK/T-DM1 cells,  
SE-JK/TZ cells, and T-DM1 were treated with SK-BR-3 cells, only the cytotoxicity of  
T-DM1 was observed. When SE-NK/TZ cells, SE-NK/T-DM1 cells, and T-DM1 were 




expected, the treatment of SE-NK/T-DM1 cells induced the greatest number of cancer cell 
deaths compared to other treatments. Next, the cytolytic activity of NK92 cells was 
identified by comparing SE-JK/TZ cells and SE-NK/TZ cells. When incubated with  
SK-BR-3 cells, SE-NK/TZ cells induced a greater number of cancer cell deaths compared 
to SE-JK/TZ cells. Similarly, the cytotoxicity of SE-JK/T-DM1 cells and SE-NK/T-DM1 
cells were compared via incubation with SK-BR-3 cells. Again, SE-NK/T-DM1 cells 
showed the greatest anti-cancer activity, and only the anti-cancer activity of NK92 cells 
was visible in Her2-neative MDA-MB-231 cells when they were incubated with the same 
treatments. These results indicated that the cytotoxicity of SE-NK/T-DM1 cells results 
from a combination of anti-cancer activities of T-DM1 and NK92 cells. 
The mechanism of NK92 cell activity was examined. Addition of interleukin-2  
(IL-2) induced the release of interferon-γ (IFN-γ) from NK92 cells and improved the 
cytolytic activity of unmodified NK92 cells against SK-BR-3 cells. Although IL-2 induced 
the SE-NK/T-DM1 cells to release IFN-γ, there was no difference in cytotoxicity against  
SK-BR-3 cells between SE-NK/T-DM1 cells with or without IL-2. This indicates that the 
cytotoxicity did not result solely from the release of cytokines from NK92 cells. Perforin 
and granzyme release was indirectly measured by analyzing the expression level of 
degranulation marker CD107a. Compared to the control and T-DM1+NK92 cells, the  
SE-NK/T-DM1 cells expressed a higher level of CD107a when incubated with SK-BR-3 
cells. No significant expression of CD107a was observed when the SE-NK/T-DM1 cells 
were incubated with MDA-MB-231 cells. These results indicate that the cytotoxic activity 





In vivo efficacy of SE-NK/T-DM1 cells was examined in female NOD scid gamma 
(NSG, NOD-scid IL2Rgnull) mice. NSG mice bearing Her2-positive Calu-3 tumors were 
injected weekly with T-DM1, 1×107 NK cells, 1×107 T-DM+NK92 cells,  
1×106 SE-NK/T-DM1 cells, and 1×107 SE-NK/T-DM1 cells for 3 weeks. At the end  
point, SE-NK/T-DM1 cells significantly suppressed the Calu-3 tumor growth when  
compared to the T-DM1+NK92 cells. Adverse effects related to the administration of  
SE-NK/T-DM1 cells were not observed, for body weights did not change over the 
treatment course. When MDA-MB-231 cells were exposed to similar treatments, only the 
effects of NK92 cells were observed. A biodistribution study was conducted 24 hours  
after the administration of 1×107 NK92 cells, 1×107 T-DM1+NK92 cells, and  
1×107 SE-NK/T-DM1 cells. NK92 cells were detected by flow cytometry from the  
single-cell suspension prepared from each harvested organ. Animals treated with  
SE-NK/T-DM1 cells showed significantly higher accumulation of NK92 cells in the tumor 
site than other treatments. 
 
4.2.4. Conclusion 
Chemotherapy and immunotherapy were successfully integrated to generate  
SE-NK/T-DM1 cells. Surface engineering of T-DM1 on NK92 cells did not induce 
cytotoxicity. Although T-DM1 dissociated from the SE-NK/T-DM1 cells over time, a 
significant amount of T-DM1 was available on the NK92 cell membrane for up to 48 hours. 
In vitro and in vivo experiments have demonstrated the antigen-specific cytolytic activity 
of SE-NK/T-DM1 cells. The cytotoxicity of SE-NK/T-DM1 cells resulted from the 




significantly suppressed the tumor growth in Her2-positive Calu-3 animal models 
compared to T-DM1+NK92 cells. The in vivo biodistribution study confirmed that T-DM1 
on the surface of NK92 cells enhanced the tumor-targeted migration of SE-NK/T-DM1 
cells. As demonstrated by SE-NK/T-DM1 cells, transient surface modification with ADCs 
could redirect active immune cells toward tumor tissue with enhanced anti-cancer efficacy. 
As ADC technology continues to develop, surface-engineered immune cells with ADCs 
may progressively act as potent chemoimmunotherapeutic agents directed toward various 
tumor antigens.  
 
4.3. Future Studies 
As stated throughout this dissertation, cell surface engineering with hydrophobic 
interaction is a noninvasive, nontoxic, reliable, and rapid surface chemistry that provides 
transient modifications to various types of cells. Any synthetic and natural biomaterials 
that can be hydrophobized with lipid conjugations can potentially be incorporated into the 
cell membrane. Experimental studies presented in Chapter 2 and Chapter 3 demonstrated 
proof of the concept that cells can be remodeled for a specific purpose by modifying the 
cell surface with bioactive materials. While the objectives of each study have been 
accomplished, additional studies must be conducted to provide a comprehensive analysis 
of the surface-engineered therapeutic cells for possible clinical transition. 
 
4.3.1. Risk of Differentiation and In Vivo Migration of SDF-1 Modified MSCs 
Lipid-conjugated SDF-1 uniformly modified the MSCs in Chapter 2. The effects of 




MSCs could differentiate into endothelial-like cells when exposed to 50 ng/mL of SDF-1 
for 14 days.51 Although the retention time of membrane-embedded SDF-1 is short, the 
effects of grafting SDF-1 onto the MSC membrane should be evaluated in terms of cell 
differentiation. Tang et al. stated that MSC differentiation due to SDF-1 exposure could be 
suppressed by treating the MSCs with the inhibitor NG-nitro-L-arginine methyl ester  
(L-NAME).51 Transient modification with SDF-1 with surface engineering may be 
beneficial to avoid the differentiation of MSCs.  
In order to investigate the potential MSC differentiation due to the surface-embedded 
SDF-1, unmodified MSCs; SDF-1 surface-engineered MSCs; MSCs with equivalent 
amount of free SDF-1; MSCs with free SDF-1 (50 ng/mL); SDF-1 surface-engineered 
MSCs with L-NAME; SDF-1 with equivalent free SDF-1 and L-NAME; and MSCs with 
free SDF-1 (50 ng/mL) and L-NAME should be incubated for 14 days. After the 
differentiation period, the expression levels of endothelial cell markers, such as CD31 and 
VIII-related factor, on the collected cells should be evaluated through flow cytometry and 
western blotting.51    
Enhanced migration of surface-engineered MSCs with SDF-1 was demonstrated 
using a transwell system. SDF-1 modified MSCs demonstrated enhanced chemotaxis 
toward increasing CXCR4 concentrations. As reported in the literature, delivery of MSCs 
to the ischemic left ventricles takes advantage of the CXCR4/SDF-1 axis.51-55 In  
earlier stages of acute myocardial infarction (MI), injured cardiomyocytes express SDF-1 
in order to recruit the CXCR4-expressing MSCs for cardiac repair. However, the 
expression of SDF-1 declines in the injured sites, and the expression of CXCR4 on MSCs 




CXCR4-modified MSCs toward SDF-1 at an early stage of acute MI.6 Conversely, the 
SDF-1-modified MSCs, as introduced in Chapter 2, can be employed at the later stage of 
acute MI for enhanced migration toward CXCR4. In order to determine the benefits of 
enhanced MSC migration toward the ischemic heart, both systems should be evaluated in 
animal models of MI, preferably in rat models with rat MSCs, SDF-1 and CXCR4. 
Sprague-Dawley rats anesthetized with ketamine and xylazine should be intubated and 
ventilated for left anterior descending (LAD) artery ligation.7,51,56 Successful performance 
of ligation can be confirmed by the blanching of myocardium distal to the ligation and 
electrocardiography.57 To evaluate the homing effects of rCXCR4 and rSDF-1 at early and 
late stages of MI, the ligated animals should be administered CXCR4-modified rMSCs or 
rSDF-1-modified rMSCs at 24 hours or a week after the ligation procedure through tail 
vein infusion. Control groups should receive a thoracotomy with or without the injection 
of unmodified rMSCs, CXCR4-modified MSCs, or SDF-1-modified MSCs. Because of the 
characteristic CXCR4 and SDF-1 expressions at the infarcted sites as described above, 
rCXCR4-modified rMSCs are expected to accumulate in the injured heart in early stage 
MI, and rSDF-1 modified rMSCs should migrate toward the injured heart in late stage MI. 
The migration of surface-modified rMSCs and accumulation at the infarct site can be 
visualized using single-photon emission computed tomography (SPECT) or MRI by  
prelabeling the rMSCs with radioisotopes or MRI contrast agents.58,59 Cardiac function 
parameters—including left ventricular ejection fraction (LVEF), left ventricular  
end-diastolic volume (LVEDV), left ventricular end-systole volume (LVESV), left 
ventricular stroke volume (LVSV), left ventricular cardiac output (LVCO), left ventricular 




analyzed by MRI before and 4 weeks after the administration of rMSCs.60 Also, the heart 
will be harvested from each animal to compare the presence of cardiomyocytes and  
the degree of restored cardiac functions before and after the treatment through 
immunohistological staining, using antibodies specific for cardio Troponin I, GLUT1, 
GLUT4, PFK, GAPDH and p70s6k antibodies.60 The presence of cardiomyocytes, 
glucose transporters, and glucose metabolism-related enzymes will indicate the 
regeneration of the damaged heart. 
 
4.3.2. Relaxivity of SPIONs on Surface Modified Jurkat Cells  
In Chapter 2, SPION-modified Jurkat cells were imaged using T2*-weighted 
sequence for MRI analysis. The primary objective was to visualize the presence of 
SPION-modified Jurkat cells using MRI. Other properties of SPION-modified  
Jurkat cells as MRI contrast agents have not been studied in this dissertation. One of the 
important properties of MRI contrast agents is relaxivity. Relaxivity indicates the ability 
of magnetic agents to increase the relaxation rate of the surrounding water proton 
spins.61 In other words, relaxivity measures the sensitivity of the contrast agent to 
produce more distinguished MRI images. Because the relaxivity of identical contrast 
agents can be different due to temperature, field strength, and delivery methods,  
SPION-modified Jurkat cells may show different levels of relaxivity from free SPIONs. 
Unfortunately, MRI study designs and results of SPION-modified Jurkat cells are 
insufficient to calculate the relaxivity. The efficacy of an MRI contrast agent is not only 
determined by the pharmacokinetic properties but also by magnetic properties; hence,  




Following the experimental designs described by Rohrer et al. and Shevtsov et al., 
relaxation rates R1 and R2 will be measured from agar phantoms containing a constant 
number of Jurkat cells modified with various amounts of SPIONs.62,63 R1 of Jurkat cells 
with various concentrations of surface-modified SPIONs will be measured with a 
saturation recovery sequence. From the collected data, relaxation time T1 can be 
calculated with Equation 4.1 where S is the measured signal and So is a constant signal 
at equilibrium. Relaxation time T2 can be measured by multiple echoes on Jurkat cells 
 
S = So (1-e
(-TR/T1))        (4.1) 
 
with various concentrations of surface-modified SPIONs. The collected data can be 
represented as an exponential decay with Equation 4.2. R1 and R2 can be acquired from 
 
S = So (e
(-TE/T2))                                      (4.2) 
 
T1 and T2 using the inverse relationship (R1= 1/T1 and R2= 1/T2). Finally, linear plots 
can be obtained using the Equation 4.3 and 4.4 with the slopes of each plot, r1 and r2, 
representing the T1- and T2-relaxivities. 
 
1/∆T1 = r1*[SPIONs on Jurkat cells]   (4.3) 
 






4.3.3. Internalization of Surface-Embedded SPIONs through Endocytosis 
Surface-engineered SPIONs on Jurkat cells remained on the cell membrane; 
however, the long-term fate of membrane-embedded SIPONs has not been studied. In 
order to investigate the endocytosis of surface-embedded SIPONs, the presence of 
internalized SPIONs on unmodified Jurkat cells, Jurkat cells with surface-engineered 
SPIONs, and Jurkat cells with internalized SPIONS, should be determined over time. 
Jurkat cells with internalized SPIONs can be prepared by incubating Jurkat cells with 
SPIONs overnight in cell culture conditions. Unmodified Jurkat cells, Jurkat cells with 
surface-engineered SPIONs, and Jurkat cells with internalized SPIONs cells collected at 
different time points will be fixed and stained with Prussian blue dye to identify the 
endocytosed SPIONs.64 Moreover, as Lim et al. demonstrated the visualization of 
endocytosed nanoclusters through TEM images; endocytosis of SPIONs by Jurkat cells 
can also be observed with TEM imaging.65 Jurkat cells with surface-engineered SPIONs 
and Jurkat cells exposed to SPIONs for 30 minutes will be fixed and processed for TEM 
observation. Formation of macropinosomes, ruffle closures, cup closures, and presence 
of intracellular vesicles and endosomal vesicles may indicate the endocytosis of SPIONs 
by Jurkat cells.  
 
4.3.4. Real-Time Tracking of Therapeutic Cells Modified with SPIONs 
In Chapter 2, Jurkat cells were modified with the lipid-conjugated SPIONs and 
seeded on a phantom gel. MRI contrast agents on the cell surface were able to produce 
sharp contrast images. Prior to testing the real-time tracking ability of SPION-modified 




followed the distribution pattern of SPION microbubbles that Barrefelt and coworkers have 
described.66 Free SPIONs may have predominately accumulated in the lungs initially and 
then gradually shifted to the spleen and liver.66 Macrophages in the lung displayed 
increased iron accumulation; however, macrophages of other organs followed the same 
pattern. Large accumulation of SPIONs in the organs was resolved over time, and signs of 
severe adverse effects were absent.66  
In order to examine the dissociation of SPION-modified Jurkat cells into SPIONs 
and Jurkat cells, SPION-modified Jurkat cells will be generated using 125I-labeled  
SPIONs. EDC/NHS-activated SPIONs can be radiolabeled with sulfo-SHPP and  
iodination reagent kit (Thermo Fisher Scientific, Waltham, MA) following the 
manufacture’s protocol to generate 125I-labeled SPIONs. Mice will be injected with  
125I-labeled SPION-modified Jurkat cells and blood samples will be collected at  
different time points up to 72 hours after the injection. Cells and serum will be separated 
by a density gradient centrifugation using Ficoll-Paque™ (Miltenyi Biotec, Bergisch  
Gladbach, Germany). Radioactivity of dissociated 125I-labeled SPION will be 
 detected in the serum faction using a liquid scintillation counter. Anti-human  
CD3 antibodies conjugated with magnetic beads will isolate Jurkat cells from the cell 
fraction, and the radioactivity from Jurkat cells will be measured. Attenuation of 
radioactivity in the cell faction indicates the loss of SPIONs from the Jurkat cell  
surface. Lastly, histological samples of major organs will be analyzed to examine the 
presence of dissociated SPIONs and Jurkat cells. After understanding the effects of 
dissociated SPIONs, real-time tracking of SPION-modified therapeutic cells can be 




4.3.5. Degree of DMPE-PEG Conjugation on SPIONs and T-DM1 
The degree of DMPE-PEG conjugation on SPIONs and T-DM1 has not been 
analyzed. DMPE-PEG-NH2 was conjugated on carboxyl-terminated SPIONs through 
EDC/NHS chemistry, and DMPE-PEG-NHS was attached to available primary amines of 
T-DM1. In order to complete the characterization of DMPE-PEG-SIPONs and  
DMPE-PEG-T-DM1 and to present them as “ready-to-use” tools, the degree of  
DMPE-PEG conjugation on both SPIONs and T-DM1 should be determined to provide 
consistent chemical properties. The degree of DMPE-PEG conjugation on SPIONs can be 
measured by comparing the concentrations of free carboxylic acid groups before and after 
the conjugation. Toluidine blue O dye absorption assay (TBO assay) is often used to 
determine the degree of carboxylation.67 DMPE-PEG-SPIONs and unmodified SPIONs 
incubated with TBO solution should be repeatedly washed to remove excess TBO dyes. 
TBO dye can be desorbed from SPIONs via incubation in 20% SDS solution at 40°C for 
30 minutes. The resulting supernatant can be measured at 625 nm to determine the 
concentration of free carboxylic aids.  
The degree of DMPE-PEG conjugation on T-DM1 can be measured by comparing 
the concentrations of free primary amines before and after the conjugation. Colorimetric 
tests using 2,4,6-trinitrobenzene sulfonic acid (TNBSAor TNBS) quantitate free primary 
amines on proteins.68 DMPE-PEG-T-DM1 and unmodified T-DM1 should be incubated 
with dilute TNBSA in 37°C for 2 hours. After the addition of 10% SDS stop solution, the 
change in absorbance can be measured at 335 nm.  
Alternatively, the concentrations of conjugated DMPE-PEGs on SPIONs and T-DM1 




Fatty acid assay quantitatively measures the amount of free lipids with alkyl chains of  
8-carbon or more. When analyzed with the assay, DMPE-PEG-SPIONs and  
DMPE-PEG-T-DM1 will generate colorimetric changes that can be measured at 570 nm. 
The absorbance measurements can be converted to the conjugated amount of lipids using 
a standard curve obtained with free DMPE. 
 
4.3.6. Concentration-Dependent DMPE-PEG Toxicity 
SDF-1-modified MSCs, SPION-modified Jurkat cells, and SE-NK/T-DM1 cells 
were generated by applying a small amount of DMPE-PEG conjugates onto a fixed 
 number of cells. The tested amounts of DMPE-PEG conjugates did not show signs of 
cytotoxicity when applied to cells; however, the maximum tolerated amount of  
DMPE-PEG conjugates should be reported for safety assessment. As a study model,  
the cytotoxicity of increasing amounts of DMPE-PEGs and DMPE-PEG-T-DM1 up to  
1 mg/mL should be evaluated on NK92 cell modification. The changes in cell viability and 
stress level can be examined through viability assay and lactate dehydrogenase (LDH) 
assay. Flow cytometric analysis of live and dead NK92 cells after the modification 
can be identified with calcein-AM and ethidium homodimer-1 dyes after the modification. 
LDH assay measures the level of LDH released from the cells with a damaged  
membrane. LDH released from the damaged cells converts resazurin into fluorescent 
resorufin, which can be detected with a fluorescent reader (560 nm/590 nm). LDH  
levels of NK92 cells after the modification, with increasing concentrations of  
DMPE-PEGs and DMPE-PEG-T-DM1, may represent the adverse effects occurring at 




4.3.7. Quantification of Internalized T-DM1 
Upon binding to Her2, T-DM1 was transferred from the SE-NK/T-DM1 cells to 
target cancer cells. Although fluorescent imaging confirmed the presence of internalized 
T-DM1 in the cytoplasm of target cancer cells, a more quantitative approach to measure 
the concentration of T-DM1 in the cytoplasm should be conducted. Following the 
experimental procedures described in Chapter 3, Her2-positive and Her2-negative cancer 
cells should be treated with T-DM1, T-DM1 with geldanamycin, and SE-NM/T-DM1 cells 
for 30 minutes and the unbound cells should be removed. Cancer cells will be detached 
from the plate at 1-hour and 6-hour post-treatment and lysed via differential lysis. Fractions 
from the membrane and cytosol will be applied to human IgG ELISA. Colorimetric 
changes will be plotted to determine the amount of internalized T-DM1. Also, anti-human 
Fc antibodies will be used to detect the presence of T-DM1 in each lysate by western 
blotting. The efficiency of T-DM1 internalization via Her2 binding can be analyzed by 
comparing the T-DM1 concentrations on the membrane and in the cytosol.  
 
4.3.8. Mechanism of SE-NK/T-DM1 Cells 
Experimental results in Chapter 3 demonstrated that the incubation of  
SE-NK/T-DM1 cells with Her2-positive SK-BR-3 cells induced the expression of 
degranulation marker, CD107a, on NK92 cells. This observation indicates that NK92 cells 
released perforins and granzymes upon engaging apoptotic cancer cells. In a normal state, 
CD107a co-localizes with perforin/granzyme containing secretory lysosomes.70,71 Upon 
NK92 cell activation, the lysosomes migrate towards the membrane and release perforin 




cell membrane for a brief moment and recycles back into the lysosome. Therefore, the 
expression of CD107a is indirect evidence of perforin and granzyme release. However, 
physical evidence of perforin and granzyme release needs to be provided. Quantitative 
analysis of released perforins and granzyme can be attained by analyzing the expression 
level of perforin, using flow cytometry, and then measuring the concentration of released 
granzymes with ELISA. 
 
4.3.9. Pharmacokinetics of SE-NK/T-DM1 Cells 
It is anticipated that the administered SE-NK/T-DM1 cells will dissociate into 
trastuzumab, DM1, and NK92 cells. Because NK92 cells are carrying T-DM1,  
all pharmacokinetic parameters of T-DM1—especially the drug exposure and  
clearance—may be different from T-DM1 as a single agent. Pharmacokinetics of NK92 
cells may be difficult to obtain due to the fact that NK92 cells are living drugs. However, 
several studies have indirectly gathered some of the pharmacokinetic parameters,  
including organ accumulation time and circulation time, by analyzing the  
accumulation of NK92 cells in the organs by MRI imaging.72-75 As demonstrated by  
CAR-T cells,76 the circulating time of NK92 cells can also be determined by isolating the 
NK92 cells in the bloodstream of animals treated with SE-NK/T-DM1 cells. 
Pharmacokinetic properties of SE-NK/T-DM1 may be different from individual NK92 
cells due to the membrane-anchored T-DM1. Therefore, studies to evaluate the  
in vivo stability of SE-NK/T-DM1 cells and their dissociation into NK92 cells, trastuzumab, 
and DM1 should be conducted to provide a better understanding of the in vivo  




pharmacokinetic studies using [3H]DM1 and have reported that the  
thiosuccinimide linkage in ADCsis less labile in vivo with only fractional loss of  
SMCC-DM1.77 Similar experimental designs can be used to study the in vivo  
stability and pharmacokinetic of SE-NK/T-DM1. Radioactive T-[3H]DM1 obtained  
from Creative Biolabs (NY, USA) can be hydrophobized with DMPE-PEG-NHS for 
surface engineering of NK92 cells. Blood samples should be collected at different time 
points after the administration of SE-NK/T-[3H]DM1 cells. Serum and cells should be 
separated with a density gradient centrifugation using Ficoll-Paque™. Serum fractions can 
be applied on protein L-coated plates to detect the dissociated T-[3H]DM1  
and trastuzumab. After immobilizing T-[3H]DM1 and trastuzumab on each well, 
radioactivity of each well should be measured with liquid scintillation counter  
to detect T-[3H]DM1. Subsequently, anti-human Fc antibodies conjugated with HRP 
should be applied to collected supernatants from each well to quantify both T-[3H]DM1  
and trastuzumab. The radioactivity of collected supernatant can be measured to  
determine the amount of released [3H]DM1. NK92 cells enriched from the cell  
fraction—using anti-human CD56 antibodies conjugated with magnetic beads—should  
be counted by flow cytometry. NK92 cells retaining T-[3H]DM1 on the surface can  
be identified by applying fluorescently labeled anti-human Fc antibodies and  
measuring radioactivity. Moreover, histological studies should be conducted to  
evaluate the accumulation of SE-NK/T-DM1 cells or each individual component  
in all major organs. It is important to obtain these pharmacokinetic profiles in  





4.3.10. Chou-Talalay Method of Combinatorial Effects 
The anti-cancer efficacy of SE-NK/T-DM1 cells is a summed effect of T-DM1 and 
NK92 cells. The combinatorial effects of T-DM1 and NK92 cells in SE-NK/T-DM1 cells 
can be defined as synergism, additive effect, or antagonism through the  
Chou-Talalay method.78,79 Many drug combinations proposed for cancer have been 
evaluated for synergetic effects with the Chou-Talalay method.80-83 Although current 
employment of the Chou-Talalay method is fairly limited to examine the combinatorial 
effects of small molecular drugs and proteins, several studies have utilized the  
Chou-Talalay method to analyze synergetic effects of oncolytic herpes simplex viruses 
(HSV) and therapeutic proteins.81,84,85 The experimental methods described by  
Cheema et al. can be modified to determine the synergy between T-DM1 and  
NK92 cells in SE-NK/T-DM1 cells; however, both in vitro and in vivo study  
results of SE-NK/T-DM1 cells reported in Chapter 3 are insufficient to conduct  
the Chou-Talalay analysis. In order to evaluate the combinatorial effects in SE-NK/T-DM1 
cells, the anti-cancer effects of various concentrations of T-DM1 and different numbers of 
NK92 cells should be obtained as separate agents. Also, the anti-cancer effects of changing 
the concentration of T-DM1 and the number of NK92 cells in SE-NK/T-DM1 cells  
should be analyzed. The results acquired from each experiment can be used to  
obtain individual and combined dosage response curves and EC50 values that can be  
fit to Chou-Talalay models. Chou-Talalay combination indices (CIs) can be calculated  
for each fraction affected (Fa), i.e., level of cancer cell death using Equation 4.5, where 
Dx1 and Dx2 are the dosages of T-DM1 and NK92 cells required to reach a particular Fa, 




reach the same Fa.85 CI=1, CI>1, and CI<1 represent additive effect, antagonism, and 
synergism, respectively. CompuSyn software is available for computerized analytical 
simulations using the Chou-Talalay method.78 
 
CI= (D1/Dx1) + (D2/Dx2) + (D1)(D2)/[(Dx1)(Dx2)]                     (4.5) 
 
4.3.11. Improving Cytotoxicity of NK92 Cells 
The in vivo tumor efficacy study of Chapter 3 was conducted without any cytokine 
supplement. The anti-cancer activity of SE-NK/T-DM1 cells can be enhanced with 
supplementary cytokines, such as IL-2, IL-12, IL-15 and IL-18.86-88 These cytokines 
regulate NK cell survival, proliferation and function. Ni et al. have reported that mouse NK 
cells preactivated with murine IL-12, IL-15, and IL-18 expressed high levels of IL-2Rα.86 
In the presence of CD4+ T cells that secrete IL-2 tumor, high numbers of NK cells persisted 
and accumulated in the tumor tissue.86 Similarly, Leong and colleagues have preactivated 
human NK cells with IL-12, IL-15, and IL-18 and adoptively transferred them to NSG 
mice.89 With co-administration of IL-2, these preactivated NK cells showed enhanced 
survival, proliferation, IFN-γ production, and cytotoxicity. Therefore, administering  
NK92 cells with cytokine supplements can increase the persistence and effectiveness of the  
SE-NK/T-DM1 cells. As reported by Romee et al., NK92 cells should be preactivated in 
culture media containing 10 ng/mL of IL-12, 50 ng/mL of IL-18, and 1 ng/mL of IL-15  
for 16 hours.90 The in vivo anti-cancer efficacy and toxicity of SE-NK/T-DM1 cells should 
be compared with and without preactivation of NK92 cells. Once the effects of preactivated 




and SE-NK/T-DM1 cells without the preactivation should be carefully conducted in animal 
models to develop a supplementary activation cocktail for the enhanced anti-cancer therapy 
of SE-NK/T-DM1 cells.78,81  
 
4.3.12. Her2-Positive Breast Cancer and Hematological Cancers 
Although SE-NK/T-DM1 demonstrated tumor growth suppression in Her2-positive 
Calu-3 lung cancer models, the studies were originally designed to test their efficacy in 
Her2-positive breast cancer models. Unfortunately, it was difficult to generate breast 
cancer models using Her2-positive cell lines due to poor tumorigenic potentials of  
SK-BR-3 cells.91 Despite the difficulty in model generation, the SE-NK/T-DM1 cells 
should be tested against breast cancer since T-DM1 has been consistently supported with 
evidence as a treatment of breast cancer. In order to investigate the potential clinical impact, 
the anti-cancer activity of SE-NK/T-DM1 cells should be tested in patient-derived breast 
cancer xenograft models. DeRose et al. described an effective method to generate  
patient-derived tumor models that retain essential features of the original tumors.92 
Following the protocol, patient-derived breast cancer xenograft models may be generated 
by implanting a mixture of patient-derived Her2-positive cancer cells and MSCs onto the 
mammary fat pad of NOD-SCID mice.  
CAR-T cells have advanced to provide therapeutic breakthrough for solid cancers. 
Current approaches of cancer-targeted drug delivery are limited to certain types of cancers 
with overexpressed tumor antigens. Because most of the antigens expressed in cancer cells 
are also expressed at low levels in healthy tissues, adverse on-target off-tumor effects may 




tumors. Due to this fact, a significant number of CAR-T cell clinical trials continue to be 
focused on hematological cancers, such as lymphoma, acute lymphoblastic leukemia 
(ALL), chronic lymphocytic leukemia (CLL), B-cell acute lymphoblastic leukemia  
(B-ALL), non-Hodgkin's lymphoma (NHL), and diffuse large cell lymphoma (DLCL).1,2,93 
For the treatment of these malignant diseases, CAR-T cells targeting CD19, CD20, and 
CD22 have been developed and shown significant clinical success.1,93,94 For the cell surface 
engineering approach, coltuximab ravtansine (SAR3419), an anti-CD19 monoclonal 
antibody conjugated with maytansinoid DM4, can be anchored on NK92 cells.95 Recent 
reports on a Phase II study stated that coltuximab ravtansine was well tolerated with a low 
clinical response rate in ALL patients.96 Alternatively, currently available CD19 antibodies 
for diagnostics can be conjugated with SMCC-DM1 to generate CD19-speicifc ADCs. 
Similar to T-DM1, these CD19-specific ADCs can be hydrophobized with DMPE-PEG for 
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DIRECT INCORPORATION OF FUNCTIONAL PEPTIDE INTO M-DNA  
THROUGH LIGAND-TO-METAL CHARGE TRANSFER† 
 
A.1. Abstract 
Conventional nonviral gene delivery methods suffer from the toxicity of cationic 
polymer carriers. There is a significant need for a new method of gene delivery that 
overcomes the limitations and allows targeted gene delivery. In this study, we have 
developed a new method to incorporate functional peptides into DNA without the need of 
chemical conjugations by utilizing the ligand-to-metal charge transfer (LMCT) transition, 
which occurs between the divalent metal ions and the sulfhydryl group in cysteine. To 
apply the LMCT transition to incorporate cysteine-containing targeting peptides into DNA, 
divalent metal ions must be first introduced to DNA. Zn2+ ions spontaneously intercalate 
into DNA base pairs at pH 7.0 - 8.5, resulting in the conversion of normal B-DNA to  
metal-bound DNA (M-DNA). We found that the Zn2+ ions present in M-DNA could 
interact with the sulfhydryl groups in cysteines of targeting peptides through the LMCT 
transition and the M-DNA/peptide complex could specifically transfect the target cells. 
                                                          
† Modified with the permission from KS Lim, GM Valencia, YW Won, and DA Bull. ACS Macro Letters 
2017; 6: 98-102. Copyright ©  2017 American Chemical Society. Lee and Lim co-managed this project and  
co-authored the research article. Lee contributed to the transfection of PEI/M-DNA polyplex and behavior 
of C-RGD-C/M-DNA complex. Lim contributed to the characterization of PEI/M-DNA polyplex and 




Successful gene therapy is reliant upon the transfer of safe and efficient therapeutic 
nucleic acids to their target cells.1-3 Gene delivery vehicles can be divided into two 
categories: viral vectors and nonviral carriers.4,5 Each of these methods, however, suffers 
from the limitations imposed by the immunogenicity of viral compartments or the toxicity 
of cationic polymeric carriers.6-8 In particular, the development of nonviral polymer 
carriers utilizes one or more of the following principles: 1) electrostatic interaction,  
2) encapsulation, and 3) absorption.3,4,9 For efficient gene transfection, these methods 
require the use of high concentrations of cationic polymers, which can cause cytotoxicity.6,8 
Thus, there is a need for a new method of nonviral gene delivery that reduces the polymer 
use and allows targeted gene delivery without compromising transfection efficiency. 
We have focused on the ligand-to-metal charge transfer (LMCT) between Zn2+ ions 
and sulfhydryl groups of cysteines to directly bind functional peptides to nucleic  
acids.10,11 This LMCT transition between Zn2+ ions and the cysteinyl residues of peptides 
occurs at nanomolar and/or picomolar levels of affinity.12-15 To apply this LMCT transition 
to the modification of DNA with cysteine-containing peptides, Zn2+ ions must first be 
introduced to DNA. It is known that divalent metal ions, such as Zn2+, lead to the 
conversion of normal B-DNA to metal-bound DNA (M-DNA) by intercalating into the 
DNA base pairs at pH 7.0 – 8.5.13,15 Although the binding of divalent metal ions can drive 
the self-assembly of DNA,13,16 this conformational change does not affect the integrity and 
activity of DNA. 
In the present study, M-DNA was generated using Zn2+ ions, and the resulting  
M-DNA was further modified with a cancer targeting peptide, C-RGD-C, or a cell 
  
190 
penetrating peptide (CPP), C-9R-C, through the LMCT transition. The Zn2+ ions  
present in M-DNA interact with the sulfhydryl groups of cysteines present in these  
peptides (Figure A.1). The C-RGD-C peptide attached to M-DNA enhanced the gene 
transfection into the target cancer cells. Similarly, the LMCT transition and the  
electrostatic interaction simultaneously contributed to the enhanced binding of CPPs to  
M-DNA, which in turn reduced the amount of peptide necessary to achieve high  
levels of gene transfection. This method can serve as a strategy to modify DNA with  
any functional peptide.  
 
A.3. Materials and Methods 
A.3.1. Materials 
ZnCl2, MTT, and PEI were purchased from Sigma-Aldrich (St. Louis, MO). Plasmid 
DNA expressing luciferase and luciferase assay kits were obtained from Promega 
(Madison, WI). Yoyo-1 dye was purchased from Thermo Fisher scientific (Waltham, MA).  
Peptides were synthesized by the DNA/peptide Core at the University of Utah. All cell 
culture supplies were purchased from Life Technologies (Invitrogen, Grand Island, NY). 
 
A.3.2 Preparation of M-DNA 
M-DNA was prepared as described previously with some modifications.14,16,17 
Plasmid DNA, 10 µg, was mixed with the ZnCl2 stock solution at final Zn
2+ concentrations 
ranging from 1.83 mM to 7.32 mM. Thereafter, the pH of the mixture was adjusted to 7.4 
or below 7.0 by adding NaOH. This mixture was incubated for 20 minutes at room 

























A.3.3. Ethidium Fluorescence Assay 
ZnCl2 was added to DNA dissolved in MOPS buffer in the presence of ethidium 
bromide (EtBr). The fluorescence intensity of the mixture was recorded over time. The  
M-DNA prepared as described above or its parent B-DNA was diluted in MOPS buffer 
containing EtBr at a final concentration of 4 μg/mL. Resulting EtBr-labeled M-DNA and 
B-DNA were mixed with different amounts of PEI. During the incubation at room 
temperature, fluorescence intensity was measured using a fluorescence photometer at 
excitation and emission wavelengths of 516 nm and 598 nm, respectively, every 5 minutes 
up to 40 minutes. 
 
A.3.4. Preparation of Peptide/M-DNA Complex and PEI/M-DNA Polyplex 
Each peptide was dissolved in water and added to M-DNA at peptide-to-DNA 
(peptide/DNA) weight ratios of 0.125, 0.25, 0.5, and 1.0. The pH was adjusted to 7.4 or 
below 7.0. The mixture was reacted for 30 minutes at room temperature. Similarly, PEI 
was added to preformed M-DNA at PEI-to-DNA (PEI/DNA) weight ratios ranging from 
0.01 to 1.0. For the control, M-DNA was reconverted to B-DNA by lowering pH to 5.0 and 
mixed with PEI at different PEI/DNA weight ratios to form a polyplex. Natural B-DNA 
was also added with PEI at different PEI/DNA weight ratios for polyplex formation.      
 
A.3.5 Characterization 
Five micrograms of C-RGD-C were added to 1 mL of 7.32 mM ZnCl2 solution with 
or without 10 μg DNA. The pH of the mixture was adjusted to 7.4 by adding NaOH and 




C-RGD-C/M-DNA complex, and M-DNA were determined by dynamic light scattering 
(Malvern Zetasizer Nano-ZS; Malvern Instruments, UK) with three parallel measurements. 
 
A.3.6. UV Spectrophotometry 
Absorption spectra of the peptides, peptide/M-DNA complex, and M-DNA from 
200 nm to 450 nm were recorded at 25 °C using a Tecan Infinite 200 PRO NanoQuant 
spectrophotometer (Teacan Group Ltd, Switzerland) in 1 cm quartz cuvettes. Stock 
solutions of peptides in 0.01 M HCl were diluted to final concentrations of 1 μM with  
50 mM borate at pH 7.4 in the presence of 50 μM TCEP. 
 
A.3.7. Transfection and Cellular Uptake 
MDA-MB-231 and HEK293 cells were maintained according to the protocols 
provided from the ATCC. The MDA-MB-231 cell line was chosen to test the targeting 
ability of the C-RGD-C/M-DNA complex because this cell line is widely used in targeted 
gene delivery studies with the RGD-containing peptide. HEK293 cells were used in all 
other transfection studies because this cell line has been readily used in general gene 
transfection studies. For in vitro transfection studies, M-DNA was prepared with the 
plasmid DNA encoding luciferase; then, PEI or peptides were added to form the  
PEI/M-DNA polyplex, C-9R-C/M-DNA complex, and C-RGD-C/M-DNA complex. Cells 
were incubated for 48 hours after the transfection, and the luciferase activity in cell lysates 
was determined according to the manufacturer’s protocol. Cell viability was determined  
48 hours after the transfection using MTT assay. Yoyo-labeled plasmid DNA was prepared 




polymer-incorporated M-DBA complexes for flow cytometry (FACSCanto; BD 
Bioscience, USA). 
  
A.4. Results and Discussion 
A.4.1. M-DNA Formation and Toxicity 
The M-DNA formation was verified through an ethidium fluorescence assay.14,17 The 
effects of Zn2+ concentration and time on the conversion of B-DNA to M-DNA were 
studied at pH 7.5 (Figure A.2). M-DNA was partially generated by the incubation with 
≤3.66 mM ZnCl2, while complete conversion to M-DNA was observed in the presence of 
≥5.49 mM ZnCl2. In the absence of Zn2+, no conformational change in DNA was observed. 
It was verified that the M-DNA generated in this study was nontoxic to cells (Figure A.3). 
 
A.4.2. Comparison of PEI/M-DNA Complex and PEI/B-DNA Polyplex 
To compare our new method utilizing the LMCT transition to conventional 
electrostatic interaction, M-DNA was first condensed by the most commonly used cationic 
polymer: branched poly(ethylenimine) 25 kDa (PEI). When different amounts of PEI were 
mixed with M-DNA at pH 7.4, the migration of M-DNA was completely retarded at a 
PEI/DNA weight ratio of 0.1 (Figure A.4a), whereas the migration of reconverted  
B-DNA—generated by lowering the pH to 5.0—was retarded at a PEI/DNA weight ratio 
of 0.6 (Figure A.4b). The formation of PEI/B-DNA polyplex was completed at a PEI/DNA 
weight ratio of 0.5 (Figure A.4c). The M-DNA showed approximately 50% of fluorescence 
quenching compared to the parent B-DNA, and the addition of PEI decreased it further 






















Figure A.2. Effects of Zn2+ concentration and incubation time on M-DNA formation. 
Plasmid DNA encoding luciferase was incubated with various concentrations of ZnCl2 in 






















Figure A.3. Cytotoxicity of M-DNA generated using various concentrations of ZnCl2. 
HEK293 cells were treated with M-DNA and the cell viability was determined by MTT 










































Figure A.4. Characterization of PEI/M-DNA polyplex. Gel retardation assay of  
(a) PEI/M-DNA polyplex at pH 7.4, (b) reconverted B-DNA mixed with PEI at pH 5.0, 






















Figure A.5. EtBr replacement assays of PEI/M-DNA polyplex. Numbers in the indices  





the fluorescence of M-DNA was approximately 30% of B-DNA, and it was stable over 
time. The fluorescence intensity continued to decrease with increasing PEI concentration 
and finally dropped to below 10% of B-DNA at the PEI/DNA weight ratio of 1.0. Without 
the M-DNA formation, however, the highest PEI/DNA weight ratio could not reduce the 
fluorescence intensity to below 10% of the parent B-DNA (Figure A.6), and the 
fluorescence increased over time with PEI/B-DNA polyplexes generated at PEI/DNA 
weight ratios of 0.1 and 0.2. These results suggest that the PEI/DNA weight ratio of 0.1 
appeared to be sufficient to completely condense the M-DNA. 
The formation of PEI/M-DNA polyplex achieved higher levels of gene expression 
compared to the M-DNA (Figure A.7). The PEI/M-DNA polyplex prepared at a PEI/DNA 
weight ratio of 0.5 showed the same transfection efficiency as the PEI/B-DNA polyplex 
prepared at a PEI/DNA weight ratio of 1.0. The PEI/M-DNA polyplex at a PEI/DNA 
weight ratio of 0.1 showed almost the same levels of gene expression as the PEI/B-DNA 
polyplex at a PEI/DNA weight ratio of 0.5, indicating that the formation of M-DNA could 
reduce the minimal amount of PEI to 20%. Moreover, these results imply that the 
electrostatic interaction alone is insufficient to dramatically reduce the amount of cationic 
polymer required for efficient gene transfection. 
 
A.4.3. Behavior of C-9R-C/M-DNA Complex 
C-9R-C peptide, a well-known CPP,18-20 is expected to interact with M-DNA through 
the combination of LMCT transition and electrostatic interaction, while the control CPP, 
G-9R-G, can bind to M-DNA electrostatically. The 9R moiety binds to M-DNA through 




















Figure A.6. EtBr replacement assays of PEI/B-DNA polyplex. Numbers in the indices  
























Figure A.7. Luciferase gene transfection by PEI/M-DNA polyplex or PEI/B-DNA polyplex. The numbers in the B-DNA+PEI group 
indicate the PEI/DNA weight ratios. The numbers in other groups indicate the ZnCl2 concentrations ranging from 0.73 mM to 7.32 mM 





with Zn2+ ions present in the M-DNA via the LMCT transition.12,21 On the other hand, 
the G-9R-G peptide reacts with M-DNA only through a charge-interaction due to the 
absence of cysteine. Compared to G-9R-G peptide, C-9R-C peptide would, therefore, form 
a stronger bond with the M-DNA.  
Scanning of electronic absorption spectrum in the far UV region was performed to 
verify the binding of Zn2+ to the thiol groups in C-9R-C peptide. This scan demonstrated 
that the LMCT transition was centered near 230 nm (Figure A.8). A bathochromic shift of 
the center of the bands was also observed by the analysis of UV spectra recorded with a 
fixed amount of C-9R-C throughout the titration of Zn2+ ions. Ellman’s assay—performed 
to determine the amount of free cysteine present in the mixture—demonstrated that there 
was a significant difference in the levels of free cysteine between the concentration of 
added cysteines and the concentration of free cysteines following interaction with the  
M-DNA (Figure A.9). The gradients for each plot in Figure A.8 were 0.8531 for the  
C-9R-C only, 0.5936 for the C-9R-C+Zn2+, and 0.6908 for the C-9R-C+M-DNA, 
confirming that the amount of free cysteine was decreased by the LMCT transition. This 
result further verified the occurrence of LMCT transition between M-DNA and  
C-9R-C peptide. 
We sought to determine the minimal amount of C-9R-C peptide necessary for the 
complete condensation of M-DNA. The migration of M-DNA was completely retarded at 
a C-9R-C-to-DNA (C9RC/DNA) weight ratio of 0.08 (Figure A.10a), whereas the 
retardation of B-DNA by the formation of C-9R-C/B-DNA complex was observed at a 
C9RC/DNA weight ratio of 1.0 (Figure A.10b). G-9R-G, which can bind to M-DNA solely 






















Figure A.8. Spectrophotometric titration of C-9R-C with Zn2+. UV spectra obtained by 






















Figure A.9. The free cysteine concentration in C-9R-C and the free cysteine concentration 
after the addition of different amounts of C-9R-C peptide to M-DNA, or ZnCl2 containing 
reaction buffers. M-DNA was prepared in the presence of 7.32 mM ZnCl2 and the same 

























Figure A.10. Agarose gel electrophoresis of C-9R-C/M-DNA complex and  
G-9R-G/M-DNA complex. (a) C-9R-C/M-DNA complex, (b) C-9R-C/B-DNA complex,  
(c) G-9R-G/M-DNA complex, and (d) G-9R-G/B-DNA complex. The numbers indicate 
the peptide/DNA weight ratios. Gel retardation of (e) C-9R-C/M-DNA complex and  
(f) G-9R-G/M-DNA at pH 7.4 or at pH 5.0. Both complexes were formed at a peptide/DNA weight 









(G9RG/DNA) weight ratio of 1.0 (Figure A.10c). This G9RG/DNA weight ratio is the 
same ratio at which the parent B-DNA was condensed by G-9R-G (Figure A.10d). The  
M-DNA was incubated with C-9R-C (Figure A.10e) or G-9R-G (Figure A.10f) at  
pH 5.0 or at pH 7.4 because LMCT transition does not occur below pH 7.0,12 while the 
guanidine side groups of arginine retain their positive charge even below pH 7.0. Both 
peptides can interact with M-DNA through electrostatic interaction at pH below 7.0, but 
C-9R-C binds to M-DNA through LMCT transition at pH 7.4 in addition to the  
electrostatic interaction. C-9R-C retarded migration of the M-DNA at a C9RC/DNA 
weight ratio of 0.05 at pH 7.4. This retardation of M-DNA migration was not observed at 
pH 5.0 (Figure A.10e). There was no difference in migration, regardless of the pH, when 
the M-DNA was condensed by G-9R-G at an identical ratio (Figure A.10f). 
 The transfection efficiency (Figure A.11) and cellular uptake (Figure A.12) of  
the C-9R-C/M-DNA complex were directly proportional to the amount of C-9R-C added 
and were consistently greater than those of the C-9R-C/B-DNA complex without affecting 
the cell viability (Figure A.13). Interestingly, the C-9R-C/M-DNA complex prepared at a 
C9RC/DNA weight ratio of 0.1 exhibited the same level of gene expression as the  
C-9R-C/B-DNA complex prepared at a C9RC/DNA weight ratio of 2.0. In addition, we 
compared the transfection efficiency of the C-9R-C/M-DNA complex to that of the  
G-9R-G/M-DNA complex prepared at pH 7.4 or at pH 5.0. The transfection efficiency of 
C-9R-C/M-DNA complex relative to that of G-9R-G/M-DNA complex increased 
continuously with an increasing C9RC/DNA weight ratio at pH 7.4, while no difference in 
the relative transfection was observed at pH 5.0 (Figure A.14). These results indicate that 
























Figure A.11. Transfection of HEK293 cells with C-9R-C/M-DNA complex and  
C-9R-C/B-DNA complex. Luciferase activity was analyzed 48 hours after the transfection 
(**p<0.01, M-DNA vs. B-DNA). The numbers indicate the C9RC/DNA weight ratios.  
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Figure A.13. HEK293 cell viability following the transfection with C-9R-C/M-DNA 
complex or C-9R-C/B-DNA complex. The numbers indicate the C9RC/DNA weight ratios. 






electrostatic interaction reduces the amount of peptide necessary for a high gene 
transfection efficiency to less than 5% of the peptide amount required for regular polyplex 
formation with a cationic peptide. 
 
A.4.4. Behavior of C-RGD-C/M-DNA Complex 
In order for the LMCT transition method to be broadly applicable to gene delivery, 
there must be a capacity for targeted gene transfection. Conjugation of targeting peptides 
to nonviral vectors is one of the most well-established approaches for the development of 
targeted gene delivery.22,23 Since the direct conjugation of targeting moieties to nucleic 
acids can lead to the loss of nucleic acid activity,24,25 the direct introduction of targeting 
peptides to nucleic acids through conventional conjugation-based methodologies is not a 
viable approach. Moreover, negatively or slightly positively charged targeting peptides are 
unable to directly interact with nucleic acids through electrostatic interaction. We, therefore, 
hypothesized in the beginning that the LMCT transition could allow the incorporation of 
any peptides containing cysteine to M-DNA without the need for either chemical 
conjugation or a positively charged mediator. To prove our hypothesis, a noncyclic  
C-RGD-C peptide, one of the most validated targeting peptides for cancer, was introduced 
to M-DNA through the LMCT transition. 
The parent B-DNA or M-DNA was mixed with C-RGD-C peptide at different  
C-RGD-C-to-DNA (CRGDC/DNA) weight ratios and then electrophoresed on an agarose 
gel. Migration of B-DNA was not retarded even at the highest CRGDC/DNA weight ratio. 
Addition of C-RGD-C peptide to the M-DNA, however, partially retarded the M-DNA 
























Figure A.14. Transfection efficiency of C-9R-C/M-DNA complex relative to that of  
G-9R-G/M-DNA complex in HEK293 cells. Peptide/DNA complexes were prepared at pH 






absorption spectrum in the far UV region to verify the LMCT transition between  
C-RGD-C peptide and Zn2+ ions present in M-DNA, which is centered near 230 nm  
(Figure A.16a). The UV spectra recorded with a fixed amount of C-RGD-C peptide 
throughout the Zn2+ titration was analyzed to confirm the LMCT transition between  
C-RGD-C peptide and Zn2+. The incremental additions of Zn2+ to C-RGD-C peptide up to 
Zn/Cys ratio of 0.5 led to an increase in absorbance values near 230 nm. The absorbance 
spectra of C-RGD-C/M-DNA complex acquired by subtracting the background absorbance 
from each spectrum showed that the LMCT transition reached a steady state at Zn/Cys ratio 
of 0.5 (Figure A.16b). The absorption at 230 nm, where the bathochromic shift of the center 
of the bands was observed, was increased as a function of the Zn/Cys binding (Figure A.17). 
These results provided evidence for the binding of C-RGD-C to M-DNA through the 
LMCT transition.  
Finally, we verified the capacity for targeted gene expression by the  
C-RGD-C/M-DNA complex in cancer cells. MDA-MB-231 cells, a breast cancer  
cell line, and HEK293 cells—both of which have been used widely in general  
gene transfection studies—were transfected with one of the following groups: 
1) C-RGD-C/M-DNA complex; 2) parent B-DNA mixed with C-RGD-C peptide; and  
3) M-DNA. Hydrodynamic diameters and zeta potentials of the M-DNA, Zn/C-RGD-C 
complex, and C-RGD-C/M-DNA are shown in Table A.1. In MDA-MB-231 cells, the 
levels of gene expression relative to M-DNA transfection was increased as the 
CRGDC/DNA weight ratio increased in the C-RGD-C/M-DNA complex group, whereas 
addition of C-RGD-C peptide to the B-DNA did not lead to a meaningful increase in  




















Figure A.15. Agarose gel electrophoresis of M-DNA or B-DNA modified with C-RGD-C 
peptide. The M-DNA prepared with 7.32 mM ZnCl2 was reacted with C-RGD-C peptide 



























Figure A.16. Spectrophotometric analysis of C-RGD-C/M-DNA complex formation.  
(a) UV spectra of C-RGD-C/M-DNA complex at CRGDC/DNA weight ratio 0.5/1.0. 
These results indicate that C-RGD-C peptide binds to Zn2+ added on top of M-DNA.  
(b) UV-difference spectra generated by subtracting the absorbance of peptide from each 
spectrum from (a). These findings indicate that the LMCT occurs with Zn2+ containing  












































    





M-DNA 186.97 ± 5.80 0.25 ± 0.01 -33.36 ± 1.76 
C-RGD-C/M-DNA (0.5/1.0) 131.70 ± 8.00 0.54 ± 0.02 -23.25 ± 0.49 









of the C-RGD-C/M-DNA complex (Figure A.18b). This indicates that the gene expression 
increased as a consequence of C-RGD-C/M-DNA complex formation, which had not been 
observed by the addition of C-RGD-C peptide to B-DNA. The transfection studies on 
HEK293 cells further confirm the targeting ability of the C-RGD-C/M-DNA complex. In 
the HEK293 cells, there was no difference in the levels of luciferase activity between the 
treatments of C-RGD-C/M-DNA complex and M-DNA (Figure A.19a, b), indicating that 
the integration of C-RGD-C peptide into M-DNA had no effect on the gene transfection 
into the nontargeted HEK293 cells. In addition, we compared the cellular uptake of  
C-RGD-C/M-DNA complex to that of C-RGD-C+B-DNA in MDA-MB-231 cells and 
HEK293 cells (Figure A.20). The C-RGD-C/M-DNA complex internalized into the cancer 
cells more efficiently than the B-DNA mixed with C-RGD-C peptide, whereas no 
difference in cellular uptake was observed between C-RGD-C/M-DNA and  
C-RGD-C+B-DNA in the normal cells. 
 
A.5. Conclusion 
We have explored the feasibility of LMCT transition as a novel means of directly 
incorporating functional peptides, regardless of their charge density, within DNA. Cationic 
peptides containing cysteines can facilitate and strengthen the binding to M-DNA through 
the LMCT transition in combination with electrostatic interaction. Using this strategy, the 
minimal amount of C-9R-C peptide necessary for reliable gene expression was 
significantly reduced in comparison to conventional polyplex formation. The LMCT 
transition method has been further employed to enable the direct incorporation of targeting 


































Figure A.18. Luciferase activity (a) and cell viability (b) of MDA-MB-231 cells transfected 
with C-RGD-C/M-DNA complex. The M-DNA prepared with 7.32 mM ZnCl2 was 
reacted with C-RGD-C peptide at CRGDC/DNA weight ratio of 0.25 or 0.5. The B-DNA 


























Figure A.19. Luciferase activity (a) and cell viability (b) of HEK293 cells transfected with 
C-RGD-C/M-DNA complex. The M-DNA prepared with 7.32 mM ZnCl2 was reacted  
with C-RGD-C peptide at CRGDC/DNA weight ratio of 0.5. The B-DNA mixed with  




























Figure A.20. Cellular uptake of C-RGD-C/B-DNA complex or C-RGD-C/M-DNA complex in (a) MDA-MB-231 cells or  
(b) HEK293 cells. The numbers represent peptide/DNA weight ratios
Control B-DNA M-DNA 
0.25 0.5 0.25 0.5 
M-DNA + C-RGD-C B-DNA + C-RGD-C 
b 
Control B-DNA M-DNA 
0.25 0.5 0.25 0.5 





in the target cancer cells upon treatment with the C-RGD-C/M-DNA complex indicates 
that the direct introduction of targeting peptides to M-DNA is a feasible technique for 
targeted gene delivery. Consequently, the LMCT transition is a promising strategy to 
modify metal-bound nucleic acids without the requirement for chemical conjugation or 
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